[
  {
    "Column": "record",
    "Description": "record: Record number",
    "Answer_Options": "NA"
  },
  {
    "Column": "uuid",
    "Description": "uuid: Participant identifier",
    "Answer_Options": "NA"
  },
  {
    "Column": "date",
    "Description": "date: Completion time and date",
    "Answer_Options": "NA"
  },
  {
    "Column": "status",
    "Description": "status: Participant status",
    "Answer_Options": "1=Terminated,2=Overquota,3=Qualified,4=Partial"
  },
  {
    "Column": "hASOCBNBr1",
    "Description": "hASOCBNBr1: ASOC - ASOC / BNB QUOTAS",
    "Answer_Options": "0=NO TO: ASOC,1=ASOC",
    "ParentQuestion": "hASOCBNB"
  },
  {
    "Column": "hASOCBNBr2",
    "Description": "hASOCBNBr2: BnB - ASOC / BNB QUOTAS",
    "Answer_Options": "0=NO TO: BnB,1=BnB",
    "ParentQuestion": "hASOCBNB"
  },
  {
    "Column": "hASOCBNBr3",
    "Description": "hASOCBNBr3: NEITHER - ASOC / BNB QUOTAS",
    "Answer_Options": "0=NO TO: NEITHER,1=NEITHER",
    "ParentQuestion": "hASOCBNB"
  },
  {
    "Column": "dTier",
    "Description": "dTier: Tier",
    "Answer_Options": "1=NT,2=T1,3=T2,4=T3,5=T4"
  },
  {
    "Column": "dPriority",
    "Description": "dPriority: Priority",
    "Answer_Options": "0=Priority 0,1=Priority 1"
  },
  {
    "Column": "S1",
    "Description": "S1: You are about to enter a market research survey. We are being asked to pass on to our client details of adverse events about individual patients or groups of patients and / or product complaints that are raised during the course of market research sur",
    "Answer_Options": "1=I would like to proceed and protect my identity,2=I would like to proceed and give permission for my contact details to be passed on to the Drug Safety department of the,3=I don't want to proceed"
  },
  {
    "Column": "S2",
    "Description": "S2: What is your primary specialty/role?",
    "Answer_Options": "1=Cardiologist,2=Internal Medicine / General Practitioner / Primary Care / Family Practice,3=Nephrologist,4=Endocrinologist,5=Lipidologist,6=Nurse Practitioner,7=Physician’s Assistant,99=Other"
  },
  {
    "Column": "S2a",
    "Description": "S2a: In what type of doctor’s office do you work?",
    "Answer_Options": "1=Cardiologist,2=Internal Medicine / General Practitioner / Primary Care / Family Practice,3=Other"
  },
  {
    "Column": "hQuotaSPECIALTY_OnList",
    "Description": "hQuotaSPECIALTY_OnList: Hidden for hQuotaSPECIALTY_OnList",
    "Answer_Options": "1=CARDS TIERS 1,2=CARDS TIER 4,3=NEPHS TIER 1,4=NEPHS TIER 4,5=ENDOS TIERS 1,6=ENDOS TIER 4,7=PCPS TIER 1,8=PCPS TIER 4,9=CARDS TIERS 2,10=CARDS TIERS 3,11=NEPHS TIER 2,12=NEPHS TIER 3,13=ENDOS TIERS 2,14=ENDOS TIERS 3,15=PCPS TIER 2,16=PCPS TIER 3"
  },
  {
    "Column": "S3a",
    "Description": "S3a: What type of Cardiologist are you primarily?",
    "Answer_Options": "1=Interventional Cardiologist,2=General Cardiologist,3=Preventative Cardiologist,4=Lipidologist"
  },
  {
    "Column": "S3b",
    "Description": "S3b: Do you have a special interest in or are you specialized in cardiology?",
    "Answer_Options": "1=Yes,2=No"
  },
  {
    "Column": "S3c",
    "Description": "S3c: Do you have a special interest in or are you specialized in lipidology?",
    "Answer_Options": "1=Yes,2=No"
  },
  {
    "Column": "S4",
    "Description": "S4: Are you currently board certified or eligible in your specialty?",
    "Answer_Options": "1=Board Eligible,2=Board Certified,3=Neither"
  },
  {
    "Column": "S5r1",
    "Description": "S5r1: Advertising Agency - Are you or is any member of your family currently employed by, or have a commercial affiliation with any of the following?",
    "Answer_Options": "0=NO TO: Advertising Agency,1=Advertising Agency",
    "ParentQuestion": "S5"
  },
  {
    "Column": "S5r2",
    "Description": "S5r2: Marketing/Market Research Firm - Are you or is any member of your family currently employed by, or have a commercial affiliation with any of the following?",
    "Answer_Options": "0=NO TO: Marketing/Market Research Firm,1=Marketing/Market Research Firm",
    "ParentQuestion": "S5"
  },
  {
    "Column": "S5r3",
    "Description": "S5r3: Public Relations Firm - Are you or is any member of your family currently employed by, or have a commercial affiliation with any of the following?",
    "Answer_Options": "0=NO TO: Public Relations Firm,1=Public Relations Firm",
    "ParentQuestion": "S5"
  },
  {
    "Column": "S5r4",
    "Description": "S5r4: Any media company (Print, Radio, TV, Internet) - Are you or is any member of your family currently employed by, or have a commercial affiliation with any of the following?",
    "Answer_Options": "0=NO TO: Any media company (Print, Radio, TV, Internet),1=Any media company (Print, Radio, TV, Internet)",
    "ParentQuestion": "S5"
  },
  {
    "Column": "S5r5",
    "Description": "S5r5: Pharmaceutical Drug / Device Manufacturer (outside of clinical trials) - Are you or is any member of your family currently employed by, or have a commercial affiliation with any of the following?",
    "Answer_Options": "0=NO TO: Pharmaceutical Drug / Device Manufacturer (outside of clinical trials),1=Pharmaceutical Drug / Device Manufacturer (outside of clinical trials)",
    "ParentQuestion": "S5"
  },
  {
    "Column": "S5r6",
    "Description": "S5r6: Governmental Regulatory Agency (e.g., Food & Drug Administration (FDA)) - Are you or is any member of your family currently employed by, or have a commercial affiliation with any of the following?",
    "Answer_Options": "0=NO TO: Governmental Regulatory Agency (e.g., Food & Drug Administration (FDA)),1=Governmental Regulatory Agency (e.g., Food & Drug Administration (FDA))",
    "ParentQuestion": "S5"
  },
  {
    "Column": "S5r7",
    "Description": "S5r7: None of these - Are you or is any member of your family currently employed by, or have a commercial affiliation with any of the following?",
    "Answer_Options": "0=NO TO: None of these,1=None of these",
    "ParentQuestion": "S5"
  },
  {
    "Column": "S6",
    "Description": "S6: How many years have you been in clinical practice, post residency/training?",
    "Answer_Options": "NA"
  },
  {
    "Column": "S7",
    "Description": "S7: And to confirm, are you currently practicing full-time (i.e. 40+ hours weekly across all settings) or part-time?",
    "Answer_Options": "1=Full-Time,2=Part-Time"
  },
  {
    "Column": "S8r1c1",
    "Description": "S8r1c1: Treating/Managing patients - Approximately what percentage of your professional time is spent performing each of the following activities?",
    "Answer_Options": "NA",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S8r2c1",
    "Description": "S8r2c1: Performing academic functions (e.g., teaching, publishing) - Approximately what percentage of your professional time is spent performing each of the following activities?",
    "Answer_Options": "NA",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S8r3c1",
    "Description": "S8r3c1: Participating in clinical research - Approximately what percentage of your professional time is spent performing each of the following activities?",
    "Answer_Options": "NA",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S8r4c1",
    "Description": "S8r4c1: Performing other functions - Approximately what percentage of your professional time is spent performing each of the following activities?",
    "Answer_Options": "NA",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S9",
    "Description": "S9: Which of the following best represents the setting in which you spend most of your professional time?",
    "Answer_Options": "1=Private Solo Practice,2=Group Practice / Clinic (single specialty),3=Group Practice / Clinic (multi-specialty),4=Staff HMO,5=Hospital-based practice,6=VA Hospital,7=None of the above,8=Integrated delivery network (IDN),9=Private Group Practice,10=Multi-specialty Practice / Comprehensive Care,11=Community Hospital,12=Academic/University Hospital"
  },
  {
    "Column": "S10r1",
    "Description": "S10r1: Using your best estimate, how many adult patients, age 18 or older, do you personally manage in your practice in a month?By ‘personally’, we mean patients for whom you are a primary treatment decision maker.",
    "Answer_Options": "NA",
    "ParentQuestion": "S10"
  },
  {
    "Column": "S11r1",
    "Description": "S11r1: Of those adult patients for whom you are the primary treatment decision maker, roughly how many have a confirmed diagnosis of hypercholesterolemia with established cardiovascular disease (CVD)?",
    "Answer_Options": "NA",
    "ParentQuestion": "S11"
  },
  {
    "Column": "S12W3r1",
    "Description": "S12W3r1: Over 5 years ago - Of those, how many patients have had an event (MI, CAD, coronary revascularization, stent placement, etc.) …",
    "Answer_Options": "NA",
    "ParentQuestion": "S12W3"
  },
  {
    "Column": "S12W3r2",
    "Description": "S12W3r2: Within the last 3-5 years - Of those, how many patients have had an event (MI, CAD, coronary revascularization, stent placement, etc.) …",
    "Answer_Options": "NA",
    "ParentQuestion": "S12W3"
  },
  {
    "Column": "S12W3r3",
    "Description": "S12W3r3: Within the 1-2 years - Of those, how many patients have had an event (MI, CAD, coronary revascularization, stent placement, etc.) …",
    "Answer_Options": "NA",
    "ParentQuestion": "S12W3"
  },
  {
    "Column": "S12W3r4",
    "Description": "S12W3r4: Within the last year - Of those, how many patients have had an event (MI, CAD, coronary revascularization, stent placement, etc.) …",
    "Answer_Options": "NA",
    "ParentQuestion": "S12W3"
  },
  {
    "Column": "S12r1c1",
    "Description": "S12r1c1: Atherosclerotic Cardiovascular Disease (ASCVD) - Of those adult patients, how many have been diagnosed with…?",
    "Answer_Options": "NA",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r2c1",
    "Description": "S12r2c1: Familial Hypercholesterolemia (FH) - Of those adult patients, how many have been diagnosed with…?",
    "Answer_Options": "NA",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r3c1",
    "Description": "S12r3c1: Other primary prevention related conditions that require prescription drug therapy to lower LDL-C - Of those adult patients, how many have been diagnosed with…?",
    "Answer_Options": "NA",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S13r1c1",
    "Description": "S13r1c1: # of patients - Atherosclerotic Cardiovascular Disease (ASCVD) - Thinking of the adult patients currently on prescription drug therapy for ASCVD, for how many of them are you the primary treatment decision maker?",
    "Answer_Options": "NA",
    "ParentQuestion": "S13"
  },
  {
    "Column": "S13r1c2",
    "Description": "S13r1c2: # of patients on prescription drug therapy for whom you are the primary treatment decision maker - Atherosclerotic Cardiovascular Disease (ASCVD) - Thinking of the adult patients currently on prescription drug therapy for ASCVD, for how many of t",
    "Answer_Options": "NA",
    "ParentQuestion": "S13"
  },
  {
    "Column": "S13r2c1",
    "Description": "S13r2c1: # of patients - Familial Hypercholesterolemia (FH) - Thinking of the adult patients currently on prescription drug therapy for ASCVD, for how many of them are you the primary treatment decision maker?",
    "Answer_Options": "NA",
    "ParentQuestion": "S13"
  },
  {
    "Column": "S13r2c2",
    "Description": "S13r2c2: # of patients on prescription drug therapy for whom you are the primary treatment decision maker - Familial Hypercholesterolemia (FH) - Thinking of the adult patients currently on prescription drug therapy for ASCVD, for how many of them are you",
    "Answer_Options": "NA",
    "ParentQuestion": "S13"
  },
  {
    "Column": "S13r3c1",
    "Description": "S13r3c1: # of patients - Other primary prevention related conditions that require prescription drug therapy to lower LDL-C - Thinking of the adult patients currently on prescription drug therapy for ASCVD, for how many of them are you the primary treatmen",
    "Answer_Options": "NA",
    "ParentQuestion": "S13"
  },
  {
    "Column": "S13r3c2",
    "Description": "S13r3c2: # of patients on prescription drug therapy for whom you are the primary treatment decision maker - Other primary prevention related conditions that require prescription drug therapy to lower LDL-C - Thinking of the adult patients currently on pre",
    "Answer_Options": "NA",
    "ParentQuestion": "S13"
  },
  {
    "Column": "A1a",
    "Description": "A1a: In total, approximately how many adult patients are you currently managing with elevated LDL-C?",
    "Answer_Options": "NA"
  },
  {
    "Column": "FLAG_A1avsS11",
    "Description": "FLAG_A1avsS11: FLAG IF A RESPONDENT ANSWERS A1a WITH A NUMBER LOWER THAN IN S11",
    "Answer_Options": "0=Not Flagged,1=Flagged"
  },
  {
    "Column": "A1dr1",
    "Description": "A1dr1: Diet & Exercise alone - Of those adult patients with elevated LDL-C, what % are managed with …?",
    "Answer_Options": "NA",
    "ParentQuestion": "A1d"
  },
  {
    "Column": "A1dr2",
    "Description": "A1dr2: Prescription Treatment for LDL-C along with Diet & Exercise - Of those adult patients with elevated LDL-C, what % are managed with …?",
    "Answer_Options": "NA",
    "ParentQuestion": "A1d"
  },
  {
    "Column": "A1er1",
    "Description": "A1er1: Familial Hypercholesterolemia (with or without a prior history of a CV event) - Of those adult patients with elevated LDL-C who are currently treated with prescription treatment along with diet and exercise, what % are in each of the following cate",
    "Answer_Options": "NA",
    "ParentQuestion": "A1e"
  },
  {
    "Column": "A1er2",
    "Description": "A1er2: No prior history of a CV event (and no FH) - Of those adult patients with elevated LDL-C who are currently treated with prescription treatment along with diet and exercise, what % are in each of the following categories?",
    "Answer_Options": "NA",
    "ParentQuestion": "A1e"
  },
  {
    "Column": "A1er3",
    "Description": "A1er3: Prior history of a CV event (and no FH) - Of those adult patients with elevated LDL-C who are currently treated with prescription treatment along with diet and exercise, what % are in each of the following categories?",
    "Answer_Options": "NA",
    "ParentQuestion": "A1e"
  },
  {
    "Column": "A1dar1",
    "Description": "A1dar1: What % are at low to medium risk for a CV event? - Of those adult patients with elevated LDL-C who are currently treated with prescription treatment along with diet and exercise and had no prior history of a CV event (and no FH), what % are in eac",
    "Answer_Options": "NA",
    "ParentQuestion": "A1da"
  },
  {
    "Column": "A1dar2",
    "Description": "A1dar2: What % are at high risk for a CV event? - Of those adult patients with elevated LDL-C who are currently treated with prescription treatment along with diet and exercise and had no prior history of a CV event (and no FH), what % are in each of the",
    "Answer_Options": "NA",
    "ParentQuestion": "A1da"
  },
  {
    "Column": "T",
    "Description": "T: # of patients with high-LDC treated with prescriptions",
    "Answer_Options": "NA"
  },
  {
    "Column": "PT1",
    "Description": "PT1: Patient type 1 (prior event or no prior event but high risk)",
    "Answer_Options": "NA"
  },
  {
    "Column": "PT2",
    "Description": "PT2: Patient type 2 (no prior event and low-to-med risk)",
    "Answer_Options": "NA"
  },
  {
    "Column": "A1fr1",
    "Description": "A1fr1: CAD - Of those adult patients with elevated LDL-C who are currently treated with prescription treatment along with diet and exercise and have had a prior CV event, what % are in each of the following categories?",
    "Answer_Options": "NA",
    "ParentQuestion": "A1f"
  },
  {
    "Column": "A1fr2",
    "Description": "A1fr2: PAD - Of those adult patients with elevated LDL-C who are currently treated with prescription treatment along with diet and exercise and have had a prior CV event, what % are in each of the following categories?",
    "Answer_Options": "NA",
    "ParentQuestion": "A1f"
  },
  {
    "Column": "A1fr3",
    "Description": "A1fr3: Revascularization - Of those adult patients with elevated LDL-C who are currently treated with prescription treatment along with diet and exercise and have had a prior CV event, what % are in each of the following categories?",
    "Answer_Options": "NA",
    "ParentQuestion": "A1f"
  },
  {
    "Column": "A1",
    "Description": "A1: Approximately how many TOTAL adult patients do you have with (e.g., MI, stroke, or symptomatic PAD)?",
    "Answer_Options": "NA"
  },
  {
    "Column": "A1a_1",
    "Description": "A1a_1: What percentage of your adult patients with require additional therapy on top of maximally tolerated statin therapy to lower LDL-C and/or to reduce the risk of future CV events?",
    "Answer_Options": "NA"
  },
  {
    "Column": "A1b",
    "Description": "A1b: Approximately how many TOTAL adult patients do you have with ?",
    "Answer_Options": "NA"
  },
  {
    "Column": "A1c",
    "Description": "A1c: What percentage of your adult patients with require additional lowering of LDL-C on top of maximally tolerated statin therapy?",
    "Answer_Options": "NA"
  },
  {
    "Column": "hTreatments",
    "Description": "hTreatments: Hidden for TPPs",
    "Answer_Options": "1=[rel Leqvio.png],2=[rel Praluent_Leqvio.png],3=[rel Repatha.png],4=Zetia (ezetimibe) or generic,5=[rel Nexletol_Nexlizet.png],6=Other,7=No additional therapy"
  },
  {
    "Column": "A3r1c1",
    "Description": "A3r1c1: Leqvio (inclisiran) - Adults with established CVD (with history of event) or at high risk for CV events (without a prior event) - For your NEXT 100 patients with uncontrolled LDL-C in each of those groups, for how many would you prescribe each of",
    "Answer_Options": "NA",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3r2c1",
    "Description": "A3r2c1: Praluent (alirocumab) - Adults with established CVD (with history of event) or at high risk for CV events (without a prior event) - For your NEXT 100 patients with uncontrolled LDL-C in each of those groups, for how many would you prescribe each o",
    "Answer_Options": "NA",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3r3c1",
    "Description": "A3r3c1: Repatha (evolocumab) - Adults with established CVD (with history of event) or at high risk for CV events (without a prior event) - For your NEXT 100 patients with uncontrolled LDL-C in each of those groups, for how many would you prescribe each of",
    "Answer_Options": "NA",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3r4c1",
    "Description": "A3r4c1: Zetia (ezetimibe) or generic - Adults with established CVD (with history of event) or at high risk for CV events (without a prior event) - For your NEXT 100 patients with uncontrolled LDL-C in each of those groups, for how many would you prescribe",
    "Answer_Options": "NA",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3r5c1",
    "Description": "A3r5c1: Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - Adults with established CVD (with history of event) or at high risk for CV events (without a prior event) - For your NEXT 100 patients with uncontrolled LDL-C in each of those",
    "Answer_Options": "NA",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3r6c1",
    "Description": "A3r6c1: Other - Adults with established CVD (with history of event) or at high risk for CV events (without a prior event) - For your NEXT 100 patients with uncontrolled LDL-C in each of those groups, for how many would you prescribe each of the following",
    "Answer_Options": "NA",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3r7c1",
    "Description": "A3r7c1: No additional therapy - Adults with established CVD (with history of event) or at high risk for CV events (without a prior event) - For your NEXT 100 patients with uncontrolled LDL-C in each of those groups, for how many would you prescribe each o",
    "Answer_Options": "NA",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3r1c2",
    "Description": "A3r1c2: Leqvio (inclisiran) - Adults with low to medium risk for CV events (without a prior event) - For your NEXT 100 patients with uncontrolled LDL-C in each of those groups, for how many would you prescribe each of the following treatments? Please keep",
    "Answer_Options": "NA",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3r2c2",
    "Description": "A3r2c2: Praluent (alirocumab) - Adults with low to medium risk for CV events (without a prior event) - For your NEXT 100 patients with uncontrolled LDL-C in each of those groups, for how many would you prescribe each of the following treatments? Please ke",
    "Answer_Options": "NA",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3r3c2",
    "Description": "A3r3c2: Repatha (evolocumab) - Adults with low to medium risk for CV events (without a prior event) - For your NEXT 100 patients with uncontrolled LDL-C in each of those groups, for how many would you prescribe each of the following treatments? Please kee",
    "Answer_Options": "NA",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3r4c2",
    "Description": "A3r4c2: Zetia (ezetimibe) or generic - Adults with low to medium risk for CV events (without a prior event) - For your NEXT 100 patients with uncontrolled LDL-C in each of those groups, for how many would you prescribe each of the following treatments? Pl",
    "Answer_Options": "NA",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3r5c2",
    "Description": "A3r5c2: Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - Adults with low to medium risk for CV events (without a prior event) - For your NEXT 100 patients with uncontrolled LDL-C in each of those groups, for how many would you prescr",
    "Answer_Options": "NA",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3r6c2",
    "Description": "A3r6c2: Other - Adults with low to medium risk for CV events (without a prior event) - For your NEXT 100 patients with uncontrolled LDL-C in each of those groups, for how many would you prescribe each of the following treatments? Please keep in mind that",
    "Answer_Options": "NA",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3r7c2",
    "Description": "A3r7c2: No additional therapy - Adults with low to medium risk for CV events (without a prior event) - For your NEXT 100 patients with uncontrolled LDL-C in each of those groups, for how many would you prescribe each of the following treatments? Please ke",
    "Answer_Options": "NA",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A5r1c1",
    "Description": "A5r1c1: Leqvio (inclisiran) - Current Prescribing - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that many patients often do not receive",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r2c1",
    "Description": "A5r2c1: Praluent (alirocumab) - Current Prescribing - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that many patients often do not receiv",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r3c1",
    "Description": "A5r3c1: Repatha (evolocumab) - Current Prescribing - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that many patients often do not receive",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r4c1",
    "Description": "A5r4c1: Zetia (ezetimibe) or generic - Current Prescribing - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that many patients often do not",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r5c1",
    "Description": "A5r5c1: Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - Current Prescribing - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r6c1",
    "Description": "A5r6c1: Other - Current Prescribing - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that many patients often do not receive additional adv",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r7c1",
    "Description": "A5r7c1: No additional therapy - Current Prescribing - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that many patients often do not receiv",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r1c2",
    "Description": "A5r1c2: Leqvio (inclisiran) - Near Future with any Leqvio issues addressed - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that many patie",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r2c2",
    "Description": "A5r2c2: Praluent (alirocumab) - Near Future with any Leqvio issues addressed - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that many pat",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r3c2",
    "Description": "A5r3c2: Repatha (evolocumab) - Near Future with any Leqvio issues addressed - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that many pati",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r4c2",
    "Description": "A5r4c2: Zetia (ezetimibe) or generic - Near Future with any Leqvio issues addressed - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that m",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r5c2",
    "Description": "A5r5c2: Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - Near Future with any Leqvio issues addressed - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the followi",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r6c2",
    "Description": "A5r6c2: Other - Near Future with any Leqvio issues addressed - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that many patients often do n",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r7c2",
    "Description": "A5r7c2: No additional therapy - Near Future with any Leqvio issues addressed - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that many pat",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r1c3",
    "Description": "A5r1c3: Leqvio (inclisiran) - Current Prescribing - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that many patients often do not receive",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r2c3",
    "Description": "A5r2c3: Praluent (alirocumab) - Current Prescribing - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that many patients often do not receiv",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r3c3",
    "Description": "A5r3c3: Repatha (evolocumab) - Current Prescribing - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that many patients often do not receive",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r4c3",
    "Description": "A5r4c3: Zetia (ezetimibe) or generic - Current Prescribing - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that many patients often do not",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r5c3",
    "Description": "A5r5c3: Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - Current Prescribing - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r6c3",
    "Description": "A5r6c3: Other - Current Prescribing - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that many patients often do not receive additional adv",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r7c3",
    "Description": "A5r7c3: No additional therapy - Current Prescribing - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that many patients often do not receiv",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r1c4",
    "Description": "A5r1c4: Leqvio (inclisiran) - Near Future with any Leqvio issues addressed - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that many patie",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r2c4",
    "Description": "A5r2c4: Praluent (alirocumab) - Near Future with any Leqvio issues addressed - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that many pat",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r3c4",
    "Description": "A5r3c4: Repatha (evolocumab) - Near Future with any Leqvio issues addressed - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that many pati",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r4c4",
    "Description": "A5r4c4: Zetia (ezetimibe) or generic - Near Future with any Leqvio issues addressed - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that m",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r5c4",
    "Description": "A5r5c4: Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - Near Future with any Leqvio issues addressed - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the followi",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r6c4",
    "Description": "A5r6c4: Other - Near Future with any Leqvio issues addressed - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that many patients often do n",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "A5r7c4",
    "Description": "A5r7c4: No additional therapy - Near Future with any Leqvio issues addressed - With all of that in mind, for your NEXT 100 patients in each of the same groups, how many would you prescribe each of the following treatments?Please keep in mind that many pat",
    "Answer_Options": "NA",
    "ParentQuestion": "A5"
  },
  {
    "Column": "dumRanBlockBC",
    "Description": "dumRanBlockBC: Hidden for TPPs",
    "Answer_Options": "1=B1,2=B2,3=B2a,4=B2b"
  },
  {
    "Column": "B1",
    "Description": "B1: You can click on the image to enlarge.[rel Product_W.png] What is your impression of this treatment?",
    "Answer_Options": "1=1 $ {\" – \" if gv.request.device.isMobileDevice() else \"\"}Very unfavorable,2=2,3=3,4=4,5=5,6=6,7=7 $ {\" – \" if gv.request.device.isMobileDevice() else \"\"}Extremely favorable"
  },
  {
    "Column": "B2",
    "Description": "B2: You can click on the image to enlarge.[rel Product_X.png]What is your impression of this treatment?",
    "Answer_Options": "1=1 $ {\" – \" if gv.request.device.isMobileDevice() else \"\"}Very unfavorable,2=2,3=3,4=4,5=5,6=6,7=7 $ {\" – \" if gv.request.device.isMobileDevice() else \"\"}Extremely favorable"
  },
  {
    "Column": "B2a",
    "Description": "B2a: You can click on the image to enlarge.[rel Product_Y_v2.png]What is your impression of this treatment?",
    "Answer_Options": "1=1 $ {\" – \" if gv.request.device.isMobileDevice() else \"\"}Very unfavorable,2=2,3=3,4=4,5=5,6=6,7=7 $ {\" – \" if gv.request.device.isMobileDevice() else \"\"}Extremely favorable"
  },
  {
    "Column": "B2b",
    "Description": "B2b: You can click on the image to enlarge.[rel Product_Z.png]What is your impression of this treatment?",
    "Answer_Options": "1=1 $ {\" – \" if gv.request.device.isMobileDevice() else \"\"}Very unfavorable,2=2,3=3,4=4,5=5,6=6,7=7 $ {\" – \" if gv.request.device.isMobileDevice() else \"\"}Extremely favorable"
  },
  {
    "Column": "hConjVersion",
    "Description": "hConjVersion: Conjoint Version",
    "Answer_Options": "1=Version 1,2=Version 2,3=Version 3,4=Version 4"
  },
  {
    "Column": "hPatientTypeOrder",
    "Description": "hPatientTypeOrder: Patient Type order",
    "Answer_Options": "12=Adults with established CVD ==> Adults with risk factors for CV events,21=Adults with risk factors for CV events ==> Adults with established CVD"
  },
  {
    "Column": "hPatientType_1",
    "Description": "hPatientType_1: PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_PatientType_1",
    "Description": "Leqvio_PatientType_1: Leqvio_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_Efficacy_1",
    "Description": "Leqvio_Efficacy_1: Leqvio_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~50%80% of patients persistent to treatment at 12m, compared to 57% on,2=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,3=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,4=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o"
  },
  {
    "Column": "Leqvio_Dosing_1",
    "Description": "Leqvio_Dosing_1: Leqvio_Dosing",
    "Answer_Options": "1=Q6MHCP-Administered Injectable(Maintenance Dosing),2=Q6MHCP-Administered Injectable(Maintenance Dosing),3=Q6MHCP-Administered Injectable(Maintenance Dosing),4=Q6MHCP-Administered Injectable(Maintenance Dosing)"
  },
  {
    "Column": "Leqvio_MOA_1",
    "Description": "Leqvio_MOA_1: Leqvio_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor,3=PCSK9 inhibitor,4=PCSK9 inhibitor"
  },
  {
    "Column": "Leqvio_Indication_1",
    "Description": "Leqvio_Indication_1: Leqvio_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,3=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,4=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of CV death (including CHD death"
  },
  {
    "Column": "Praluent_PatientType_1",
    "Description": "Praluent_PatientType_1: Praluent_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Praluent_Efficacy_1",
    "Description": "Praluent_Efficacy_1: Praluent_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~50% In another clinical study of adults with HoFH, PRALUENT lowered bad choleste,2="
  },
  {
    "Column": "Praluent_Dosing_1",
    "Description": "Praluent_Dosing_1: Praluent_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2="
  },
  {
    "Column": "Praluent_MOA_1",
    "Description": "Praluent_MOA_1: Praluent_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Praluent_Indication_1",
    "Description": "Praluent_Indication_1: Praluent_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Repatha_PatientType_1",
    "Description": "Repatha_PatientType_1: Repatha_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Repatha_Efficacy_1",
    "Description": "Repatha_Efficacy_1: Repatha_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,"
  },
  {
    "Column": "Repatha_Dosing_1",
    "Description": "Repatha_Dosing_1: Repatha_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2=Q2WPatient self-administered Injectable"
  },
  {
    "Column": "Repatha_MOA_1",
    "Description": "Repatha_MOA_1: Repatha_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor"
  },
  {
    "Column": "Repatha_Indication_1",
    "Description": "Repatha_Indication_1: Repatha_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: Indicated to reduce risk of CV events in patients with clinical ASCVD (without a prior CV"
  },
  {
    "Column": "Product_W_PatientType_1",
    "Description": "Product_W_PatientType_1: Product_W_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_W_Efficacy_1",
    "Description": "Product_W_Efficacy_1: Product_W_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~49% Mean % change in Lp(a) from Baseline to end of study is ~63%,2="
  },
  {
    "Column": "Product_W_Dosing_1",
    "Description": "Product_W_Dosing_1: Product_W_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2="
  },
  {
    "Column": "Product_W_MOA_1",
    "Description": "Product_W_MOA_1: Product_W_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor plus selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Product_W_Indication_1",
    "Description": "Product_W_Indication_1: Product_W_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2="
  },
  {
    "Column": "Product_X_PatientType_1",
    "Description": "Product_X_PatientType_1: Product_X_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_X_Efficacy_1",
    "Description": "Product_X_Efficacy_1: Product_X_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to Day 365 is ~33% Mean % change in Lp(a) from Baseline to end of study is ~55% In Es,2=Mean % change in LDL from Baseline to end of study is ~45% Mean % change in Lp(a) from Baseline to end of study is ~55%"
  },
  {
    "Column": "Product_X_Dosing_1",
    "Description": "Product_X_Dosing_1: Product_X_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2=QDnon-fasting oral"
  },
  {
    "Column": "Product_X_MOA_1",
    "Description": "Product_X_MOA_1: Product_X_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor,2=Cholesterol ester transfer protein (CETP) inhibitor"
  },
  {
    "Column": "Product_X_Indication_1",
    "Description": "Product_X_Indication_1: Product_X_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Y_PatientType_1",
    "Description": "Product_Y_PatientType_1: Product_Y_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Y_Efficacy_1",
    "Description": "Product_Y_Efficacy_1: Product_Y_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60%,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: Primary Endpoint: 20% RRR on MACE+ (including MA"
  },
  {
    "Column": "Product_Y_Dosing_1",
    "Description": "Product_Y_Dosing_1: Product_Y_Dosing",
    "Answer_Options": "1=QDfasting oral,2=QDfasting oral"
  },
  {
    "Column": "Product_Y_MOA_1",
    "Description": "Product_Y_MOA_1: Product_Y_MOA",
    "Answer_Options": "1=Small molecule PCSK9 inhibitor,2=Small molecule PCSK9 inhibitor"
  },
  {
    "Column": "Product_Y_Indication_1",
    "Description": "Product_Y_Indication_1: Product_Y_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Z_PatientType_1",
    "Description": "Product_Z_PatientType_1: Product_Z_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Z_Efficacy_1",
    "Description": "Product_Z_Efficacy_1: Product_Z_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~65%,2="
  },
  {
    "Column": "Product_Z_Dosing_1",
    "Description": "Product_Z_Dosing_1: Product_Z_Dosing",
    "Answer_Options": "1=QM Patient Self-administered Injectable,2="
  },
  {
    "Column": "Product_Z_MOA_1",
    "Description": "Product_Z_MOA_1: Product_Z_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Product_Z_Indication_1",
    "Description": "Product_Z_Indication_1: Product_Z_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, t,2="
  },
  {
    "Column": "Nexlitol_PatientType_1",
    "Description": "Nexlitol_PatientType_1: Nexlitol_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Nexlitol_Efficacy_1",
    "Description": "Nexlitol_Efficacy_1: Nexlitol_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Nexlitol_Dosing_1",
    "Description": "Nexlitol_Dosing_1: Nexlitol_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Nexlitol_MOA_1",
    "Description": "Nexlitol_MOA_1: Nexlitol_MOA",
    "Answer_Options": "1=ACL inhibitor,2="
  },
  {
    "Column": "Nexlitol_Indication_1",
    "Description": "Nexlitol_Indication_1: Nexlitol_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Zetia_PatientType_1",
    "Description": "Zetia_PatientType_1: Zetia_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Zetia_Efficacy_1",
    "Description": "Zetia_Efficacy_1: Zetia_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Zetia_Dosing_1",
    "Description": "Zetia_Dosing_1: Zetia_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Zetia_MOA_1",
    "Description": "Zetia_MOA_1: Zetia_MOA",
    "Answer_Options": "1=selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Zetia_Indication_1",
    "Description": "Zetia_Indication_1: Zetia_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Other_Therapies_PatientType_1",
    "Description": "Other_Therapies_PatientType_1: Other_Therapies_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Other_Therapies_Efficacy_1",
    "Description": "Other_Therapies_Efficacy_1: Other_Therapies_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Dosing_1",
    "Description": "Other_Therapies_Dosing_1: Other_Therapies_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_MOA_1",
    "Description": "Other_Therapies_MOA_1: Other_Therapies_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Indication_1",
    "Description": "Other_Therapies_Indication_1: Other_Therapies_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_PatientType_1",
    "Description": "No_Addl_Therap_PatientType_1: No_Addl_Therap_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "No_Addl_Therap_Efficacy_1",
    "Description": "No_Addl_Therap_Efficacy_1: No_Addl_Therap_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Dosing_1",
    "Description": "No_Addl_Therap_Dosing_1: No_Addl_Therap_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_MOA_1",
    "Description": "No_Addl_Therap_MOA_1: No_Addl_Therap_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Indication_1",
    "Description": "No_Addl_Therap_Indication_1: No_Addl_Therap_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "B3_1r1c1",
    "Description": "B3_1r1c1: Leqvio - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_1"
  },
  {
    "Column": "B3_1r2c1",
    "Description": "B3_1r2c1: PRALUENT - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_1"
  },
  {
    "Column": "B3_1r3c1",
    "Description": "B3_1r3c1: REPATHA - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_1"
  },
  {
    "Column": "B3_1r4c1",
    "Description": "B3_1r4c1: Product W - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_1"
  },
  {
    "Column": "B3_1r5c1",
    "Description": "B3_1r5c1: Product X - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_1"
  },
  {
    "Column": "B3_1r6c1",
    "Description": "B3_1r6c1: Product Y - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_1"
  },
  {
    "Column": "B3_1r7c1",
    "Description": "B3_1r7c1: Product Z - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_1"
  },
  {
    "Column": "B3_1r8c1",
    "Description": "B3_1r8c1: NEXLETOL / NEXLIZET - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_1"
  },
  {
    "Column": "B3_1r9c1",
    "Description": "B3_1r9c1: ZETIA (ezetimibe) - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_1"
  },
  {
    "Column": "B3_1r10c1",
    "Description": "B3_1r10c1: Other treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_1"
  },
  {
    "Column": "B3_1r11c1",
    "Description": "B3_1r11c1: No additional treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_1"
  },
  {
    "Column": "B3_1r1c2",
    "Description": "B3_1r1c2: Leqvio - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_1"
  },
  {
    "Column": "B3_1r2c2",
    "Description": "B3_1r2c2: PRALUENT - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_1"
  },
  {
    "Column": "B3_1r3c2",
    "Description": "B3_1r3c2: REPATHA - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_1"
  },
  {
    "Column": "B3_1r4c2",
    "Description": "B3_1r4c2: Product W - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_1"
  },
  {
    "Column": "B3_1r5c2",
    "Description": "B3_1r5c2: Product X - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_1"
  },
  {
    "Column": "B3_1r6c2",
    "Description": "B3_1r6c2: Product Y - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_1"
  },
  {
    "Column": "B3_1r7c2",
    "Description": "B3_1r7c2: Product Z - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_1"
  },
  {
    "Column": "B3_1r8c2",
    "Description": "B3_1r8c2: NEXLETOL / NEXLIZET - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_1"
  },
  {
    "Column": "B3_1r9c2",
    "Description": "B3_1r9c2: ZETIA (ezetimibe) - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_1"
  },
  {
    "Column": "B3_1r10c2",
    "Description": "B3_1r10c2: Other treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_1"
  },
  {
    "Column": "B3_1r11c2",
    "Description": "B3_1r11c2: No additional treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_1"
  },
  {
    "Column": "B3_1r1dum1",
    "Description": "B3_1r1dum1: Leqvio - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r2dum1",
    "Description": "B3_1r2dum1: PRALUENT - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r3dum1",
    "Description": "B3_1r3dum1: REPATHA - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r4dum1",
    "Description": "B3_1r4dum1: Product W - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r5dum1",
    "Description": "B3_1r5dum1: Product X - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r6dum1",
    "Description": "B3_1r6dum1: Product Y - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r7dum1",
    "Description": "B3_1r7dum1: Product Z - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r8dum1",
    "Description": "B3_1r8dum1: NEXLETOL / NEXLIZET - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r9dum1",
    "Description": "B3_1r9dum1: ZETIA (ezetimibe) - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r10dum1",
    "Description": "B3_1r10dum1: Other treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r11dum1",
    "Description": "B3_1r11dum1: No additional treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r1dum2",
    "Description": "B3_1r1dum2: Leqvio - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r2dum2",
    "Description": "B3_1r2dum2: PRALUENT - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r3dum2",
    "Description": "B3_1r3dum2: REPATHA - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r4dum2",
    "Description": "B3_1r4dum2: Product W - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r5dum2",
    "Description": "B3_1r5dum2: Product X - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r6dum2",
    "Description": "B3_1r6dum2: Product Y - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r7dum2",
    "Description": "B3_1r7dum2: Product Z - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r8dum2",
    "Description": "B3_1r8dum2: NEXLETOL / NEXLIZET - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r9dum2",
    "Description": "B3_1r9dum2: ZETIA (ezetimibe) - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r10dum2",
    "Description": "B3_1r10dum2: Other treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r11dum2",
    "Description": "B3_1r11dum2: No additional treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r1dum3",
    "Description": "B3_1r1dum3: Leqvio - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r2dum3",
    "Description": "B3_1r2dum3: PRALUENT - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r3dum3",
    "Description": "B3_1r3dum3: REPATHA - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r4dum3",
    "Description": "B3_1r4dum3: Product W - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r5dum3",
    "Description": "B3_1r5dum3: Product X - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r6dum3",
    "Description": "B3_1r6dum3: Product Y - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r7dum3",
    "Description": "B3_1r7dum3: Product Z - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r8dum3",
    "Description": "B3_1r8dum3: NEXLETOL / NEXLIZET - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r9dum3",
    "Description": "B3_1r9dum3: ZETIA (ezetimibe) - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r10dum3",
    "Description": "B3_1r10dum3: Other treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r11dum3",
    "Description": "B3_1r11dum3: No additional treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r1dum4",
    "Description": "B3_1r1dum4: Leqvio - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r2dum4",
    "Description": "B3_1r2dum4: PRALUENT - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r3dum4",
    "Description": "B3_1r3dum4: REPATHA - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r4dum4",
    "Description": "B3_1r4dum4: Product W - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r5dum4",
    "Description": "B3_1r5dum4: Product X - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r6dum4",
    "Description": "B3_1r6dum4: Product Y - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r7dum4",
    "Description": "B3_1r7dum4: Product Z - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r8dum4",
    "Description": "B3_1r8dum4: NEXLETOL / NEXLIZET - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r9dum4",
    "Description": "B3_1r9dum4: ZETIA (ezetimibe) - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r10dum4",
    "Description": "B3_1r10dum4: Other treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r11dum4",
    "Description": "B3_1r11dum4: No additional treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r1dum5",
    "Description": "B3_1r1dum5: Leqvio - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r2dum5",
    "Description": "B3_1r2dum5: PRALUENT - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r3dum5",
    "Description": "B3_1r3dum5: REPATHA - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r4dum5",
    "Description": "B3_1r4dum5: Product W - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r5dum5",
    "Description": "B3_1r5dum5: Product X - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r6dum5",
    "Description": "B3_1r6dum5: Product Y - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r7dum5",
    "Description": "B3_1r7dum5: Product Z - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r8dum5",
    "Description": "B3_1r8dum5: NEXLETOL / NEXLIZET - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r9dum5",
    "Description": "B3_1r9dum5: ZETIA (ezetimibe) - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r10dum5",
    "Description": "B3_1r10dum5: Other treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_1r11dum5",
    "Description": "B3_1r11dum5: No additional treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "hPatientType_2",
    "Description": "hPatientType_2: PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_PatientType_2",
    "Description": "Leqvio_PatientType_2: Leqvio_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_Efficacy_2",
    "Description": "Leqvio_Efficacy_2: Leqvio_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~50%80% of patients persistent to treatment at 12m, compared to 57% on,2=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,3=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,4=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o"
  },
  {
    "Column": "Leqvio_Dosing_2",
    "Description": "Leqvio_Dosing_2: Leqvio_Dosing",
    "Answer_Options": "1=Q6MHCP-Administered Injectable(Maintenance Dosing),2=Q6MHCP-Administered Injectable(Maintenance Dosing),3=Q6MHCP-Administered Injectable(Maintenance Dosing),4=Q6MHCP-Administered Injectable(Maintenance Dosing)"
  },
  {
    "Column": "Leqvio_MOA_2",
    "Description": "Leqvio_MOA_2: Leqvio_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor,3=PCSK9 inhibitor,4=PCSK9 inhibitor"
  },
  {
    "Column": "Leqvio_Indication_2",
    "Description": "Leqvio_Indication_2: Leqvio_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,3=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,4=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of CV death (including CHD death"
  },
  {
    "Column": "Praluent_PatientType_2",
    "Description": "Praluent_PatientType_2: Praluent_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Praluent_Efficacy_2",
    "Description": "Praluent_Efficacy_2: Praluent_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~50% In another clinical study of adults with HoFH, PRALUENT lowered bad choleste,2="
  },
  {
    "Column": "Praluent_Dosing_2",
    "Description": "Praluent_Dosing_2: Praluent_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2="
  },
  {
    "Column": "Praluent_MOA_2",
    "Description": "Praluent_MOA_2: Praluent_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Praluent_Indication_2",
    "Description": "Praluent_Indication_2: Praluent_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Repatha_PatientType_2",
    "Description": "Repatha_PatientType_2: Repatha_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Repatha_Efficacy_2",
    "Description": "Repatha_Efficacy_2: Repatha_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,"
  },
  {
    "Column": "Repatha_Dosing_2",
    "Description": "Repatha_Dosing_2: Repatha_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2=Q2WPatient self-administered Injectable"
  },
  {
    "Column": "Repatha_MOA_2",
    "Description": "Repatha_MOA_2: Repatha_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor"
  },
  {
    "Column": "Repatha_Indication_2",
    "Description": "Repatha_Indication_2: Repatha_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: Indicated to reduce risk of CV events in patients with clinical ASCVD (without a prior CV"
  },
  {
    "Column": "Product_W_PatientType_2",
    "Description": "Product_W_PatientType_2: Product_W_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_W_Efficacy_2",
    "Description": "Product_W_Efficacy_2: Product_W_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~49% Mean % change in Lp(a) from Baseline to end of study is ~63%,2="
  },
  {
    "Column": "Product_W_Dosing_2",
    "Description": "Product_W_Dosing_2: Product_W_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2="
  },
  {
    "Column": "Product_W_MOA_2",
    "Description": "Product_W_MOA_2: Product_W_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor plus selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Product_W_Indication_2",
    "Description": "Product_W_Indication_2: Product_W_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2="
  },
  {
    "Column": "Product_X_PatientType_2",
    "Description": "Product_X_PatientType_2: Product_X_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_X_Efficacy_2",
    "Description": "Product_X_Efficacy_2: Product_X_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to Day 365 is ~33% Mean % change in Lp(a) from Baseline to end of study is ~55% In Es,2=Mean % change in LDL from Baseline to end of study is ~45% Mean % change in Lp(a) from Baseline to end of study is ~55%"
  },
  {
    "Column": "Product_X_Dosing_2",
    "Description": "Product_X_Dosing_2: Product_X_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2=QDnon-fasting oral"
  },
  {
    "Column": "Product_X_MOA_2",
    "Description": "Product_X_MOA_2: Product_X_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor,2=Cholesterol ester transfer protein (CETP) inhibitor"
  },
  {
    "Column": "Product_X_Indication_2",
    "Description": "Product_X_Indication_2: Product_X_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Y_PatientType_2",
    "Description": "Product_Y_PatientType_2: Product_Y_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Y_Efficacy_2",
    "Description": "Product_Y_Efficacy_2: Product_Y_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60%,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: Primary Endpoint: 20% RRR on MACE+ (including MA"
  },
  {
    "Column": "Product_Y_Dosing_2",
    "Description": "Product_Y_Dosing_2: Product_Y_Dosing",
    "Answer_Options": "1=QDfasting oral,2=QDfasting oral"
  },
  {
    "Column": "Product_Y_MOA_2",
    "Description": "Product_Y_MOA_2: Product_Y_MOA",
    "Answer_Options": "1=Small molecule PCSK9 inhibitor,2=Small molecule PCSK9 inhibitor"
  },
  {
    "Column": "Product_Y_Indication_2",
    "Description": "Product_Y_Indication_2: Product_Y_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Z_PatientType_2",
    "Description": "Product_Z_PatientType_2: Product_Z_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Z_Efficacy_2",
    "Description": "Product_Z_Efficacy_2: Product_Z_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~65%,2="
  },
  {
    "Column": "Product_Z_Dosing_2",
    "Description": "Product_Z_Dosing_2: Product_Z_Dosing",
    "Answer_Options": "1=QM Patient Self-administered Injectable,2="
  },
  {
    "Column": "Product_Z_MOA_2",
    "Description": "Product_Z_MOA_2: Product_Z_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Product_Z_Indication_2",
    "Description": "Product_Z_Indication_2: Product_Z_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, t,2="
  },
  {
    "Column": "Nexlitol_PatientType_2",
    "Description": "Nexlitol_PatientType_2: Nexlitol_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Nexlitol_Efficacy_2",
    "Description": "Nexlitol_Efficacy_2: Nexlitol_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Nexlitol_Dosing_2",
    "Description": "Nexlitol_Dosing_2: Nexlitol_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Nexlitol_MOA_2",
    "Description": "Nexlitol_MOA_2: Nexlitol_MOA",
    "Answer_Options": "1=ACL inhibitor,2="
  },
  {
    "Column": "Nexlitol_Indication_2",
    "Description": "Nexlitol_Indication_2: Nexlitol_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Zetia_PatientType_2",
    "Description": "Zetia_PatientType_2: Zetia_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Zetia_Efficacy_2",
    "Description": "Zetia_Efficacy_2: Zetia_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Zetia_Dosing_2",
    "Description": "Zetia_Dosing_2: Zetia_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Zetia_MOA_2",
    "Description": "Zetia_MOA_2: Zetia_MOA",
    "Answer_Options": "1=selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Zetia_Indication_2",
    "Description": "Zetia_Indication_2: Zetia_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Other_Therapies_PatientType_2",
    "Description": "Other_Therapies_PatientType_2: Other_Therapies_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Other_Therapies_Efficacy_2",
    "Description": "Other_Therapies_Efficacy_2: Other_Therapies_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Dosing_2",
    "Description": "Other_Therapies_Dosing_2: Other_Therapies_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_MOA_2",
    "Description": "Other_Therapies_MOA_2: Other_Therapies_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Indication_2",
    "Description": "Other_Therapies_Indication_2: Other_Therapies_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_PatientType_2",
    "Description": "No_Addl_Therap_PatientType_2: No_Addl_Therap_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "No_Addl_Therap_Efficacy_2",
    "Description": "No_Addl_Therap_Efficacy_2: No_Addl_Therap_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Dosing_2",
    "Description": "No_Addl_Therap_Dosing_2: No_Addl_Therap_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_MOA_2",
    "Description": "No_Addl_Therap_MOA_2: No_Addl_Therap_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Indication_2",
    "Description": "No_Addl_Therap_Indication_2: No_Addl_Therap_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "B3_2r1c1",
    "Description": "B3_2r1c1: Leqvio - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_2"
  },
  {
    "Column": "B3_2r2c1",
    "Description": "B3_2r2c1: PRALUENT - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_2"
  },
  {
    "Column": "B3_2r3c1",
    "Description": "B3_2r3c1: REPATHA - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_2"
  },
  {
    "Column": "B3_2r4c1",
    "Description": "B3_2r4c1: Product W - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_2"
  },
  {
    "Column": "B3_2r5c1",
    "Description": "B3_2r5c1: Product X - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_2"
  },
  {
    "Column": "B3_2r6c1",
    "Description": "B3_2r6c1: Product Y - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_2"
  },
  {
    "Column": "B3_2r7c1",
    "Description": "B3_2r7c1: Product Z - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_2"
  },
  {
    "Column": "B3_2r8c1",
    "Description": "B3_2r8c1: NEXLETOL / NEXLIZET - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_2"
  },
  {
    "Column": "B3_2r9c1",
    "Description": "B3_2r9c1: ZETIA (ezetimibe) - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_2"
  },
  {
    "Column": "B3_2r10c1",
    "Description": "B3_2r10c1: Other treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_2"
  },
  {
    "Column": "B3_2r11c1",
    "Description": "B3_2r11c1: No additional treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_2"
  },
  {
    "Column": "B3_2r1c2",
    "Description": "B3_2r1c2: Leqvio - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_2"
  },
  {
    "Column": "B3_2r2c2",
    "Description": "B3_2r2c2: PRALUENT - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_2"
  },
  {
    "Column": "B3_2r3c2",
    "Description": "B3_2r3c2: REPATHA - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_2"
  },
  {
    "Column": "B3_2r4c2",
    "Description": "B3_2r4c2: Product W - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_2"
  },
  {
    "Column": "B3_2r5c2",
    "Description": "B3_2r5c2: Product X - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_2"
  },
  {
    "Column": "B3_2r6c2",
    "Description": "B3_2r6c2: Product Y - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_2"
  },
  {
    "Column": "B3_2r7c2",
    "Description": "B3_2r7c2: Product Z - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_2"
  },
  {
    "Column": "B3_2r8c2",
    "Description": "B3_2r8c2: NEXLETOL / NEXLIZET - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_2"
  },
  {
    "Column": "B3_2r9c2",
    "Description": "B3_2r9c2: ZETIA (ezetimibe) - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_2"
  },
  {
    "Column": "B3_2r10c2",
    "Description": "B3_2r10c2: Other treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_2"
  },
  {
    "Column": "B3_2r11c2",
    "Description": "B3_2r11c2: No additional treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_2"
  },
  {
    "Column": "B3_2r1dum1",
    "Description": "B3_2r1dum1: Leqvio - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r2dum1",
    "Description": "B3_2r2dum1: PRALUENT - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r3dum1",
    "Description": "B3_2r3dum1: REPATHA - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r4dum1",
    "Description": "B3_2r4dum1: Product W - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r5dum1",
    "Description": "B3_2r5dum1: Product X - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r6dum1",
    "Description": "B3_2r6dum1: Product Y - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r7dum1",
    "Description": "B3_2r7dum1: Product Z - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r8dum1",
    "Description": "B3_2r8dum1: NEXLETOL / NEXLIZET - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r9dum1",
    "Description": "B3_2r9dum1: ZETIA (ezetimibe) - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r10dum1",
    "Description": "B3_2r10dum1: Other treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r11dum1",
    "Description": "B3_2r11dum1: No additional treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r1dum2",
    "Description": "B3_2r1dum2: Leqvio - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r2dum2",
    "Description": "B3_2r2dum2: PRALUENT - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r3dum2",
    "Description": "B3_2r3dum2: REPATHA - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r4dum2",
    "Description": "B3_2r4dum2: Product W - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r5dum2",
    "Description": "B3_2r5dum2: Product X - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r6dum2",
    "Description": "B3_2r6dum2: Product Y - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r7dum2",
    "Description": "B3_2r7dum2: Product Z - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r8dum2",
    "Description": "B3_2r8dum2: NEXLETOL / NEXLIZET - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r9dum2",
    "Description": "B3_2r9dum2: ZETIA (ezetimibe) - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r10dum2",
    "Description": "B3_2r10dum2: Other treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r11dum2",
    "Description": "B3_2r11dum2: No additional treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r1dum3",
    "Description": "B3_2r1dum3: Leqvio - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r2dum3",
    "Description": "B3_2r2dum3: PRALUENT - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r3dum3",
    "Description": "B3_2r3dum3: REPATHA - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r4dum3",
    "Description": "B3_2r4dum3: Product W - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r5dum3",
    "Description": "B3_2r5dum3: Product X - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r6dum3",
    "Description": "B3_2r6dum3: Product Y - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r7dum3",
    "Description": "B3_2r7dum3: Product Z - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r8dum3",
    "Description": "B3_2r8dum3: NEXLETOL / NEXLIZET - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r9dum3",
    "Description": "B3_2r9dum3: ZETIA (ezetimibe) - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r10dum3",
    "Description": "B3_2r10dum3: Other treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r11dum3",
    "Description": "B3_2r11dum3: No additional treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r1dum4",
    "Description": "B3_2r1dum4: Leqvio - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r2dum4",
    "Description": "B3_2r2dum4: PRALUENT - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r3dum4",
    "Description": "B3_2r3dum4: REPATHA - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r4dum4",
    "Description": "B3_2r4dum4: Product W - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r5dum4",
    "Description": "B3_2r5dum4: Product X - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r6dum4",
    "Description": "B3_2r6dum4: Product Y - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r7dum4",
    "Description": "B3_2r7dum4: Product Z - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r8dum4",
    "Description": "B3_2r8dum4: NEXLETOL / NEXLIZET - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r9dum4",
    "Description": "B3_2r9dum4: ZETIA (ezetimibe) - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r10dum4",
    "Description": "B3_2r10dum4: Other treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r11dum4",
    "Description": "B3_2r11dum4: No additional treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r1dum5",
    "Description": "B3_2r1dum5: Leqvio - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r2dum5",
    "Description": "B3_2r2dum5: PRALUENT - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r3dum5",
    "Description": "B3_2r3dum5: REPATHA - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r4dum5",
    "Description": "B3_2r4dum5: Product W - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r5dum5",
    "Description": "B3_2r5dum5: Product X - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r6dum5",
    "Description": "B3_2r6dum5: Product Y - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r7dum5",
    "Description": "B3_2r7dum5: Product Z - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r8dum5",
    "Description": "B3_2r8dum5: NEXLETOL / NEXLIZET - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r9dum5",
    "Description": "B3_2r9dum5: ZETIA (ezetimibe) - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r10dum5",
    "Description": "B3_2r10dum5: Other treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_2r11dum5",
    "Description": "B3_2r11dum5: No additional treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "hPatientType_3",
    "Description": "hPatientType_3: PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_PatientType_3",
    "Description": "Leqvio_PatientType_3: Leqvio_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_Efficacy_3",
    "Description": "Leqvio_Efficacy_3: Leqvio_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~50%80% of patients persistent to treatment at 12m, compared to 57% on,2=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,3=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,4=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o"
  },
  {
    "Column": "Leqvio_Dosing_3",
    "Description": "Leqvio_Dosing_3: Leqvio_Dosing",
    "Answer_Options": "1=Q6MHCP-Administered Injectable(Maintenance Dosing),2=Q6MHCP-Administered Injectable(Maintenance Dosing),3=Q6MHCP-Administered Injectable(Maintenance Dosing),4=Q6MHCP-Administered Injectable(Maintenance Dosing)"
  },
  {
    "Column": "Leqvio_MOA_3",
    "Description": "Leqvio_MOA_3: Leqvio_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor,3=PCSK9 inhibitor,4=PCSK9 inhibitor"
  },
  {
    "Column": "Leqvio_Indication_3",
    "Description": "Leqvio_Indication_3: Leqvio_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,3=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,4=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of CV death (including CHD death"
  },
  {
    "Column": "Praluent_PatientType_3",
    "Description": "Praluent_PatientType_3: Praluent_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Praluent_Efficacy_3",
    "Description": "Praluent_Efficacy_3: Praluent_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~50% In another clinical study of adults with HoFH, PRALUENT lowered bad choleste,2="
  },
  {
    "Column": "Praluent_Dosing_3",
    "Description": "Praluent_Dosing_3: Praluent_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2="
  },
  {
    "Column": "Praluent_MOA_3",
    "Description": "Praluent_MOA_3: Praluent_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Praluent_Indication_3",
    "Description": "Praluent_Indication_3: Praluent_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Repatha_PatientType_3",
    "Description": "Repatha_PatientType_3: Repatha_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Repatha_Efficacy_3",
    "Description": "Repatha_Efficacy_3: Repatha_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,"
  },
  {
    "Column": "Repatha_Dosing_3",
    "Description": "Repatha_Dosing_3: Repatha_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2=Q2WPatient self-administered Injectable"
  },
  {
    "Column": "Repatha_MOA_3",
    "Description": "Repatha_MOA_3: Repatha_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor"
  },
  {
    "Column": "Repatha_Indication_3",
    "Description": "Repatha_Indication_3: Repatha_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: Indicated to reduce risk of CV events in patients with clinical ASCVD (without a prior CV"
  },
  {
    "Column": "Product_W_PatientType_3",
    "Description": "Product_W_PatientType_3: Product_W_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_W_Efficacy_3",
    "Description": "Product_W_Efficacy_3: Product_W_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~49% Mean % change in Lp(a) from Baseline to end of study is ~63%,2="
  },
  {
    "Column": "Product_W_Dosing_3",
    "Description": "Product_W_Dosing_3: Product_W_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2="
  },
  {
    "Column": "Product_W_MOA_3",
    "Description": "Product_W_MOA_3: Product_W_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor plus selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Product_W_Indication_3",
    "Description": "Product_W_Indication_3: Product_W_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2="
  },
  {
    "Column": "Product_X_PatientType_3",
    "Description": "Product_X_PatientType_3: Product_X_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_X_Efficacy_3",
    "Description": "Product_X_Efficacy_3: Product_X_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to Day 365 is ~33% Mean % change in Lp(a) from Baseline to end of study is ~55% In Es,2=Mean % change in LDL from Baseline to end of study is ~45% Mean % change in Lp(a) from Baseline to end of study is ~55%"
  },
  {
    "Column": "Product_X_Dosing_3",
    "Description": "Product_X_Dosing_3: Product_X_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2=QDnon-fasting oral"
  },
  {
    "Column": "Product_X_MOA_3",
    "Description": "Product_X_MOA_3: Product_X_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor,2=Cholesterol ester transfer protein (CETP) inhibitor"
  },
  {
    "Column": "Product_X_Indication_3",
    "Description": "Product_X_Indication_3: Product_X_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Y_PatientType_3",
    "Description": "Product_Y_PatientType_3: Product_Y_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Y_Efficacy_3",
    "Description": "Product_Y_Efficacy_3: Product_Y_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60%,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: Primary Endpoint: 20% RRR on MACE+ (including MA"
  },
  {
    "Column": "Product_Y_Dosing_3",
    "Description": "Product_Y_Dosing_3: Product_Y_Dosing",
    "Answer_Options": "1=QDfasting oral,2=QDfasting oral"
  },
  {
    "Column": "Product_Y_MOA_3",
    "Description": "Product_Y_MOA_3: Product_Y_MOA",
    "Answer_Options": "1=Small molecule PCSK9 inhibitor,2=Small molecule PCSK9 inhibitor"
  },
  {
    "Column": "Product_Y_Indication_3",
    "Description": "Product_Y_Indication_3: Product_Y_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Z_PatientType_3",
    "Description": "Product_Z_PatientType_3: Product_Z_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Z_Efficacy_3",
    "Description": "Product_Z_Efficacy_3: Product_Z_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~65%,2="
  },
  {
    "Column": "Product_Z_Dosing_3",
    "Description": "Product_Z_Dosing_3: Product_Z_Dosing",
    "Answer_Options": "1=QM Patient Self-administered Injectable,2="
  },
  {
    "Column": "Product_Z_MOA_3",
    "Description": "Product_Z_MOA_3: Product_Z_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Product_Z_Indication_3",
    "Description": "Product_Z_Indication_3: Product_Z_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, t,2="
  },
  {
    "Column": "Nexlitol_PatientType_3",
    "Description": "Nexlitol_PatientType_3: Nexlitol_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Nexlitol_Efficacy_3",
    "Description": "Nexlitol_Efficacy_3: Nexlitol_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Nexlitol_Dosing_3",
    "Description": "Nexlitol_Dosing_3: Nexlitol_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Nexlitol_MOA_3",
    "Description": "Nexlitol_MOA_3: Nexlitol_MOA",
    "Answer_Options": "1=ACL inhibitor,2="
  },
  {
    "Column": "Nexlitol_Indication_3",
    "Description": "Nexlitol_Indication_3: Nexlitol_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Zetia_PatientType_3",
    "Description": "Zetia_PatientType_3: Zetia_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Zetia_Efficacy_3",
    "Description": "Zetia_Efficacy_3: Zetia_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Zetia_Dosing_3",
    "Description": "Zetia_Dosing_3: Zetia_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Zetia_MOA_3",
    "Description": "Zetia_MOA_3: Zetia_MOA",
    "Answer_Options": "1=selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Zetia_Indication_3",
    "Description": "Zetia_Indication_3: Zetia_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Other_Therapies_PatientType_3",
    "Description": "Other_Therapies_PatientType_3: Other_Therapies_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Other_Therapies_Efficacy_3",
    "Description": "Other_Therapies_Efficacy_3: Other_Therapies_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Dosing_3",
    "Description": "Other_Therapies_Dosing_3: Other_Therapies_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_MOA_3",
    "Description": "Other_Therapies_MOA_3: Other_Therapies_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Indication_3",
    "Description": "Other_Therapies_Indication_3: Other_Therapies_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_PatientType_3",
    "Description": "No_Addl_Therap_PatientType_3: No_Addl_Therap_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "No_Addl_Therap_Efficacy_3",
    "Description": "No_Addl_Therap_Efficacy_3: No_Addl_Therap_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Dosing_3",
    "Description": "No_Addl_Therap_Dosing_3: No_Addl_Therap_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_MOA_3",
    "Description": "No_Addl_Therap_MOA_3: No_Addl_Therap_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Indication_3",
    "Description": "No_Addl_Therap_Indication_3: No_Addl_Therap_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "B3_3r1c1",
    "Description": "B3_3r1c1: Leqvio - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_3"
  },
  {
    "Column": "B3_3r2c1",
    "Description": "B3_3r2c1: PRALUENT - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_3"
  },
  {
    "Column": "B3_3r3c1",
    "Description": "B3_3r3c1: REPATHA - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_3"
  },
  {
    "Column": "B3_3r4c1",
    "Description": "B3_3r4c1: Product W - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_3"
  },
  {
    "Column": "B3_3r5c1",
    "Description": "B3_3r5c1: Product X - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_3"
  },
  {
    "Column": "B3_3r6c1",
    "Description": "B3_3r6c1: Product Y - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_3"
  },
  {
    "Column": "B3_3r7c1",
    "Description": "B3_3r7c1: Product Z - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_3"
  },
  {
    "Column": "B3_3r8c1",
    "Description": "B3_3r8c1: NEXLETOL / NEXLIZET - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_3"
  },
  {
    "Column": "B3_3r9c1",
    "Description": "B3_3r9c1: ZETIA (ezetimibe) - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_3"
  },
  {
    "Column": "B3_3r10c1",
    "Description": "B3_3r10c1: Other treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_3"
  },
  {
    "Column": "B3_3r11c1",
    "Description": "B3_3r11c1: No additional treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_3"
  },
  {
    "Column": "B3_3r1c2",
    "Description": "B3_3r1c2: Leqvio - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_3"
  },
  {
    "Column": "B3_3r2c2",
    "Description": "B3_3r2c2: PRALUENT - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_3"
  },
  {
    "Column": "B3_3r3c2",
    "Description": "B3_3r3c2: REPATHA - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_3"
  },
  {
    "Column": "B3_3r4c2",
    "Description": "B3_3r4c2: Product W - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_3"
  },
  {
    "Column": "B3_3r5c2",
    "Description": "B3_3r5c2: Product X - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_3"
  },
  {
    "Column": "B3_3r6c2",
    "Description": "B3_3r6c2: Product Y - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_3"
  },
  {
    "Column": "B3_3r7c2",
    "Description": "B3_3r7c2: Product Z - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_3"
  },
  {
    "Column": "B3_3r8c2",
    "Description": "B3_3r8c2: NEXLETOL / NEXLIZET - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_3"
  },
  {
    "Column": "B3_3r9c2",
    "Description": "B3_3r9c2: ZETIA (ezetimibe) - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_3"
  },
  {
    "Column": "B3_3r10c2",
    "Description": "B3_3r10c2: Other treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_3"
  },
  {
    "Column": "B3_3r11c2",
    "Description": "B3_3r11c2: No additional treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_3"
  },
  {
    "Column": "B3_3r1dum1",
    "Description": "B3_3r1dum1: Leqvio - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r2dum1",
    "Description": "B3_3r2dum1: PRALUENT - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r3dum1",
    "Description": "B3_3r3dum1: REPATHA - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r4dum1",
    "Description": "B3_3r4dum1: Product W - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r5dum1",
    "Description": "B3_3r5dum1: Product X - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r6dum1",
    "Description": "B3_3r6dum1: Product Y - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r7dum1",
    "Description": "B3_3r7dum1: Product Z - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r8dum1",
    "Description": "B3_3r8dum1: NEXLETOL / NEXLIZET - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r9dum1",
    "Description": "B3_3r9dum1: ZETIA (ezetimibe) - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r10dum1",
    "Description": "B3_3r10dum1: Other treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r11dum1",
    "Description": "B3_3r11dum1: No additional treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r1dum2",
    "Description": "B3_3r1dum2: Leqvio - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r2dum2",
    "Description": "B3_3r2dum2: PRALUENT - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r3dum2",
    "Description": "B3_3r3dum2: REPATHA - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r4dum2",
    "Description": "B3_3r4dum2: Product W - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r5dum2",
    "Description": "B3_3r5dum2: Product X - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r6dum2",
    "Description": "B3_3r6dum2: Product Y - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r7dum2",
    "Description": "B3_3r7dum2: Product Z - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r8dum2",
    "Description": "B3_3r8dum2: NEXLETOL / NEXLIZET - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r9dum2",
    "Description": "B3_3r9dum2: ZETIA (ezetimibe) - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r10dum2",
    "Description": "B3_3r10dum2: Other treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r11dum2",
    "Description": "B3_3r11dum2: No additional treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r1dum3",
    "Description": "B3_3r1dum3: Leqvio - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r2dum3",
    "Description": "B3_3r2dum3: PRALUENT - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r3dum3",
    "Description": "B3_3r3dum3: REPATHA - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r4dum3",
    "Description": "B3_3r4dum3: Product W - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r5dum3",
    "Description": "B3_3r5dum3: Product X - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r6dum3",
    "Description": "B3_3r6dum3: Product Y - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r7dum3",
    "Description": "B3_3r7dum3: Product Z - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r8dum3",
    "Description": "B3_3r8dum3: NEXLETOL / NEXLIZET - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r9dum3",
    "Description": "B3_3r9dum3: ZETIA (ezetimibe) - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r10dum3",
    "Description": "B3_3r10dum3: Other treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r11dum3",
    "Description": "B3_3r11dum3: No additional treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r1dum4",
    "Description": "B3_3r1dum4: Leqvio - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r2dum4",
    "Description": "B3_3r2dum4: PRALUENT - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r3dum4",
    "Description": "B3_3r3dum4: REPATHA - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r4dum4",
    "Description": "B3_3r4dum4: Product W - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r5dum4",
    "Description": "B3_3r5dum4: Product X - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r6dum4",
    "Description": "B3_3r6dum4: Product Y - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r7dum4",
    "Description": "B3_3r7dum4: Product Z - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r8dum4",
    "Description": "B3_3r8dum4: NEXLETOL / NEXLIZET - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r9dum4",
    "Description": "B3_3r9dum4: ZETIA (ezetimibe) - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r10dum4",
    "Description": "B3_3r10dum4: Other treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r11dum4",
    "Description": "B3_3r11dum4: No additional treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r1dum5",
    "Description": "B3_3r1dum5: Leqvio - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r2dum5",
    "Description": "B3_3r2dum5: PRALUENT - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r3dum5",
    "Description": "B3_3r3dum5: REPATHA - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r4dum5",
    "Description": "B3_3r4dum5: Product W - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r5dum5",
    "Description": "B3_3r5dum5: Product X - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r6dum5",
    "Description": "B3_3r6dum5: Product Y - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r7dum5",
    "Description": "B3_3r7dum5: Product Z - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r8dum5",
    "Description": "B3_3r8dum5: NEXLETOL / NEXLIZET - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r9dum5",
    "Description": "B3_3r9dum5: ZETIA (ezetimibe) - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r10dum5",
    "Description": "B3_3r10dum5: Other treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_3r11dum5",
    "Description": "B3_3r11dum5: No additional treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "hPatientType_4",
    "Description": "hPatientType_4: PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_PatientType_4",
    "Description": "Leqvio_PatientType_4: Leqvio_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_Efficacy_4",
    "Description": "Leqvio_Efficacy_4: Leqvio_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~50%80% of patients persistent to treatment at 12m, compared to 57% on,2=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,3=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,4=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o"
  },
  {
    "Column": "Leqvio_Dosing_4",
    "Description": "Leqvio_Dosing_4: Leqvio_Dosing",
    "Answer_Options": "1=Q6MHCP-Administered Injectable(Maintenance Dosing),2=Q6MHCP-Administered Injectable(Maintenance Dosing),3=Q6MHCP-Administered Injectable(Maintenance Dosing),4=Q6MHCP-Administered Injectable(Maintenance Dosing)"
  },
  {
    "Column": "Leqvio_MOA_4",
    "Description": "Leqvio_MOA_4: Leqvio_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor,3=PCSK9 inhibitor,4=PCSK9 inhibitor"
  },
  {
    "Column": "Leqvio_Indication_4",
    "Description": "Leqvio_Indication_4: Leqvio_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,3=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,4=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of CV death (including CHD death"
  },
  {
    "Column": "Praluent_PatientType_4",
    "Description": "Praluent_PatientType_4: Praluent_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Praluent_Efficacy_4",
    "Description": "Praluent_Efficacy_4: Praluent_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~50% In another clinical study of adults with HoFH, PRALUENT lowered bad choleste,2="
  },
  {
    "Column": "Praluent_Dosing_4",
    "Description": "Praluent_Dosing_4: Praluent_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2="
  },
  {
    "Column": "Praluent_MOA_4",
    "Description": "Praluent_MOA_4: Praluent_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Praluent_Indication_4",
    "Description": "Praluent_Indication_4: Praluent_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Repatha_PatientType_4",
    "Description": "Repatha_PatientType_4: Repatha_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Repatha_Efficacy_4",
    "Description": "Repatha_Efficacy_4: Repatha_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,"
  },
  {
    "Column": "Repatha_Dosing_4",
    "Description": "Repatha_Dosing_4: Repatha_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2=Q2WPatient self-administered Injectable"
  },
  {
    "Column": "Repatha_MOA_4",
    "Description": "Repatha_MOA_4: Repatha_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor"
  },
  {
    "Column": "Repatha_Indication_4",
    "Description": "Repatha_Indication_4: Repatha_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: Indicated to reduce risk of CV events in patients with clinical ASCVD (without a prior CV"
  },
  {
    "Column": "Product_W_PatientType_4",
    "Description": "Product_W_PatientType_4: Product_W_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_W_Efficacy_4",
    "Description": "Product_W_Efficacy_4: Product_W_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~49% Mean % change in Lp(a) from Baseline to end of study is ~63%,2="
  },
  {
    "Column": "Product_W_Dosing_4",
    "Description": "Product_W_Dosing_4: Product_W_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2="
  },
  {
    "Column": "Product_W_MOA_4",
    "Description": "Product_W_MOA_4: Product_W_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor plus selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Product_W_Indication_4",
    "Description": "Product_W_Indication_4: Product_W_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2="
  },
  {
    "Column": "Product_X_PatientType_4",
    "Description": "Product_X_PatientType_4: Product_X_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_X_Efficacy_4",
    "Description": "Product_X_Efficacy_4: Product_X_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to Day 365 is ~33% Mean % change in Lp(a) from Baseline to end of study is ~55% In Es,2=Mean % change in LDL from Baseline to end of study is ~45% Mean % change in Lp(a) from Baseline to end of study is ~55%"
  },
  {
    "Column": "Product_X_Dosing_4",
    "Description": "Product_X_Dosing_4: Product_X_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2=QDnon-fasting oral"
  },
  {
    "Column": "Product_X_MOA_4",
    "Description": "Product_X_MOA_4: Product_X_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor,2=Cholesterol ester transfer protein (CETP) inhibitor"
  },
  {
    "Column": "Product_X_Indication_4",
    "Description": "Product_X_Indication_4: Product_X_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Y_PatientType_4",
    "Description": "Product_Y_PatientType_4: Product_Y_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Y_Efficacy_4",
    "Description": "Product_Y_Efficacy_4: Product_Y_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60%,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: Primary Endpoint: 20% RRR on MACE+ (including MA"
  },
  {
    "Column": "Product_Y_Dosing_4",
    "Description": "Product_Y_Dosing_4: Product_Y_Dosing",
    "Answer_Options": "1=QDfasting oral,2=QDfasting oral"
  },
  {
    "Column": "Product_Y_MOA_4",
    "Description": "Product_Y_MOA_4: Product_Y_MOA",
    "Answer_Options": "1=Small molecule PCSK9 inhibitor,2=Small molecule PCSK9 inhibitor"
  },
  {
    "Column": "Product_Y_Indication_4",
    "Description": "Product_Y_Indication_4: Product_Y_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Z_PatientType_4",
    "Description": "Product_Z_PatientType_4: Product_Z_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Z_Efficacy_4",
    "Description": "Product_Z_Efficacy_4: Product_Z_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~65%,2="
  },
  {
    "Column": "Product_Z_Dosing_4",
    "Description": "Product_Z_Dosing_4: Product_Z_Dosing",
    "Answer_Options": "1=QM Patient Self-administered Injectable,2="
  },
  {
    "Column": "Product_Z_MOA_4",
    "Description": "Product_Z_MOA_4: Product_Z_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Product_Z_Indication_4",
    "Description": "Product_Z_Indication_4: Product_Z_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, t,2="
  },
  {
    "Column": "Nexlitol_PatientType_4",
    "Description": "Nexlitol_PatientType_4: Nexlitol_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Nexlitol_Efficacy_4",
    "Description": "Nexlitol_Efficacy_4: Nexlitol_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Nexlitol_Dosing_4",
    "Description": "Nexlitol_Dosing_4: Nexlitol_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Nexlitol_MOA_4",
    "Description": "Nexlitol_MOA_4: Nexlitol_MOA",
    "Answer_Options": "1=ACL inhibitor,2="
  },
  {
    "Column": "Nexlitol_Indication_4",
    "Description": "Nexlitol_Indication_4: Nexlitol_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Zetia_PatientType_4",
    "Description": "Zetia_PatientType_4: Zetia_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Zetia_Efficacy_4",
    "Description": "Zetia_Efficacy_4: Zetia_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Zetia_Dosing_4",
    "Description": "Zetia_Dosing_4: Zetia_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Zetia_MOA_4",
    "Description": "Zetia_MOA_4: Zetia_MOA",
    "Answer_Options": "1=selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Zetia_Indication_4",
    "Description": "Zetia_Indication_4: Zetia_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Other_Therapies_PatientType_4",
    "Description": "Other_Therapies_PatientType_4: Other_Therapies_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Other_Therapies_Efficacy_4",
    "Description": "Other_Therapies_Efficacy_4: Other_Therapies_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Dosing_4",
    "Description": "Other_Therapies_Dosing_4: Other_Therapies_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_MOA_4",
    "Description": "Other_Therapies_MOA_4: Other_Therapies_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Indication_4",
    "Description": "Other_Therapies_Indication_4: Other_Therapies_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_PatientType_4",
    "Description": "No_Addl_Therap_PatientType_4: No_Addl_Therap_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "No_Addl_Therap_Efficacy_4",
    "Description": "No_Addl_Therap_Efficacy_4: No_Addl_Therap_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Dosing_4",
    "Description": "No_Addl_Therap_Dosing_4: No_Addl_Therap_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_MOA_4",
    "Description": "No_Addl_Therap_MOA_4: No_Addl_Therap_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Indication_4",
    "Description": "No_Addl_Therap_Indication_4: No_Addl_Therap_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "B3_4r1c1",
    "Description": "B3_4r1c1: Leqvio - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_4"
  },
  {
    "Column": "B3_4r2c1",
    "Description": "B3_4r2c1: PRALUENT - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_4"
  },
  {
    "Column": "B3_4r3c1",
    "Description": "B3_4r3c1: REPATHA - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_4"
  },
  {
    "Column": "B3_4r4c1",
    "Description": "B3_4r4c1: Product W - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_4"
  },
  {
    "Column": "B3_4r5c1",
    "Description": "B3_4r5c1: Product X - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_4"
  },
  {
    "Column": "B3_4r6c1",
    "Description": "B3_4r6c1: Product Y - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_4"
  },
  {
    "Column": "B3_4r7c1",
    "Description": "B3_4r7c1: Product Z - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_4"
  },
  {
    "Column": "B3_4r8c1",
    "Description": "B3_4r8c1: NEXLETOL / NEXLIZET - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_4"
  },
  {
    "Column": "B3_4r9c1",
    "Description": "B3_4r9c1: ZETIA (ezetimibe) - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_4"
  },
  {
    "Column": "B3_4r10c1",
    "Description": "B3_4r10c1: Other treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_4"
  },
  {
    "Column": "B3_4r11c1",
    "Description": "B3_4r11c1: No additional treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_4"
  },
  {
    "Column": "B3_4r1c2",
    "Description": "B3_4r1c2: Leqvio - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_4"
  },
  {
    "Column": "B3_4r2c2",
    "Description": "B3_4r2c2: PRALUENT - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_4"
  },
  {
    "Column": "B3_4r3c2",
    "Description": "B3_4r3c2: REPATHA - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_4"
  },
  {
    "Column": "B3_4r4c2",
    "Description": "B3_4r4c2: Product W - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_4"
  },
  {
    "Column": "B3_4r5c2",
    "Description": "B3_4r5c2: Product X - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_4"
  },
  {
    "Column": "B3_4r6c2",
    "Description": "B3_4r6c2: Product Y - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_4"
  },
  {
    "Column": "B3_4r7c2",
    "Description": "B3_4r7c2: Product Z - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_4"
  },
  {
    "Column": "B3_4r8c2",
    "Description": "B3_4r8c2: NEXLETOL / NEXLIZET - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_4"
  },
  {
    "Column": "B3_4r9c2",
    "Description": "B3_4r9c2: ZETIA (ezetimibe) - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_4"
  },
  {
    "Column": "B3_4r10c2",
    "Description": "B3_4r10c2: Other treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_4"
  },
  {
    "Column": "B3_4r11c2",
    "Description": "B3_4r11c2: No additional treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_4"
  },
  {
    "Column": "B3_4r1dum1",
    "Description": "B3_4r1dum1: Leqvio - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r2dum1",
    "Description": "B3_4r2dum1: PRALUENT - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r3dum1",
    "Description": "B3_4r3dum1: REPATHA - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r4dum1",
    "Description": "B3_4r4dum1: Product W - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r5dum1",
    "Description": "B3_4r5dum1: Product X - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r6dum1",
    "Description": "B3_4r6dum1: Product Y - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r7dum1",
    "Description": "B3_4r7dum1: Product Z - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r8dum1",
    "Description": "B3_4r8dum1: NEXLETOL / NEXLIZET - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r9dum1",
    "Description": "B3_4r9dum1: ZETIA (ezetimibe) - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r10dum1",
    "Description": "B3_4r10dum1: Other treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r11dum1",
    "Description": "B3_4r11dum1: No additional treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r1dum2",
    "Description": "B3_4r1dum2: Leqvio - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r2dum2",
    "Description": "B3_4r2dum2: PRALUENT - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r3dum2",
    "Description": "B3_4r3dum2: REPATHA - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r4dum2",
    "Description": "B3_4r4dum2: Product W - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r5dum2",
    "Description": "B3_4r5dum2: Product X - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r6dum2",
    "Description": "B3_4r6dum2: Product Y - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r7dum2",
    "Description": "B3_4r7dum2: Product Z - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r8dum2",
    "Description": "B3_4r8dum2: NEXLETOL / NEXLIZET - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r9dum2",
    "Description": "B3_4r9dum2: ZETIA (ezetimibe) - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r10dum2",
    "Description": "B3_4r10dum2: Other treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r11dum2",
    "Description": "B3_4r11dum2: No additional treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r1dum3",
    "Description": "B3_4r1dum3: Leqvio - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r2dum3",
    "Description": "B3_4r2dum3: PRALUENT - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r3dum3",
    "Description": "B3_4r3dum3: REPATHA - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r4dum3",
    "Description": "B3_4r4dum3: Product W - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r5dum3",
    "Description": "B3_4r5dum3: Product X - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r6dum3",
    "Description": "B3_4r6dum3: Product Y - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r7dum3",
    "Description": "B3_4r7dum3: Product Z - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r8dum3",
    "Description": "B3_4r8dum3: NEXLETOL / NEXLIZET - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r9dum3",
    "Description": "B3_4r9dum3: ZETIA (ezetimibe) - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r10dum3",
    "Description": "B3_4r10dum3: Other treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r11dum3",
    "Description": "B3_4r11dum3: No additional treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r1dum4",
    "Description": "B3_4r1dum4: Leqvio - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r2dum4",
    "Description": "B3_4r2dum4: PRALUENT - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r3dum4",
    "Description": "B3_4r3dum4: REPATHA - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r4dum4",
    "Description": "B3_4r4dum4: Product W - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r5dum4",
    "Description": "B3_4r5dum4: Product X - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r6dum4",
    "Description": "B3_4r6dum4: Product Y - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r7dum4",
    "Description": "B3_4r7dum4: Product Z - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r8dum4",
    "Description": "B3_4r8dum4: NEXLETOL / NEXLIZET - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r9dum4",
    "Description": "B3_4r9dum4: ZETIA (ezetimibe) - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r10dum4",
    "Description": "B3_4r10dum4: Other treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r11dum4",
    "Description": "B3_4r11dum4: No additional treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r1dum5",
    "Description": "B3_4r1dum5: Leqvio - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r2dum5",
    "Description": "B3_4r2dum5: PRALUENT - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r3dum5",
    "Description": "B3_4r3dum5: REPATHA - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r4dum5",
    "Description": "B3_4r4dum5: Product W - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r5dum5",
    "Description": "B3_4r5dum5: Product X - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r6dum5",
    "Description": "B3_4r6dum5: Product Y - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r7dum5",
    "Description": "B3_4r7dum5: Product Z - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r8dum5",
    "Description": "B3_4r8dum5: NEXLETOL / NEXLIZET - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r9dum5",
    "Description": "B3_4r9dum5: ZETIA (ezetimibe) - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r10dum5",
    "Description": "B3_4r10dum5: Other treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_4r11dum5",
    "Description": "B3_4r11dum5: No additional treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "hPatientType_5",
    "Description": "hPatientType_5: PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_PatientType_5",
    "Description": "Leqvio_PatientType_5: Leqvio_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_Efficacy_5",
    "Description": "Leqvio_Efficacy_5: Leqvio_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~50%80% of patients persistent to treatment at 12m, compared to 57% on,2=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,3=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,4=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o"
  },
  {
    "Column": "Leqvio_Dosing_5",
    "Description": "Leqvio_Dosing_5: Leqvio_Dosing",
    "Answer_Options": "1=Q6MHCP-Administered Injectable(Maintenance Dosing),2=Q6MHCP-Administered Injectable(Maintenance Dosing),3=Q6MHCP-Administered Injectable(Maintenance Dosing),4=Q6MHCP-Administered Injectable(Maintenance Dosing)"
  },
  {
    "Column": "Leqvio_MOA_5",
    "Description": "Leqvio_MOA_5: Leqvio_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor,3=PCSK9 inhibitor,4=PCSK9 inhibitor"
  },
  {
    "Column": "Leqvio_Indication_5",
    "Description": "Leqvio_Indication_5: Leqvio_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,3=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,4=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of CV death (including CHD death"
  },
  {
    "Column": "Praluent_PatientType_5",
    "Description": "Praluent_PatientType_5: Praluent_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Praluent_Efficacy_5",
    "Description": "Praluent_Efficacy_5: Praluent_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~50% In another clinical study of adults with HoFH, PRALUENT lowered bad choleste,2="
  },
  {
    "Column": "Praluent_Dosing_5",
    "Description": "Praluent_Dosing_5: Praluent_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2="
  },
  {
    "Column": "Praluent_MOA_5",
    "Description": "Praluent_MOA_5: Praluent_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Praluent_Indication_5",
    "Description": "Praluent_Indication_5: Praluent_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Repatha_PatientType_5",
    "Description": "Repatha_PatientType_5: Repatha_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Repatha_Efficacy_5",
    "Description": "Repatha_Efficacy_5: Repatha_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,"
  },
  {
    "Column": "Repatha_Dosing_5",
    "Description": "Repatha_Dosing_5: Repatha_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2=Q2WPatient self-administered Injectable"
  },
  {
    "Column": "Repatha_MOA_5",
    "Description": "Repatha_MOA_5: Repatha_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor"
  },
  {
    "Column": "Repatha_Indication_5",
    "Description": "Repatha_Indication_5: Repatha_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: Indicated to reduce risk of CV events in patients with clinical ASCVD (without a prior CV"
  },
  {
    "Column": "Product_W_PatientType_5",
    "Description": "Product_W_PatientType_5: Product_W_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_W_Efficacy_5",
    "Description": "Product_W_Efficacy_5: Product_W_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~49% Mean % change in Lp(a) from Baseline to end of study is ~63%,2="
  },
  {
    "Column": "Product_W_Dosing_5",
    "Description": "Product_W_Dosing_5: Product_W_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2="
  },
  {
    "Column": "Product_W_MOA_5",
    "Description": "Product_W_MOA_5: Product_W_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor plus selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Product_W_Indication_5",
    "Description": "Product_W_Indication_5: Product_W_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2="
  },
  {
    "Column": "Product_X_PatientType_5",
    "Description": "Product_X_PatientType_5: Product_X_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_X_Efficacy_5",
    "Description": "Product_X_Efficacy_5: Product_X_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to Day 365 is ~33% Mean % change in Lp(a) from Baseline to end of study is ~55% In Es,2=Mean % change in LDL from Baseline to end of study is ~45% Mean % change in Lp(a) from Baseline to end of study is ~55%"
  },
  {
    "Column": "Product_X_Dosing_5",
    "Description": "Product_X_Dosing_5: Product_X_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2=QDnon-fasting oral"
  },
  {
    "Column": "Product_X_MOA_5",
    "Description": "Product_X_MOA_5: Product_X_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor,2=Cholesterol ester transfer protein (CETP) inhibitor"
  },
  {
    "Column": "Product_X_Indication_5",
    "Description": "Product_X_Indication_5: Product_X_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Y_PatientType_5",
    "Description": "Product_Y_PatientType_5: Product_Y_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Y_Efficacy_5",
    "Description": "Product_Y_Efficacy_5: Product_Y_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60%,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: Primary Endpoint: 20% RRR on MACE+ (including MA"
  },
  {
    "Column": "Product_Y_Dosing_5",
    "Description": "Product_Y_Dosing_5: Product_Y_Dosing",
    "Answer_Options": "1=QDfasting oral,2=QDfasting oral"
  },
  {
    "Column": "Product_Y_MOA_5",
    "Description": "Product_Y_MOA_5: Product_Y_MOA",
    "Answer_Options": "1=Small molecule PCSK9 inhibitor,2=Small molecule PCSK9 inhibitor"
  },
  {
    "Column": "Product_Y_Indication_5",
    "Description": "Product_Y_Indication_5: Product_Y_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Z_PatientType_5",
    "Description": "Product_Z_PatientType_5: Product_Z_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Z_Efficacy_5",
    "Description": "Product_Z_Efficacy_5: Product_Z_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~65%,2="
  },
  {
    "Column": "Product_Z_Dosing_5",
    "Description": "Product_Z_Dosing_5: Product_Z_Dosing",
    "Answer_Options": "1=QM Patient Self-administered Injectable,2="
  },
  {
    "Column": "Product_Z_MOA_5",
    "Description": "Product_Z_MOA_5: Product_Z_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Product_Z_Indication_5",
    "Description": "Product_Z_Indication_5: Product_Z_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, t,2="
  },
  {
    "Column": "Nexlitol_PatientType_5",
    "Description": "Nexlitol_PatientType_5: Nexlitol_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Nexlitol_Efficacy_5",
    "Description": "Nexlitol_Efficacy_5: Nexlitol_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Nexlitol_Dosing_5",
    "Description": "Nexlitol_Dosing_5: Nexlitol_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Nexlitol_MOA_5",
    "Description": "Nexlitol_MOA_5: Nexlitol_MOA",
    "Answer_Options": "1=ACL inhibitor,2="
  },
  {
    "Column": "Nexlitol_Indication_5",
    "Description": "Nexlitol_Indication_5: Nexlitol_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Zetia_PatientType_5",
    "Description": "Zetia_PatientType_5: Zetia_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Zetia_Efficacy_5",
    "Description": "Zetia_Efficacy_5: Zetia_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Zetia_Dosing_5",
    "Description": "Zetia_Dosing_5: Zetia_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Zetia_MOA_5",
    "Description": "Zetia_MOA_5: Zetia_MOA",
    "Answer_Options": "1=selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Zetia_Indication_5",
    "Description": "Zetia_Indication_5: Zetia_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Other_Therapies_PatientType_5",
    "Description": "Other_Therapies_PatientType_5: Other_Therapies_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Other_Therapies_Efficacy_5",
    "Description": "Other_Therapies_Efficacy_5: Other_Therapies_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Dosing_5",
    "Description": "Other_Therapies_Dosing_5: Other_Therapies_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_MOA_5",
    "Description": "Other_Therapies_MOA_5: Other_Therapies_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Indication_5",
    "Description": "Other_Therapies_Indication_5: Other_Therapies_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_PatientType_5",
    "Description": "No_Addl_Therap_PatientType_5: No_Addl_Therap_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "No_Addl_Therap_Efficacy_5",
    "Description": "No_Addl_Therap_Efficacy_5: No_Addl_Therap_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Dosing_5",
    "Description": "No_Addl_Therap_Dosing_5: No_Addl_Therap_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_MOA_5",
    "Description": "No_Addl_Therap_MOA_5: No_Addl_Therap_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Indication_5",
    "Description": "No_Addl_Therap_Indication_5: No_Addl_Therap_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "B3_5r1c1",
    "Description": "B3_5r1c1: Leqvio - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_5"
  },
  {
    "Column": "B3_5r2c1",
    "Description": "B3_5r2c1: PRALUENT - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_5"
  },
  {
    "Column": "B3_5r3c1",
    "Description": "B3_5r3c1: REPATHA - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_5"
  },
  {
    "Column": "B3_5r4c1",
    "Description": "B3_5r4c1: Product W - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_5"
  },
  {
    "Column": "B3_5r5c1",
    "Description": "B3_5r5c1: Product X - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_5"
  },
  {
    "Column": "B3_5r6c1",
    "Description": "B3_5r6c1: Product Y - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_5"
  },
  {
    "Column": "B3_5r7c1",
    "Description": "B3_5r7c1: Product Z - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_5"
  },
  {
    "Column": "B3_5r8c1",
    "Description": "B3_5r8c1: NEXLETOL / NEXLIZET - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_5"
  },
  {
    "Column": "B3_5r9c1",
    "Description": "B3_5r9c1: ZETIA (ezetimibe) - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_5"
  },
  {
    "Column": "B3_5r10c1",
    "Description": "B3_5r10c1: Other treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_5"
  },
  {
    "Column": "B3_5r11c1",
    "Description": "B3_5r11c1: No additional treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_5"
  },
  {
    "Column": "B3_5r1c2",
    "Description": "B3_5r1c2: Leqvio - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_5"
  },
  {
    "Column": "B3_5r2c2",
    "Description": "B3_5r2c2: PRALUENT - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_5"
  },
  {
    "Column": "B3_5r3c2",
    "Description": "B3_5r3c2: REPATHA - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_5"
  },
  {
    "Column": "B3_5r4c2",
    "Description": "B3_5r4c2: Product W - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_5"
  },
  {
    "Column": "B3_5r5c2",
    "Description": "B3_5r5c2: Product X - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_5"
  },
  {
    "Column": "B3_5r6c2",
    "Description": "B3_5r6c2: Product Y - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_5"
  },
  {
    "Column": "B3_5r7c2",
    "Description": "B3_5r7c2: Product Z - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_5"
  },
  {
    "Column": "B3_5r8c2",
    "Description": "B3_5r8c2: NEXLETOL / NEXLIZET - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_5"
  },
  {
    "Column": "B3_5r9c2",
    "Description": "B3_5r9c2: ZETIA (ezetimibe) - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_5"
  },
  {
    "Column": "B3_5r10c2",
    "Description": "B3_5r10c2: Other treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_5"
  },
  {
    "Column": "B3_5r11c2",
    "Description": "B3_5r11c2: No additional treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_5"
  },
  {
    "Column": "B3_5r1dum1",
    "Description": "B3_5r1dum1: Leqvio - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r2dum1",
    "Description": "B3_5r2dum1: PRALUENT - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r3dum1",
    "Description": "B3_5r3dum1: REPATHA - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r4dum1",
    "Description": "B3_5r4dum1: Product W - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r5dum1",
    "Description": "B3_5r5dum1: Product X - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r6dum1",
    "Description": "B3_5r6dum1: Product Y - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r7dum1",
    "Description": "B3_5r7dum1: Product Z - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r8dum1",
    "Description": "B3_5r8dum1: NEXLETOL / NEXLIZET - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r9dum1",
    "Description": "B3_5r9dum1: ZETIA (ezetimibe) - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r10dum1",
    "Description": "B3_5r10dum1: Other treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r11dum1",
    "Description": "B3_5r11dum1: No additional treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r1dum2",
    "Description": "B3_5r1dum2: Leqvio - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r2dum2",
    "Description": "B3_5r2dum2: PRALUENT - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r3dum2",
    "Description": "B3_5r3dum2: REPATHA - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r4dum2",
    "Description": "B3_5r4dum2: Product W - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r5dum2",
    "Description": "B3_5r5dum2: Product X - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r6dum2",
    "Description": "B3_5r6dum2: Product Y - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r7dum2",
    "Description": "B3_5r7dum2: Product Z - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r8dum2",
    "Description": "B3_5r8dum2: NEXLETOL / NEXLIZET - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r9dum2",
    "Description": "B3_5r9dum2: ZETIA (ezetimibe) - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r10dum2",
    "Description": "B3_5r10dum2: Other treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r11dum2",
    "Description": "B3_5r11dum2: No additional treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r1dum3",
    "Description": "B3_5r1dum3: Leqvio - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r2dum3",
    "Description": "B3_5r2dum3: PRALUENT - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r3dum3",
    "Description": "B3_5r3dum3: REPATHA - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r4dum3",
    "Description": "B3_5r4dum3: Product W - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r5dum3",
    "Description": "B3_5r5dum3: Product X - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r6dum3",
    "Description": "B3_5r6dum3: Product Y - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r7dum3",
    "Description": "B3_5r7dum3: Product Z - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r8dum3",
    "Description": "B3_5r8dum3: NEXLETOL / NEXLIZET - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r9dum3",
    "Description": "B3_5r9dum3: ZETIA (ezetimibe) - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r10dum3",
    "Description": "B3_5r10dum3: Other treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r11dum3",
    "Description": "B3_5r11dum3: No additional treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r1dum4",
    "Description": "B3_5r1dum4: Leqvio - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r2dum4",
    "Description": "B3_5r2dum4: PRALUENT - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r3dum4",
    "Description": "B3_5r3dum4: REPATHA - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r4dum4",
    "Description": "B3_5r4dum4: Product W - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r5dum4",
    "Description": "B3_5r5dum4: Product X - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r6dum4",
    "Description": "B3_5r6dum4: Product Y - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r7dum4",
    "Description": "B3_5r7dum4: Product Z - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r8dum4",
    "Description": "B3_5r8dum4: NEXLETOL / NEXLIZET - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r9dum4",
    "Description": "B3_5r9dum4: ZETIA (ezetimibe) - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r10dum4",
    "Description": "B3_5r10dum4: Other treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r11dum4",
    "Description": "B3_5r11dum4: No additional treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r1dum5",
    "Description": "B3_5r1dum5: Leqvio - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r2dum5",
    "Description": "B3_5r2dum5: PRALUENT - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r3dum5",
    "Description": "B3_5r3dum5: REPATHA - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r4dum5",
    "Description": "B3_5r4dum5: Product W - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r5dum5",
    "Description": "B3_5r5dum5: Product X - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r6dum5",
    "Description": "B3_5r6dum5: Product Y - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r7dum5",
    "Description": "B3_5r7dum5: Product Z - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r8dum5",
    "Description": "B3_5r8dum5: NEXLETOL / NEXLIZET - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r9dum5",
    "Description": "B3_5r9dum5: ZETIA (ezetimibe) - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r10dum5",
    "Description": "B3_5r10dum5: Other treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_5r11dum5",
    "Description": "B3_5r11dum5: No additional treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "hPatientType_6",
    "Description": "hPatientType_6: PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_PatientType_6",
    "Description": "Leqvio_PatientType_6: Leqvio_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_Efficacy_6",
    "Description": "Leqvio_Efficacy_6: Leqvio_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~50%80% of patients persistent to treatment at 12m, compared to 57% on,2=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,3=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,4=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o"
  },
  {
    "Column": "Leqvio_Dosing_6",
    "Description": "Leqvio_Dosing_6: Leqvio_Dosing",
    "Answer_Options": "1=Q6MHCP-Administered Injectable(Maintenance Dosing),2=Q6MHCP-Administered Injectable(Maintenance Dosing),3=Q6MHCP-Administered Injectable(Maintenance Dosing),4=Q6MHCP-Administered Injectable(Maintenance Dosing)"
  },
  {
    "Column": "Leqvio_MOA_6",
    "Description": "Leqvio_MOA_6: Leqvio_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor,3=PCSK9 inhibitor,4=PCSK9 inhibitor"
  },
  {
    "Column": "Leqvio_Indication_6",
    "Description": "Leqvio_Indication_6: Leqvio_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,3=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,4=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of CV death (including CHD death"
  },
  {
    "Column": "Praluent_PatientType_6",
    "Description": "Praluent_PatientType_6: Praluent_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Praluent_Efficacy_6",
    "Description": "Praluent_Efficacy_6: Praluent_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~50% In another clinical study of adults with HoFH, PRALUENT lowered bad choleste,2="
  },
  {
    "Column": "Praluent_Dosing_6",
    "Description": "Praluent_Dosing_6: Praluent_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2="
  },
  {
    "Column": "Praluent_MOA_6",
    "Description": "Praluent_MOA_6: Praluent_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Praluent_Indication_6",
    "Description": "Praluent_Indication_6: Praluent_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Repatha_PatientType_6",
    "Description": "Repatha_PatientType_6: Repatha_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Repatha_Efficacy_6",
    "Description": "Repatha_Efficacy_6: Repatha_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,"
  },
  {
    "Column": "Repatha_Dosing_6",
    "Description": "Repatha_Dosing_6: Repatha_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2=Q2WPatient self-administered Injectable"
  },
  {
    "Column": "Repatha_MOA_6",
    "Description": "Repatha_MOA_6: Repatha_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor"
  },
  {
    "Column": "Repatha_Indication_6",
    "Description": "Repatha_Indication_6: Repatha_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: Indicated to reduce risk of CV events in patients with clinical ASCVD (without a prior CV"
  },
  {
    "Column": "Product_W_PatientType_6",
    "Description": "Product_W_PatientType_6: Product_W_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_W_Efficacy_6",
    "Description": "Product_W_Efficacy_6: Product_W_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~49% Mean % change in Lp(a) from Baseline to end of study is ~63%,2="
  },
  {
    "Column": "Product_W_Dosing_6",
    "Description": "Product_W_Dosing_6: Product_W_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2="
  },
  {
    "Column": "Product_W_MOA_6",
    "Description": "Product_W_MOA_6: Product_W_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor plus selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Product_W_Indication_6",
    "Description": "Product_W_Indication_6: Product_W_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2="
  },
  {
    "Column": "Product_X_PatientType_6",
    "Description": "Product_X_PatientType_6: Product_X_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_X_Efficacy_6",
    "Description": "Product_X_Efficacy_6: Product_X_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to Day 365 is ~33% Mean % change in Lp(a) from Baseline to end of study is ~55% In Es,2=Mean % change in LDL from Baseline to end of study is ~45% Mean % change in Lp(a) from Baseline to end of study is ~55%"
  },
  {
    "Column": "Product_X_Dosing_6",
    "Description": "Product_X_Dosing_6: Product_X_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2=QDnon-fasting oral"
  },
  {
    "Column": "Product_X_MOA_6",
    "Description": "Product_X_MOA_6: Product_X_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor,2=Cholesterol ester transfer protein (CETP) inhibitor"
  },
  {
    "Column": "Product_X_Indication_6",
    "Description": "Product_X_Indication_6: Product_X_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Y_PatientType_6",
    "Description": "Product_Y_PatientType_6: Product_Y_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Y_Efficacy_6",
    "Description": "Product_Y_Efficacy_6: Product_Y_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60%,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: Primary Endpoint: 20% RRR on MACE+ (including MA"
  },
  {
    "Column": "Product_Y_Dosing_6",
    "Description": "Product_Y_Dosing_6: Product_Y_Dosing",
    "Answer_Options": "1=QDfasting oral,2=QDfasting oral"
  },
  {
    "Column": "Product_Y_MOA_6",
    "Description": "Product_Y_MOA_6: Product_Y_MOA",
    "Answer_Options": "1=Small molecule PCSK9 inhibitor,2=Small molecule PCSK9 inhibitor"
  },
  {
    "Column": "Product_Y_Indication_6",
    "Description": "Product_Y_Indication_6: Product_Y_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Z_PatientType_6",
    "Description": "Product_Z_PatientType_6: Product_Z_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Z_Efficacy_6",
    "Description": "Product_Z_Efficacy_6: Product_Z_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~65%,2="
  },
  {
    "Column": "Product_Z_Dosing_6",
    "Description": "Product_Z_Dosing_6: Product_Z_Dosing",
    "Answer_Options": "1=QM Patient Self-administered Injectable,2="
  },
  {
    "Column": "Product_Z_MOA_6",
    "Description": "Product_Z_MOA_6: Product_Z_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Product_Z_Indication_6",
    "Description": "Product_Z_Indication_6: Product_Z_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, t,2="
  },
  {
    "Column": "Nexlitol_PatientType_6",
    "Description": "Nexlitol_PatientType_6: Nexlitol_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Nexlitol_Efficacy_6",
    "Description": "Nexlitol_Efficacy_6: Nexlitol_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Nexlitol_Dosing_6",
    "Description": "Nexlitol_Dosing_6: Nexlitol_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Nexlitol_MOA_6",
    "Description": "Nexlitol_MOA_6: Nexlitol_MOA",
    "Answer_Options": "1=ACL inhibitor,2="
  },
  {
    "Column": "Nexlitol_Indication_6",
    "Description": "Nexlitol_Indication_6: Nexlitol_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Zetia_PatientType_6",
    "Description": "Zetia_PatientType_6: Zetia_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Zetia_Efficacy_6",
    "Description": "Zetia_Efficacy_6: Zetia_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Zetia_Dosing_6",
    "Description": "Zetia_Dosing_6: Zetia_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Zetia_MOA_6",
    "Description": "Zetia_MOA_6: Zetia_MOA",
    "Answer_Options": "1=selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Zetia_Indication_6",
    "Description": "Zetia_Indication_6: Zetia_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Other_Therapies_PatientType_6",
    "Description": "Other_Therapies_PatientType_6: Other_Therapies_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Other_Therapies_Efficacy_6",
    "Description": "Other_Therapies_Efficacy_6: Other_Therapies_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Dosing_6",
    "Description": "Other_Therapies_Dosing_6: Other_Therapies_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_MOA_6",
    "Description": "Other_Therapies_MOA_6: Other_Therapies_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Indication_6",
    "Description": "Other_Therapies_Indication_6: Other_Therapies_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_PatientType_6",
    "Description": "No_Addl_Therap_PatientType_6: No_Addl_Therap_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "No_Addl_Therap_Efficacy_6",
    "Description": "No_Addl_Therap_Efficacy_6: No_Addl_Therap_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Dosing_6",
    "Description": "No_Addl_Therap_Dosing_6: No_Addl_Therap_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_MOA_6",
    "Description": "No_Addl_Therap_MOA_6: No_Addl_Therap_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Indication_6",
    "Description": "No_Addl_Therap_Indication_6: No_Addl_Therap_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "B3_6r1c1",
    "Description": "B3_6r1c1: Leqvio - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_6"
  },
  {
    "Column": "B3_6r2c1",
    "Description": "B3_6r2c1: PRALUENT - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_6"
  },
  {
    "Column": "B3_6r3c1",
    "Description": "B3_6r3c1: REPATHA - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_6"
  },
  {
    "Column": "B3_6r4c1",
    "Description": "B3_6r4c1: Product W - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_6"
  },
  {
    "Column": "B3_6r5c1",
    "Description": "B3_6r5c1: Product X - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_6"
  },
  {
    "Column": "B3_6r6c1",
    "Description": "B3_6r6c1: Product Y - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_6"
  },
  {
    "Column": "B3_6r7c1",
    "Description": "B3_6r7c1: Product Z - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_6"
  },
  {
    "Column": "B3_6r8c1",
    "Description": "B3_6r8c1: NEXLETOL / NEXLIZET - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_6"
  },
  {
    "Column": "B3_6r9c1",
    "Description": "B3_6r9c1: ZETIA (ezetimibe) - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_6"
  },
  {
    "Column": "B3_6r10c1",
    "Description": "B3_6r10c1: Other treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_6"
  },
  {
    "Column": "B3_6r11c1",
    "Description": "B3_6r11c1: No additional treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_6"
  },
  {
    "Column": "B3_6r1c2",
    "Description": "B3_6r1c2: Leqvio - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_6"
  },
  {
    "Column": "B3_6r2c2",
    "Description": "B3_6r2c2: PRALUENT - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_6"
  },
  {
    "Column": "B3_6r3c2",
    "Description": "B3_6r3c2: REPATHA - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_6"
  },
  {
    "Column": "B3_6r4c2",
    "Description": "B3_6r4c2: Product W - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_6"
  },
  {
    "Column": "B3_6r5c2",
    "Description": "B3_6r5c2: Product X - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_6"
  },
  {
    "Column": "B3_6r6c2",
    "Description": "B3_6r6c2: Product Y - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_6"
  },
  {
    "Column": "B3_6r7c2",
    "Description": "B3_6r7c2: Product Z - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_6"
  },
  {
    "Column": "B3_6r8c2",
    "Description": "B3_6r8c2: NEXLETOL / NEXLIZET - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_6"
  },
  {
    "Column": "B3_6r9c2",
    "Description": "B3_6r9c2: ZETIA (ezetimibe) - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_6"
  },
  {
    "Column": "B3_6r10c2",
    "Description": "B3_6r10c2: Other treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_6"
  },
  {
    "Column": "B3_6r11c2",
    "Description": "B3_6r11c2: No additional treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_6"
  },
  {
    "Column": "B3_6r1dum1",
    "Description": "B3_6r1dum1: Leqvio - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r2dum1",
    "Description": "B3_6r2dum1: PRALUENT - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r3dum1",
    "Description": "B3_6r3dum1: REPATHA - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r4dum1",
    "Description": "B3_6r4dum1: Product W - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r5dum1",
    "Description": "B3_6r5dum1: Product X - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r6dum1",
    "Description": "B3_6r6dum1: Product Y - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r7dum1",
    "Description": "B3_6r7dum1: Product Z - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r8dum1",
    "Description": "B3_6r8dum1: NEXLETOL / NEXLIZET - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r9dum1",
    "Description": "B3_6r9dum1: ZETIA (ezetimibe) - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r10dum1",
    "Description": "B3_6r10dum1: Other treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r11dum1",
    "Description": "B3_6r11dum1: No additional treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r1dum2",
    "Description": "B3_6r1dum2: Leqvio - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r2dum2",
    "Description": "B3_6r2dum2: PRALUENT - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r3dum2",
    "Description": "B3_6r3dum2: REPATHA - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r4dum2",
    "Description": "B3_6r4dum2: Product W - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r5dum2",
    "Description": "B3_6r5dum2: Product X - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r6dum2",
    "Description": "B3_6r6dum2: Product Y - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r7dum2",
    "Description": "B3_6r7dum2: Product Z - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r8dum2",
    "Description": "B3_6r8dum2: NEXLETOL / NEXLIZET - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r9dum2",
    "Description": "B3_6r9dum2: ZETIA (ezetimibe) - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r10dum2",
    "Description": "B3_6r10dum2: Other treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r11dum2",
    "Description": "B3_6r11dum2: No additional treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r1dum3",
    "Description": "B3_6r1dum3: Leqvio - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r2dum3",
    "Description": "B3_6r2dum3: PRALUENT - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r3dum3",
    "Description": "B3_6r3dum3: REPATHA - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r4dum3",
    "Description": "B3_6r4dum3: Product W - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r5dum3",
    "Description": "B3_6r5dum3: Product X - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r6dum3",
    "Description": "B3_6r6dum3: Product Y - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r7dum3",
    "Description": "B3_6r7dum3: Product Z - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r8dum3",
    "Description": "B3_6r8dum3: NEXLETOL / NEXLIZET - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r9dum3",
    "Description": "B3_6r9dum3: ZETIA (ezetimibe) - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r10dum3",
    "Description": "B3_6r10dum3: Other treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r11dum3",
    "Description": "B3_6r11dum3: No additional treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r1dum4",
    "Description": "B3_6r1dum4: Leqvio - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r2dum4",
    "Description": "B3_6r2dum4: PRALUENT - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r3dum4",
    "Description": "B3_6r3dum4: REPATHA - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r4dum4",
    "Description": "B3_6r4dum4: Product W - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r5dum4",
    "Description": "B3_6r5dum4: Product X - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r6dum4",
    "Description": "B3_6r6dum4: Product Y - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r7dum4",
    "Description": "B3_6r7dum4: Product Z - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r8dum4",
    "Description": "B3_6r8dum4: NEXLETOL / NEXLIZET - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r9dum4",
    "Description": "B3_6r9dum4: ZETIA (ezetimibe) - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r10dum4",
    "Description": "B3_6r10dum4: Other treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r11dum4",
    "Description": "B3_6r11dum4: No additional treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r1dum5",
    "Description": "B3_6r1dum5: Leqvio - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r2dum5",
    "Description": "B3_6r2dum5: PRALUENT - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r3dum5",
    "Description": "B3_6r3dum5: REPATHA - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r4dum5",
    "Description": "B3_6r4dum5: Product W - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r5dum5",
    "Description": "B3_6r5dum5: Product X - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r6dum5",
    "Description": "B3_6r6dum5: Product Y - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r7dum5",
    "Description": "B3_6r7dum5: Product Z - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r8dum5",
    "Description": "B3_6r8dum5: NEXLETOL / NEXLIZET - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r9dum5",
    "Description": "B3_6r9dum5: ZETIA (ezetimibe) - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r10dum5",
    "Description": "B3_6r10dum5: Other treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_6r11dum5",
    "Description": "B3_6r11dum5: No additional treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "hPatientType_7",
    "Description": "hPatientType_7: PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_PatientType_7",
    "Description": "Leqvio_PatientType_7: Leqvio_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_Efficacy_7",
    "Description": "Leqvio_Efficacy_7: Leqvio_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~50%80% of patients persistent to treatment at 12m, compared to 57% on,2=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,3=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,4=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o"
  },
  {
    "Column": "Leqvio_Dosing_7",
    "Description": "Leqvio_Dosing_7: Leqvio_Dosing",
    "Answer_Options": "1=Q6MHCP-Administered Injectable(Maintenance Dosing),2=Q6MHCP-Administered Injectable(Maintenance Dosing),3=Q6MHCP-Administered Injectable(Maintenance Dosing),4=Q6MHCP-Administered Injectable(Maintenance Dosing)"
  },
  {
    "Column": "Leqvio_MOA_7",
    "Description": "Leqvio_MOA_7: Leqvio_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor,3=PCSK9 inhibitor,4=PCSK9 inhibitor"
  },
  {
    "Column": "Leqvio_Indication_7",
    "Description": "Leqvio_Indication_7: Leqvio_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,3=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,4=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of CV death (including CHD death"
  },
  {
    "Column": "Praluent_PatientType_7",
    "Description": "Praluent_PatientType_7: Praluent_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Praluent_Efficacy_7",
    "Description": "Praluent_Efficacy_7: Praluent_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~50% In another clinical study of adults with HoFH, PRALUENT lowered bad choleste,2="
  },
  {
    "Column": "Praluent_Dosing_7",
    "Description": "Praluent_Dosing_7: Praluent_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2="
  },
  {
    "Column": "Praluent_MOA_7",
    "Description": "Praluent_MOA_7: Praluent_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Praluent_Indication_7",
    "Description": "Praluent_Indication_7: Praluent_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Repatha_PatientType_7",
    "Description": "Repatha_PatientType_7: Repatha_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Repatha_Efficacy_7",
    "Description": "Repatha_Efficacy_7: Repatha_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,"
  },
  {
    "Column": "Repatha_Dosing_7",
    "Description": "Repatha_Dosing_7: Repatha_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2=Q2WPatient self-administered Injectable"
  },
  {
    "Column": "Repatha_MOA_7",
    "Description": "Repatha_MOA_7: Repatha_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor"
  },
  {
    "Column": "Repatha_Indication_7",
    "Description": "Repatha_Indication_7: Repatha_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: Indicated to reduce risk of CV events in patients with clinical ASCVD (without a prior CV"
  },
  {
    "Column": "Product_W_PatientType_7",
    "Description": "Product_W_PatientType_7: Product_W_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_W_Efficacy_7",
    "Description": "Product_W_Efficacy_7: Product_W_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~49% Mean % change in Lp(a) from Baseline to end of study is ~63%,2="
  },
  {
    "Column": "Product_W_Dosing_7",
    "Description": "Product_W_Dosing_7: Product_W_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2="
  },
  {
    "Column": "Product_W_MOA_7",
    "Description": "Product_W_MOA_7: Product_W_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor plus selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Product_W_Indication_7",
    "Description": "Product_W_Indication_7: Product_W_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2="
  },
  {
    "Column": "Product_X_PatientType_7",
    "Description": "Product_X_PatientType_7: Product_X_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_X_Efficacy_7",
    "Description": "Product_X_Efficacy_7: Product_X_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to Day 365 is ~33% Mean % change in Lp(a) from Baseline to end of study is ~55% In Es,2=Mean % change in LDL from Baseline to end of study is ~45% Mean % change in Lp(a) from Baseline to end of study is ~55%"
  },
  {
    "Column": "Product_X_Dosing_7",
    "Description": "Product_X_Dosing_7: Product_X_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2=QDnon-fasting oral"
  },
  {
    "Column": "Product_X_MOA_7",
    "Description": "Product_X_MOA_7: Product_X_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor,2=Cholesterol ester transfer protein (CETP) inhibitor"
  },
  {
    "Column": "Product_X_Indication_7",
    "Description": "Product_X_Indication_7: Product_X_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Y_PatientType_7",
    "Description": "Product_Y_PatientType_7: Product_Y_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Y_Efficacy_7",
    "Description": "Product_Y_Efficacy_7: Product_Y_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60%,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: Primary Endpoint: 20% RRR on MACE+ (including MA"
  },
  {
    "Column": "Product_Y_Dosing_7",
    "Description": "Product_Y_Dosing_7: Product_Y_Dosing",
    "Answer_Options": "1=QDfasting oral,2=QDfasting oral"
  },
  {
    "Column": "Product_Y_MOA_7",
    "Description": "Product_Y_MOA_7: Product_Y_MOA",
    "Answer_Options": "1=Small molecule PCSK9 inhibitor,2=Small molecule PCSK9 inhibitor"
  },
  {
    "Column": "Product_Y_Indication_7",
    "Description": "Product_Y_Indication_7: Product_Y_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Z_PatientType_7",
    "Description": "Product_Z_PatientType_7: Product_Z_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Z_Efficacy_7",
    "Description": "Product_Z_Efficacy_7: Product_Z_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~65%,2="
  },
  {
    "Column": "Product_Z_Dosing_7",
    "Description": "Product_Z_Dosing_7: Product_Z_Dosing",
    "Answer_Options": "1=QM Patient Self-administered Injectable,2="
  },
  {
    "Column": "Product_Z_MOA_7",
    "Description": "Product_Z_MOA_7: Product_Z_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Product_Z_Indication_7",
    "Description": "Product_Z_Indication_7: Product_Z_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, t,2="
  },
  {
    "Column": "Nexlitol_PatientType_7",
    "Description": "Nexlitol_PatientType_7: Nexlitol_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Nexlitol_Efficacy_7",
    "Description": "Nexlitol_Efficacy_7: Nexlitol_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Nexlitol_Dosing_7",
    "Description": "Nexlitol_Dosing_7: Nexlitol_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Nexlitol_MOA_7",
    "Description": "Nexlitol_MOA_7: Nexlitol_MOA",
    "Answer_Options": "1=ACL inhibitor,2="
  },
  {
    "Column": "Nexlitol_Indication_7",
    "Description": "Nexlitol_Indication_7: Nexlitol_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Zetia_PatientType_7",
    "Description": "Zetia_PatientType_7: Zetia_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Zetia_Efficacy_7",
    "Description": "Zetia_Efficacy_7: Zetia_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Zetia_Dosing_7",
    "Description": "Zetia_Dosing_7: Zetia_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Zetia_MOA_7",
    "Description": "Zetia_MOA_7: Zetia_MOA",
    "Answer_Options": "1=selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Zetia_Indication_7",
    "Description": "Zetia_Indication_7: Zetia_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Other_Therapies_PatientType_7",
    "Description": "Other_Therapies_PatientType_7: Other_Therapies_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Other_Therapies_Efficacy_7",
    "Description": "Other_Therapies_Efficacy_7: Other_Therapies_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Dosing_7",
    "Description": "Other_Therapies_Dosing_7: Other_Therapies_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_MOA_7",
    "Description": "Other_Therapies_MOA_7: Other_Therapies_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Indication_7",
    "Description": "Other_Therapies_Indication_7: Other_Therapies_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_PatientType_7",
    "Description": "No_Addl_Therap_PatientType_7: No_Addl_Therap_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "No_Addl_Therap_Efficacy_7",
    "Description": "No_Addl_Therap_Efficacy_7: No_Addl_Therap_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Dosing_7",
    "Description": "No_Addl_Therap_Dosing_7: No_Addl_Therap_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_MOA_7",
    "Description": "No_Addl_Therap_MOA_7: No_Addl_Therap_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Indication_7",
    "Description": "No_Addl_Therap_Indication_7: No_Addl_Therap_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "B3_7r1c1",
    "Description": "B3_7r1c1: Leqvio - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_7"
  },
  {
    "Column": "B3_7r2c1",
    "Description": "B3_7r2c1: PRALUENT - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_7"
  },
  {
    "Column": "B3_7r3c1",
    "Description": "B3_7r3c1: REPATHA - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_7"
  },
  {
    "Column": "B3_7r4c1",
    "Description": "B3_7r4c1: Product W - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_7"
  },
  {
    "Column": "B3_7r5c1",
    "Description": "B3_7r5c1: Product X - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_7"
  },
  {
    "Column": "B3_7r6c1",
    "Description": "B3_7r6c1: Product Y - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_7"
  },
  {
    "Column": "B3_7r7c1",
    "Description": "B3_7r7c1: Product Z - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_7"
  },
  {
    "Column": "B3_7r8c1",
    "Description": "B3_7r8c1: NEXLETOL / NEXLIZET - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_7"
  },
  {
    "Column": "B3_7r9c1",
    "Description": "B3_7r9c1: ZETIA (ezetimibe) - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_7"
  },
  {
    "Column": "B3_7r10c1",
    "Description": "B3_7r10c1: Other treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_7"
  },
  {
    "Column": "B3_7r11c1",
    "Description": "B3_7r11c1: No additional treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_7"
  },
  {
    "Column": "B3_7r1c2",
    "Description": "B3_7r1c2: Leqvio - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_7"
  },
  {
    "Column": "B3_7r2c2",
    "Description": "B3_7r2c2: PRALUENT - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_7"
  },
  {
    "Column": "B3_7r3c2",
    "Description": "B3_7r3c2: REPATHA - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_7"
  },
  {
    "Column": "B3_7r4c2",
    "Description": "B3_7r4c2: Product W - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_7"
  },
  {
    "Column": "B3_7r5c2",
    "Description": "B3_7r5c2: Product X - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_7"
  },
  {
    "Column": "B3_7r6c2",
    "Description": "B3_7r6c2: Product Y - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_7"
  },
  {
    "Column": "B3_7r7c2",
    "Description": "B3_7r7c2: Product Z - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_7"
  },
  {
    "Column": "B3_7r8c2",
    "Description": "B3_7r8c2: NEXLETOL / NEXLIZET - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_7"
  },
  {
    "Column": "B3_7r9c2",
    "Description": "B3_7r9c2: ZETIA (ezetimibe) - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_7"
  },
  {
    "Column": "B3_7r10c2",
    "Description": "B3_7r10c2: Other treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_7"
  },
  {
    "Column": "B3_7r11c2",
    "Description": "B3_7r11c2: No additional treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_7"
  },
  {
    "Column": "B3_7r1dum1",
    "Description": "B3_7r1dum1: Leqvio - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r2dum1",
    "Description": "B3_7r2dum1: PRALUENT - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r3dum1",
    "Description": "B3_7r3dum1: REPATHA - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r4dum1",
    "Description": "B3_7r4dum1: Product W - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r5dum1",
    "Description": "B3_7r5dum1: Product X - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r6dum1",
    "Description": "B3_7r6dum1: Product Y - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r7dum1",
    "Description": "B3_7r7dum1: Product Z - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r8dum1",
    "Description": "B3_7r8dum1: NEXLETOL / NEXLIZET - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r9dum1",
    "Description": "B3_7r9dum1: ZETIA (ezetimibe) - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r10dum1",
    "Description": "B3_7r10dum1: Other treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r11dum1",
    "Description": "B3_7r11dum1: No additional treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r1dum2",
    "Description": "B3_7r1dum2: Leqvio - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r2dum2",
    "Description": "B3_7r2dum2: PRALUENT - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r3dum2",
    "Description": "B3_7r3dum2: REPATHA - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r4dum2",
    "Description": "B3_7r4dum2: Product W - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r5dum2",
    "Description": "B3_7r5dum2: Product X - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r6dum2",
    "Description": "B3_7r6dum2: Product Y - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r7dum2",
    "Description": "B3_7r7dum2: Product Z - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r8dum2",
    "Description": "B3_7r8dum2: NEXLETOL / NEXLIZET - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r9dum2",
    "Description": "B3_7r9dum2: ZETIA (ezetimibe) - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r10dum2",
    "Description": "B3_7r10dum2: Other treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r11dum2",
    "Description": "B3_7r11dum2: No additional treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r1dum3",
    "Description": "B3_7r1dum3: Leqvio - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r2dum3",
    "Description": "B3_7r2dum3: PRALUENT - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r3dum3",
    "Description": "B3_7r3dum3: REPATHA - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r4dum3",
    "Description": "B3_7r4dum3: Product W - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r5dum3",
    "Description": "B3_7r5dum3: Product X - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r6dum3",
    "Description": "B3_7r6dum3: Product Y - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r7dum3",
    "Description": "B3_7r7dum3: Product Z - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r8dum3",
    "Description": "B3_7r8dum3: NEXLETOL / NEXLIZET - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r9dum3",
    "Description": "B3_7r9dum3: ZETIA (ezetimibe) - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r10dum3",
    "Description": "B3_7r10dum3: Other treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r11dum3",
    "Description": "B3_7r11dum3: No additional treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r1dum4",
    "Description": "B3_7r1dum4: Leqvio - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r2dum4",
    "Description": "B3_7r2dum4: PRALUENT - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r3dum4",
    "Description": "B3_7r3dum4: REPATHA - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r4dum4",
    "Description": "B3_7r4dum4: Product W - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r5dum4",
    "Description": "B3_7r5dum4: Product X - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r6dum4",
    "Description": "B3_7r6dum4: Product Y - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r7dum4",
    "Description": "B3_7r7dum4: Product Z - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r8dum4",
    "Description": "B3_7r8dum4: NEXLETOL / NEXLIZET - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r9dum4",
    "Description": "B3_7r9dum4: ZETIA (ezetimibe) - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r10dum4",
    "Description": "B3_7r10dum4: Other treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r11dum4",
    "Description": "B3_7r11dum4: No additional treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r1dum5",
    "Description": "B3_7r1dum5: Leqvio - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r2dum5",
    "Description": "B3_7r2dum5: PRALUENT - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r3dum5",
    "Description": "B3_7r3dum5: REPATHA - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r4dum5",
    "Description": "B3_7r4dum5: Product W - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r5dum5",
    "Description": "B3_7r5dum5: Product X - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r6dum5",
    "Description": "B3_7r6dum5: Product Y - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r7dum5",
    "Description": "B3_7r7dum5: Product Z - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r8dum5",
    "Description": "B3_7r8dum5: NEXLETOL / NEXLIZET - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r9dum5",
    "Description": "B3_7r9dum5: ZETIA (ezetimibe) - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r10dum5",
    "Description": "B3_7r10dum5: Other treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_7r11dum5",
    "Description": "B3_7r11dum5: No additional treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "hPatientType_8",
    "Description": "hPatientType_8: PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_PatientType_8",
    "Description": "Leqvio_PatientType_8: Leqvio_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_Efficacy_8",
    "Description": "Leqvio_Efficacy_8: Leqvio_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~50%80% of patients persistent to treatment at 12m, compared to 57% on,2=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,3=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,4=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o"
  },
  {
    "Column": "Leqvio_Dosing_8",
    "Description": "Leqvio_Dosing_8: Leqvio_Dosing",
    "Answer_Options": "1=Q6MHCP-Administered Injectable(Maintenance Dosing),2=Q6MHCP-Administered Injectable(Maintenance Dosing),3=Q6MHCP-Administered Injectable(Maintenance Dosing),4=Q6MHCP-Administered Injectable(Maintenance Dosing)"
  },
  {
    "Column": "Leqvio_MOA_8",
    "Description": "Leqvio_MOA_8: Leqvio_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor,3=PCSK9 inhibitor,4=PCSK9 inhibitor"
  },
  {
    "Column": "Leqvio_Indication_8",
    "Description": "Leqvio_Indication_8: Leqvio_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,3=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,4=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of CV death (including CHD death"
  },
  {
    "Column": "Praluent_PatientType_8",
    "Description": "Praluent_PatientType_8: Praluent_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Praluent_Efficacy_8",
    "Description": "Praluent_Efficacy_8: Praluent_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~50% In another clinical study of adults with HoFH, PRALUENT lowered bad choleste,2="
  },
  {
    "Column": "Praluent_Dosing_8",
    "Description": "Praluent_Dosing_8: Praluent_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2="
  },
  {
    "Column": "Praluent_MOA_8",
    "Description": "Praluent_MOA_8: Praluent_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Praluent_Indication_8",
    "Description": "Praluent_Indication_8: Praluent_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Repatha_PatientType_8",
    "Description": "Repatha_PatientType_8: Repatha_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Repatha_Efficacy_8",
    "Description": "Repatha_Efficacy_8: Repatha_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,"
  },
  {
    "Column": "Repatha_Dosing_8",
    "Description": "Repatha_Dosing_8: Repatha_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2=Q2WPatient self-administered Injectable"
  },
  {
    "Column": "Repatha_MOA_8",
    "Description": "Repatha_MOA_8: Repatha_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor"
  },
  {
    "Column": "Repatha_Indication_8",
    "Description": "Repatha_Indication_8: Repatha_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: Indicated to reduce risk of CV events in patients with clinical ASCVD (without a prior CV"
  },
  {
    "Column": "Product_W_PatientType_8",
    "Description": "Product_W_PatientType_8: Product_W_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_W_Efficacy_8",
    "Description": "Product_W_Efficacy_8: Product_W_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~49% Mean % change in Lp(a) from Baseline to end of study is ~63%,2="
  },
  {
    "Column": "Product_W_Dosing_8",
    "Description": "Product_W_Dosing_8: Product_W_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2="
  },
  {
    "Column": "Product_W_MOA_8",
    "Description": "Product_W_MOA_8: Product_W_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor plus selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Product_W_Indication_8",
    "Description": "Product_W_Indication_8: Product_W_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2="
  },
  {
    "Column": "Product_X_PatientType_8",
    "Description": "Product_X_PatientType_8: Product_X_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_X_Efficacy_8",
    "Description": "Product_X_Efficacy_8: Product_X_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to Day 365 is ~33% Mean % change in Lp(a) from Baseline to end of study is ~55% In Es,2=Mean % change in LDL from Baseline to end of study is ~45% Mean % change in Lp(a) from Baseline to end of study is ~55%"
  },
  {
    "Column": "Product_X_Dosing_8",
    "Description": "Product_X_Dosing_8: Product_X_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2=QDnon-fasting oral"
  },
  {
    "Column": "Product_X_MOA_8",
    "Description": "Product_X_MOA_8: Product_X_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor,2=Cholesterol ester transfer protein (CETP) inhibitor"
  },
  {
    "Column": "Product_X_Indication_8",
    "Description": "Product_X_Indication_8: Product_X_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Y_PatientType_8",
    "Description": "Product_Y_PatientType_8: Product_Y_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Y_Efficacy_8",
    "Description": "Product_Y_Efficacy_8: Product_Y_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60%,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: Primary Endpoint: 20% RRR on MACE+ (including MA"
  },
  {
    "Column": "Product_Y_Dosing_8",
    "Description": "Product_Y_Dosing_8: Product_Y_Dosing",
    "Answer_Options": "1=QDfasting oral,2=QDfasting oral"
  },
  {
    "Column": "Product_Y_MOA_8",
    "Description": "Product_Y_MOA_8: Product_Y_MOA",
    "Answer_Options": "1=Small molecule PCSK9 inhibitor,2=Small molecule PCSK9 inhibitor"
  },
  {
    "Column": "Product_Y_Indication_8",
    "Description": "Product_Y_Indication_8: Product_Y_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Z_PatientType_8",
    "Description": "Product_Z_PatientType_8: Product_Z_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Z_Efficacy_8",
    "Description": "Product_Z_Efficacy_8: Product_Z_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~65%,2="
  },
  {
    "Column": "Product_Z_Dosing_8",
    "Description": "Product_Z_Dosing_8: Product_Z_Dosing",
    "Answer_Options": "1=QM Patient Self-administered Injectable,2="
  },
  {
    "Column": "Product_Z_MOA_8",
    "Description": "Product_Z_MOA_8: Product_Z_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Product_Z_Indication_8",
    "Description": "Product_Z_Indication_8: Product_Z_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, t,2="
  },
  {
    "Column": "Nexlitol_PatientType_8",
    "Description": "Nexlitol_PatientType_8: Nexlitol_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Nexlitol_Efficacy_8",
    "Description": "Nexlitol_Efficacy_8: Nexlitol_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Nexlitol_Dosing_8",
    "Description": "Nexlitol_Dosing_8: Nexlitol_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Nexlitol_MOA_8",
    "Description": "Nexlitol_MOA_8: Nexlitol_MOA",
    "Answer_Options": "1=ACL inhibitor,2="
  },
  {
    "Column": "Nexlitol_Indication_8",
    "Description": "Nexlitol_Indication_8: Nexlitol_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Zetia_PatientType_8",
    "Description": "Zetia_PatientType_8: Zetia_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Zetia_Efficacy_8",
    "Description": "Zetia_Efficacy_8: Zetia_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Zetia_Dosing_8",
    "Description": "Zetia_Dosing_8: Zetia_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Zetia_MOA_8",
    "Description": "Zetia_MOA_8: Zetia_MOA",
    "Answer_Options": "1=selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Zetia_Indication_8",
    "Description": "Zetia_Indication_8: Zetia_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Other_Therapies_PatientType_8",
    "Description": "Other_Therapies_PatientType_8: Other_Therapies_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Other_Therapies_Efficacy_8",
    "Description": "Other_Therapies_Efficacy_8: Other_Therapies_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Dosing_8",
    "Description": "Other_Therapies_Dosing_8: Other_Therapies_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_MOA_8",
    "Description": "Other_Therapies_MOA_8: Other_Therapies_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Indication_8",
    "Description": "Other_Therapies_Indication_8: Other_Therapies_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_PatientType_8",
    "Description": "No_Addl_Therap_PatientType_8: No_Addl_Therap_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "No_Addl_Therap_Efficacy_8",
    "Description": "No_Addl_Therap_Efficacy_8: No_Addl_Therap_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Dosing_8",
    "Description": "No_Addl_Therap_Dosing_8: No_Addl_Therap_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_MOA_8",
    "Description": "No_Addl_Therap_MOA_8: No_Addl_Therap_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Indication_8",
    "Description": "No_Addl_Therap_Indication_8: No_Addl_Therap_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "B3_8r1c1",
    "Description": "B3_8r1c1: Leqvio - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_8"
  },
  {
    "Column": "B3_8r2c1",
    "Description": "B3_8r2c1: PRALUENT - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_8"
  },
  {
    "Column": "B3_8r3c1",
    "Description": "B3_8r3c1: REPATHA - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_8"
  },
  {
    "Column": "B3_8r4c1",
    "Description": "B3_8r4c1: Product W - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_8"
  },
  {
    "Column": "B3_8r5c1",
    "Description": "B3_8r5c1: Product X - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_8"
  },
  {
    "Column": "B3_8r6c1",
    "Description": "B3_8r6c1: Product Y - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_8"
  },
  {
    "Column": "B3_8r7c1",
    "Description": "B3_8r7c1: Product Z - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_8"
  },
  {
    "Column": "B3_8r8c1",
    "Description": "B3_8r8c1: NEXLETOL / NEXLIZET - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_8"
  },
  {
    "Column": "B3_8r9c1",
    "Description": "B3_8r9c1: ZETIA (ezetimibe) - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_8"
  },
  {
    "Column": "B3_8r10c1",
    "Description": "B3_8r10c1: Other treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_8"
  },
  {
    "Column": "B3_8r11c1",
    "Description": "B3_8r11c1: No additional treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_8"
  },
  {
    "Column": "B3_8r1c2",
    "Description": "B3_8r1c2: Leqvio - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_8"
  },
  {
    "Column": "B3_8r2c2",
    "Description": "B3_8r2c2: PRALUENT - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_8"
  },
  {
    "Column": "B3_8r3c2",
    "Description": "B3_8r3c2: REPATHA - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_8"
  },
  {
    "Column": "B3_8r4c2",
    "Description": "B3_8r4c2: Product W - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_8"
  },
  {
    "Column": "B3_8r5c2",
    "Description": "B3_8r5c2: Product X - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_8"
  },
  {
    "Column": "B3_8r6c2",
    "Description": "B3_8r6c2: Product Y - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_8"
  },
  {
    "Column": "B3_8r7c2",
    "Description": "B3_8r7c2: Product Z - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_8"
  },
  {
    "Column": "B3_8r8c2",
    "Description": "B3_8r8c2: NEXLETOL / NEXLIZET - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_8"
  },
  {
    "Column": "B3_8r9c2",
    "Description": "B3_8r9c2: ZETIA (ezetimibe) - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_8"
  },
  {
    "Column": "B3_8r10c2",
    "Description": "B3_8r10c2: Other treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_8"
  },
  {
    "Column": "B3_8r11c2",
    "Description": "B3_8r11c2: No additional treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_8"
  },
  {
    "Column": "B3_8r1dum1",
    "Description": "B3_8r1dum1: Leqvio - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r2dum1",
    "Description": "B3_8r2dum1: PRALUENT - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r3dum1",
    "Description": "B3_8r3dum1: REPATHA - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r4dum1",
    "Description": "B3_8r4dum1: Product W - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r5dum1",
    "Description": "B3_8r5dum1: Product X - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r6dum1",
    "Description": "B3_8r6dum1: Product Y - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r7dum1",
    "Description": "B3_8r7dum1: Product Z - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r8dum1",
    "Description": "B3_8r8dum1: NEXLETOL / NEXLIZET - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r9dum1",
    "Description": "B3_8r9dum1: ZETIA (ezetimibe) - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r10dum1",
    "Description": "B3_8r10dum1: Other treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r11dum1",
    "Description": "B3_8r11dum1: No additional treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r1dum2",
    "Description": "B3_8r1dum2: Leqvio - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r2dum2",
    "Description": "B3_8r2dum2: PRALUENT - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r3dum2",
    "Description": "B3_8r3dum2: REPATHA - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r4dum2",
    "Description": "B3_8r4dum2: Product W - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r5dum2",
    "Description": "B3_8r5dum2: Product X - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r6dum2",
    "Description": "B3_8r6dum2: Product Y - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r7dum2",
    "Description": "B3_8r7dum2: Product Z - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r8dum2",
    "Description": "B3_8r8dum2: NEXLETOL / NEXLIZET - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r9dum2",
    "Description": "B3_8r9dum2: ZETIA (ezetimibe) - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r10dum2",
    "Description": "B3_8r10dum2: Other treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r11dum2",
    "Description": "B3_8r11dum2: No additional treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r1dum3",
    "Description": "B3_8r1dum3: Leqvio - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r2dum3",
    "Description": "B3_8r2dum3: PRALUENT - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r3dum3",
    "Description": "B3_8r3dum3: REPATHA - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r4dum3",
    "Description": "B3_8r4dum3: Product W - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r5dum3",
    "Description": "B3_8r5dum3: Product X - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r6dum3",
    "Description": "B3_8r6dum3: Product Y - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r7dum3",
    "Description": "B3_8r7dum3: Product Z - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r8dum3",
    "Description": "B3_8r8dum3: NEXLETOL / NEXLIZET - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r9dum3",
    "Description": "B3_8r9dum3: ZETIA (ezetimibe) - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r10dum3",
    "Description": "B3_8r10dum3: Other treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r11dum3",
    "Description": "B3_8r11dum3: No additional treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r1dum4",
    "Description": "B3_8r1dum4: Leqvio - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r2dum4",
    "Description": "B3_8r2dum4: PRALUENT - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r3dum4",
    "Description": "B3_8r3dum4: REPATHA - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r4dum4",
    "Description": "B3_8r4dum4: Product W - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r5dum4",
    "Description": "B3_8r5dum4: Product X - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r6dum4",
    "Description": "B3_8r6dum4: Product Y - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r7dum4",
    "Description": "B3_8r7dum4: Product Z - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r8dum4",
    "Description": "B3_8r8dum4: NEXLETOL / NEXLIZET - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r9dum4",
    "Description": "B3_8r9dum4: ZETIA (ezetimibe) - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r10dum4",
    "Description": "B3_8r10dum4: Other treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r11dum4",
    "Description": "B3_8r11dum4: No additional treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r1dum5",
    "Description": "B3_8r1dum5: Leqvio - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r2dum5",
    "Description": "B3_8r2dum5: PRALUENT - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r3dum5",
    "Description": "B3_8r3dum5: REPATHA - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r4dum5",
    "Description": "B3_8r4dum5: Product W - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r5dum5",
    "Description": "B3_8r5dum5: Product X - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r6dum5",
    "Description": "B3_8r6dum5: Product Y - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r7dum5",
    "Description": "B3_8r7dum5: Product Z - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r8dum5",
    "Description": "B3_8r8dum5: NEXLETOL / NEXLIZET - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r9dum5",
    "Description": "B3_8r9dum5: ZETIA (ezetimibe) - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r10dum5",
    "Description": "B3_8r10dum5: Other treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_8r11dum5",
    "Description": "B3_8r11dum5: No additional treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "hPatientType_9",
    "Description": "hPatientType_9: PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_PatientType_9",
    "Description": "Leqvio_PatientType_9: Leqvio_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_Efficacy_9",
    "Description": "Leqvio_Efficacy_9: Leqvio_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~50%80% of patients persistent to treatment at 12m, compared to 57% on,2=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,3=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,4=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o"
  },
  {
    "Column": "Leqvio_Dosing_9",
    "Description": "Leqvio_Dosing_9: Leqvio_Dosing",
    "Answer_Options": "1=Q6MHCP-Administered Injectable(Maintenance Dosing),2=Q6MHCP-Administered Injectable(Maintenance Dosing),3=Q6MHCP-Administered Injectable(Maintenance Dosing),4=Q6MHCP-Administered Injectable(Maintenance Dosing)"
  },
  {
    "Column": "Leqvio_MOA_9",
    "Description": "Leqvio_MOA_9: Leqvio_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor,3=PCSK9 inhibitor,4=PCSK9 inhibitor"
  },
  {
    "Column": "Leqvio_Indication_9",
    "Description": "Leqvio_Indication_9: Leqvio_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,3=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,4=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of CV death (including CHD death"
  },
  {
    "Column": "Praluent_PatientType_9",
    "Description": "Praluent_PatientType_9: Praluent_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Praluent_Efficacy_9",
    "Description": "Praluent_Efficacy_9: Praluent_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~50% In another clinical study of adults with HoFH, PRALUENT lowered bad choleste,2="
  },
  {
    "Column": "Praluent_Dosing_9",
    "Description": "Praluent_Dosing_9: Praluent_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2="
  },
  {
    "Column": "Praluent_MOA_9",
    "Description": "Praluent_MOA_9: Praluent_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Praluent_Indication_9",
    "Description": "Praluent_Indication_9: Praluent_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Repatha_PatientType_9",
    "Description": "Repatha_PatientType_9: Repatha_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Repatha_Efficacy_9",
    "Description": "Repatha_Efficacy_9: Repatha_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,"
  },
  {
    "Column": "Repatha_Dosing_9",
    "Description": "Repatha_Dosing_9: Repatha_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2=Q2WPatient self-administered Injectable"
  },
  {
    "Column": "Repatha_MOA_9",
    "Description": "Repatha_MOA_9: Repatha_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor"
  },
  {
    "Column": "Repatha_Indication_9",
    "Description": "Repatha_Indication_9: Repatha_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: Indicated to reduce risk of CV events in patients with clinical ASCVD (without a prior CV"
  },
  {
    "Column": "Product_W_PatientType_9",
    "Description": "Product_W_PatientType_9: Product_W_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_W_Efficacy_9",
    "Description": "Product_W_Efficacy_9: Product_W_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~49% Mean % change in Lp(a) from Baseline to end of study is ~63%,2="
  },
  {
    "Column": "Product_W_Dosing_9",
    "Description": "Product_W_Dosing_9: Product_W_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2="
  },
  {
    "Column": "Product_W_MOA_9",
    "Description": "Product_W_MOA_9: Product_W_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor plus selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Product_W_Indication_9",
    "Description": "Product_W_Indication_9: Product_W_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2="
  },
  {
    "Column": "Product_X_PatientType_9",
    "Description": "Product_X_PatientType_9: Product_X_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_X_Efficacy_9",
    "Description": "Product_X_Efficacy_9: Product_X_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to Day 365 is ~33% Mean % change in Lp(a) from Baseline to end of study is ~55% In Es,2=Mean % change in LDL from Baseline to end of study is ~45% Mean % change in Lp(a) from Baseline to end of study is ~55%"
  },
  {
    "Column": "Product_X_Dosing_9",
    "Description": "Product_X_Dosing_9: Product_X_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2=QDnon-fasting oral"
  },
  {
    "Column": "Product_X_MOA_9",
    "Description": "Product_X_MOA_9: Product_X_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor,2=Cholesterol ester transfer protein (CETP) inhibitor"
  },
  {
    "Column": "Product_X_Indication_9",
    "Description": "Product_X_Indication_9: Product_X_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Y_PatientType_9",
    "Description": "Product_Y_PatientType_9: Product_Y_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Y_Efficacy_9",
    "Description": "Product_Y_Efficacy_9: Product_Y_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60%,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: Primary Endpoint: 20% RRR on MACE+ (including MA"
  },
  {
    "Column": "Product_Y_Dosing_9",
    "Description": "Product_Y_Dosing_9: Product_Y_Dosing",
    "Answer_Options": "1=QDfasting oral,2=QDfasting oral"
  },
  {
    "Column": "Product_Y_MOA_9",
    "Description": "Product_Y_MOA_9: Product_Y_MOA",
    "Answer_Options": "1=Small molecule PCSK9 inhibitor,2=Small molecule PCSK9 inhibitor"
  },
  {
    "Column": "Product_Y_Indication_9",
    "Description": "Product_Y_Indication_9: Product_Y_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Z_PatientType_9",
    "Description": "Product_Z_PatientType_9: Product_Z_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Z_Efficacy_9",
    "Description": "Product_Z_Efficacy_9: Product_Z_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~65%,2="
  },
  {
    "Column": "Product_Z_Dosing_9",
    "Description": "Product_Z_Dosing_9: Product_Z_Dosing",
    "Answer_Options": "1=QM Patient Self-administered Injectable,2="
  },
  {
    "Column": "Product_Z_MOA_9",
    "Description": "Product_Z_MOA_9: Product_Z_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Product_Z_Indication_9",
    "Description": "Product_Z_Indication_9: Product_Z_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, t,2="
  },
  {
    "Column": "Nexlitol_PatientType_9",
    "Description": "Nexlitol_PatientType_9: Nexlitol_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Nexlitol_Efficacy_9",
    "Description": "Nexlitol_Efficacy_9: Nexlitol_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Nexlitol_Dosing_9",
    "Description": "Nexlitol_Dosing_9: Nexlitol_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Nexlitol_MOA_9",
    "Description": "Nexlitol_MOA_9: Nexlitol_MOA",
    "Answer_Options": "1=ACL inhibitor,2="
  },
  {
    "Column": "Nexlitol_Indication_9",
    "Description": "Nexlitol_Indication_9: Nexlitol_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Zetia_PatientType_9",
    "Description": "Zetia_PatientType_9: Zetia_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Zetia_Efficacy_9",
    "Description": "Zetia_Efficacy_9: Zetia_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Zetia_Dosing_9",
    "Description": "Zetia_Dosing_9: Zetia_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Zetia_MOA_9",
    "Description": "Zetia_MOA_9: Zetia_MOA",
    "Answer_Options": "1=selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Zetia_Indication_9",
    "Description": "Zetia_Indication_9: Zetia_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Other_Therapies_PatientType_9",
    "Description": "Other_Therapies_PatientType_9: Other_Therapies_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Other_Therapies_Efficacy_9",
    "Description": "Other_Therapies_Efficacy_9: Other_Therapies_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Dosing_9",
    "Description": "Other_Therapies_Dosing_9: Other_Therapies_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_MOA_9",
    "Description": "Other_Therapies_MOA_9: Other_Therapies_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Indication_9",
    "Description": "Other_Therapies_Indication_9: Other_Therapies_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_PatientType_9",
    "Description": "No_Addl_Therap_PatientType_9: No_Addl_Therap_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "No_Addl_Therap_Efficacy_9",
    "Description": "No_Addl_Therap_Efficacy_9: No_Addl_Therap_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Dosing_9",
    "Description": "No_Addl_Therap_Dosing_9: No_Addl_Therap_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_MOA_9",
    "Description": "No_Addl_Therap_MOA_9: No_Addl_Therap_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Indication_9",
    "Description": "No_Addl_Therap_Indication_9: No_Addl_Therap_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "B3_9r1c1",
    "Description": "B3_9r1c1: Leqvio - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_9"
  },
  {
    "Column": "B3_9r2c1",
    "Description": "B3_9r2c1: PRALUENT - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_9"
  },
  {
    "Column": "B3_9r3c1",
    "Description": "B3_9r3c1: REPATHA - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_9"
  },
  {
    "Column": "B3_9r4c1",
    "Description": "B3_9r4c1: Product W - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_9"
  },
  {
    "Column": "B3_9r5c1",
    "Description": "B3_9r5c1: Product X - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_9"
  },
  {
    "Column": "B3_9r6c1",
    "Description": "B3_9r6c1: Product Y - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_9"
  },
  {
    "Column": "B3_9r7c1",
    "Description": "B3_9r7c1: Product Z - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_9"
  },
  {
    "Column": "B3_9r8c1",
    "Description": "B3_9r8c1: NEXLETOL / NEXLIZET - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_9"
  },
  {
    "Column": "B3_9r9c1",
    "Description": "B3_9r9c1: ZETIA (ezetimibe) - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_9"
  },
  {
    "Column": "B3_9r10c1",
    "Description": "B3_9r10c1: Other treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_9"
  },
  {
    "Column": "B3_9r11c1",
    "Description": "B3_9r11c1: No additional treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_9"
  },
  {
    "Column": "B3_9r1c2",
    "Description": "B3_9r1c2: Leqvio - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_9"
  },
  {
    "Column": "B3_9r2c2",
    "Description": "B3_9r2c2: PRALUENT - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_9"
  },
  {
    "Column": "B3_9r3c2",
    "Description": "B3_9r3c2: REPATHA - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_9"
  },
  {
    "Column": "B3_9r4c2",
    "Description": "B3_9r4c2: Product W - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_9"
  },
  {
    "Column": "B3_9r5c2",
    "Description": "B3_9r5c2: Product X - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_9"
  },
  {
    "Column": "B3_9r6c2",
    "Description": "B3_9r6c2: Product Y - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_9"
  },
  {
    "Column": "B3_9r7c2",
    "Description": "B3_9r7c2: Product Z - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_9"
  },
  {
    "Column": "B3_9r8c2",
    "Description": "B3_9r8c2: NEXLETOL / NEXLIZET - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_9"
  },
  {
    "Column": "B3_9r9c2",
    "Description": "B3_9r9c2: ZETIA (ezetimibe) - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_9"
  },
  {
    "Column": "B3_9r10c2",
    "Description": "B3_9r10c2: Other treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_9"
  },
  {
    "Column": "B3_9r11c2",
    "Description": "B3_9r11c2: No additional treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_9"
  },
  {
    "Column": "B3_9r1dum1",
    "Description": "B3_9r1dum1: Leqvio - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r2dum1",
    "Description": "B3_9r2dum1: PRALUENT - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r3dum1",
    "Description": "B3_9r3dum1: REPATHA - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r4dum1",
    "Description": "B3_9r4dum1: Product W - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r5dum1",
    "Description": "B3_9r5dum1: Product X - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r6dum1",
    "Description": "B3_9r6dum1: Product Y - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r7dum1",
    "Description": "B3_9r7dum1: Product Z - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r8dum1",
    "Description": "B3_9r8dum1: NEXLETOL / NEXLIZET - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r9dum1",
    "Description": "B3_9r9dum1: ZETIA (ezetimibe) - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r10dum1",
    "Description": "B3_9r10dum1: Other treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r11dum1",
    "Description": "B3_9r11dum1: No additional treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r1dum2",
    "Description": "B3_9r1dum2: Leqvio - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r2dum2",
    "Description": "B3_9r2dum2: PRALUENT - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r3dum2",
    "Description": "B3_9r3dum2: REPATHA - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r4dum2",
    "Description": "B3_9r4dum2: Product W - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r5dum2",
    "Description": "B3_9r5dum2: Product X - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r6dum2",
    "Description": "B3_9r6dum2: Product Y - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r7dum2",
    "Description": "B3_9r7dum2: Product Z - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r8dum2",
    "Description": "B3_9r8dum2: NEXLETOL / NEXLIZET - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r9dum2",
    "Description": "B3_9r9dum2: ZETIA (ezetimibe) - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r10dum2",
    "Description": "B3_9r10dum2: Other treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r11dum2",
    "Description": "B3_9r11dum2: No additional treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r1dum3",
    "Description": "B3_9r1dum3: Leqvio - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r2dum3",
    "Description": "B3_9r2dum3: PRALUENT - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r3dum3",
    "Description": "B3_9r3dum3: REPATHA - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r4dum3",
    "Description": "B3_9r4dum3: Product W - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r5dum3",
    "Description": "B3_9r5dum3: Product X - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r6dum3",
    "Description": "B3_9r6dum3: Product Y - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r7dum3",
    "Description": "B3_9r7dum3: Product Z - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r8dum3",
    "Description": "B3_9r8dum3: NEXLETOL / NEXLIZET - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r9dum3",
    "Description": "B3_9r9dum3: ZETIA (ezetimibe) - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r10dum3",
    "Description": "B3_9r10dum3: Other treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r11dum3",
    "Description": "B3_9r11dum3: No additional treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r1dum4",
    "Description": "B3_9r1dum4: Leqvio - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r2dum4",
    "Description": "B3_9r2dum4: PRALUENT - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r3dum4",
    "Description": "B3_9r3dum4: REPATHA - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r4dum4",
    "Description": "B3_9r4dum4: Product W - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r5dum4",
    "Description": "B3_9r5dum4: Product X - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r6dum4",
    "Description": "B3_9r6dum4: Product Y - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r7dum4",
    "Description": "B3_9r7dum4: Product Z - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r8dum4",
    "Description": "B3_9r8dum4: NEXLETOL / NEXLIZET - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r9dum4",
    "Description": "B3_9r9dum4: ZETIA (ezetimibe) - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r10dum4",
    "Description": "B3_9r10dum4: Other treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r11dum4",
    "Description": "B3_9r11dum4: No additional treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r1dum5",
    "Description": "B3_9r1dum5: Leqvio - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r2dum5",
    "Description": "B3_9r2dum5: PRALUENT - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r3dum5",
    "Description": "B3_9r3dum5: REPATHA - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r4dum5",
    "Description": "B3_9r4dum5: Product W - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r5dum5",
    "Description": "B3_9r5dum5: Product X - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r6dum5",
    "Description": "B3_9r6dum5: Product Y - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r7dum5",
    "Description": "B3_9r7dum5: Product Z - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r8dum5",
    "Description": "B3_9r8dum5: NEXLETOL / NEXLIZET - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r9dum5",
    "Description": "B3_9r9dum5: ZETIA (ezetimibe) - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r10dum5",
    "Description": "B3_9r10dum5: Other treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_9r11dum5",
    "Description": "B3_9r11dum5: No additional treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "hPatientType_10",
    "Description": "hPatientType_10: PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_PatientType_10",
    "Description": "Leqvio_PatientType_10: Leqvio_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_Efficacy_10",
    "Description": "Leqvio_Efficacy_10: Leqvio_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~50%80% of patients persistent to treatment at 12m, compared to 57% on,2=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,3=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,4=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o"
  },
  {
    "Column": "Leqvio_Dosing_10",
    "Description": "Leqvio_Dosing_10: Leqvio_Dosing",
    "Answer_Options": "1=Q6MHCP-Administered Injectable(Maintenance Dosing),2=Q6MHCP-Administered Injectable(Maintenance Dosing),3=Q6MHCP-Administered Injectable(Maintenance Dosing),4=Q6MHCP-Administered Injectable(Maintenance Dosing)"
  },
  {
    "Column": "Leqvio_MOA_10",
    "Description": "Leqvio_MOA_10: Leqvio_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor,3=PCSK9 inhibitor,4=PCSK9 inhibitor"
  },
  {
    "Column": "Leqvio_Indication_10",
    "Description": "Leqvio_Indication_10: Leqvio_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,3=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,4=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of CV death (including CHD death"
  },
  {
    "Column": "Praluent_PatientType_10",
    "Description": "Praluent_PatientType_10: Praluent_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Praluent_Efficacy_10",
    "Description": "Praluent_Efficacy_10: Praluent_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~50% In another clinical study of adults with HoFH, PRALUENT lowered bad choleste,2="
  },
  {
    "Column": "Praluent_Dosing_10",
    "Description": "Praluent_Dosing_10: Praluent_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2="
  },
  {
    "Column": "Praluent_MOA_10",
    "Description": "Praluent_MOA_10: Praluent_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Praluent_Indication_10",
    "Description": "Praluent_Indication_10: Praluent_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Repatha_PatientType_10",
    "Description": "Repatha_PatientType_10: Repatha_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Repatha_Efficacy_10",
    "Description": "Repatha_Efficacy_10: Repatha_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,"
  },
  {
    "Column": "Repatha_Dosing_10",
    "Description": "Repatha_Dosing_10: Repatha_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2=Q2WPatient self-administered Injectable"
  },
  {
    "Column": "Repatha_MOA_10",
    "Description": "Repatha_MOA_10: Repatha_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor"
  },
  {
    "Column": "Repatha_Indication_10",
    "Description": "Repatha_Indication_10: Repatha_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: Indicated to reduce risk of CV events in patients with clinical ASCVD (without a prior CV"
  },
  {
    "Column": "Product_W_PatientType_10",
    "Description": "Product_W_PatientType_10: Product_W_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_W_Efficacy_10",
    "Description": "Product_W_Efficacy_10: Product_W_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~49% Mean % change in Lp(a) from Baseline to end of study is ~63%,2="
  },
  {
    "Column": "Product_W_Dosing_10",
    "Description": "Product_W_Dosing_10: Product_W_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2="
  },
  {
    "Column": "Product_W_MOA_10",
    "Description": "Product_W_MOA_10: Product_W_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor plus selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Product_W_Indication_10",
    "Description": "Product_W_Indication_10: Product_W_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2="
  },
  {
    "Column": "Product_X_PatientType_10",
    "Description": "Product_X_PatientType_10: Product_X_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_X_Efficacy_10",
    "Description": "Product_X_Efficacy_10: Product_X_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to Day 365 is ~33% Mean % change in Lp(a) from Baseline to end of study is ~55% In Es,2=Mean % change in LDL from Baseline to end of study is ~45% Mean % change in Lp(a) from Baseline to end of study is ~55%"
  },
  {
    "Column": "Product_X_Dosing_10",
    "Description": "Product_X_Dosing_10: Product_X_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2=QDnon-fasting oral"
  },
  {
    "Column": "Product_X_MOA_10",
    "Description": "Product_X_MOA_10: Product_X_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor,2=Cholesterol ester transfer protein (CETP) inhibitor"
  },
  {
    "Column": "Product_X_Indication_10",
    "Description": "Product_X_Indication_10: Product_X_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Y_PatientType_10",
    "Description": "Product_Y_PatientType_10: Product_Y_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Y_Efficacy_10",
    "Description": "Product_Y_Efficacy_10: Product_Y_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60%,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: Primary Endpoint: 20% RRR on MACE+ (including MA"
  },
  {
    "Column": "Product_Y_Dosing_10",
    "Description": "Product_Y_Dosing_10: Product_Y_Dosing",
    "Answer_Options": "1=QDfasting oral,2=QDfasting oral"
  },
  {
    "Column": "Product_Y_MOA_10",
    "Description": "Product_Y_MOA_10: Product_Y_MOA",
    "Answer_Options": "1=Small molecule PCSK9 inhibitor,2=Small molecule PCSK9 inhibitor"
  },
  {
    "Column": "Product_Y_Indication_10",
    "Description": "Product_Y_Indication_10: Product_Y_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Z_PatientType_10",
    "Description": "Product_Z_PatientType_10: Product_Z_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Z_Efficacy_10",
    "Description": "Product_Z_Efficacy_10: Product_Z_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~65%,2="
  },
  {
    "Column": "Product_Z_Dosing_10",
    "Description": "Product_Z_Dosing_10: Product_Z_Dosing",
    "Answer_Options": "1=QM Patient Self-administered Injectable,2="
  },
  {
    "Column": "Product_Z_MOA_10",
    "Description": "Product_Z_MOA_10: Product_Z_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Product_Z_Indication_10",
    "Description": "Product_Z_Indication_10: Product_Z_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, t,2="
  },
  {
    "Column": "Nexlitol_PatientType_10",
    "Description": "Nexlitol_PatientType_10: Nexlitol_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Nexlitol_Efficacy_10",
    "Description": "Nexlitol_Efficacy_10: Nexlitol_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Nexlitol_Dosing_10",
    "Description": "Nexlitol_Dosing_10: Nexlitol_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Nexlitol_MOA_10",
    "Description": "Nexlitol_MOA_10: Nexlitol_MOA",
    "Answer_Options": "1=ACL inhibitor,2="
  },
  {
    "Column": "Nexlitol_Indication_10",
    "Description": "Nexlitol_Indication_10: Nexlitol_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Zetia_PatientType_10",
    "Description": "Zetia_PatientType_10: Zetia_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Zetia_Efficacy_10",
    "Description": "Zetia_Efficacy_10: Zetia_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Zetia_Dosing_10",
    "Description": "Zetia_Dosing_10: Zetia_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Zetia_MOA_10",
    "Description": "Zetia_MOA_10: Zetia_MOA",
    "Answer_Options": "1=selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Zetia_Indication_10",
    "Description": "Zetia_Indication_10: Zetia_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Other_Therapies_PatientType_10",
    "Description": "Other_Therapies_PatientType_10: Other_Therapies_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Other_Therapies_Efficacy_10",
    "Description": "Other_Therapies_Efficacy_10: Other_Therapies_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Dosing_10",
    "Description": "Other_Therapies_Dosing_10: Other_Therapies_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_MOA_10",
    "Description": "Other_Therapies_MOA_10: Other_Therapies_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Indication_10",
    "Description": "Other_Therapies_Indication_10: Other_Therapies_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_PatientType_10",
    "Description": "No_Addl_Therap_PatientType_10: No_Addl_Therap_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "No_Addl_Therap_Efficacy_10",
    "Description": "No_Addl_Therap_Efficacy_10: No_Addl_Therap_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Dosing_10",
    "Description": "No_Addl_Therap_Dosing_10: No_Addl_Therap_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_MOA_10",
    "Description": "No_Addl_Therap_MOA_10: No_Addl_Therap_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Indication_10",
    "Description": "No_Addl_Therap_Indication_10: No_Addl_Therap_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "B3_10r1c1",
    "Description": "B3_10r1c1: Leqvio - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_10"
  },
  {
    "Column": "B3_10r2c1",
    "Description": "B3_10r2c1: PRALUENT - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_10"
  },
  {
    "Column": "B3_10r3c1",
    "Description": "B3_10r3c1: REPATHA - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_10"
  },
  {
    "Column": "B3_10r4c1",
    "Description": "B3_10r4c1: Product W - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_10"
  },
  {
    "Column": "B3_10r5c1",
    "Description": "B3_10r5c1: Product X - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_10"
  },
  {
    "Column": "B3_10r6c1",
    "Description": "B3_10r6c1: Product Y - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_10"
  },
  {
    "Column": "B3_10r7c1",
    "Description": "B3_10r7c1: Product Z - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_10"
  },
  {
    "Column": "B3_10r8c1",
    "Description": "B3_10r8c1: NEXLETOL / NEXLIZET - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_10"
  },
  {
    "Column": "B3_10r9c1",
    "Description": "B3_10r9c1: ZETIA (ezetimibe) - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_10"
  },
  {
    "Column": "B3_10r10c1",
    "Description": "B3_10r10c1: Other treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_10"
  },
  {
    "Column": "B3_10r11c1",
    "Description": "B3_10r11c1: No additional treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_10"
  },
  {
    "Column": "B3_10r1c2",
    "Description": "B3_10r1c2: Leqvio - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_10"
  },
  {
    "Column": "B3_10r2c2",
    "Description": "B3_10r2c2: PRALUENT - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_10"
  },
  {
    "Column": "B3_10r3c2",
    "Description": "B3_10r3c2: REPATHA - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_10"
  },
  {
    "Column": "B3_10r4c2",
    "Description": "B3_10r4c2: Product W - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_10"
  },
  {
    "Column": "B3_10r5c2",
    "Description": "B3_10r5c2: Product X - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_10"
  },
  {
    "Column": "B3_10r6c2",
    "Description": "B3_10r6c2: Product Y - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_10"
  },
  {
    "Column": "B3_10r7c2",
    "Description": "B3_10r7c2: Product Z - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_10"
  },
  {
    "Column": "B3_10r8c2",
    "Description": "B3_10r8c2: NEXLETOL / NEXLIZET - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_10"
  },
  {
    "Column": "B3_10r9c2",
    "Description": "B3_10r9c2: ZETIA (ezetimibe) - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_10"
  },
  {
    "Column": "B3_10r10c2",
    "Description": "B3_10r10c2: Other treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_10"
  },
  {
    "Column": "B3_10r11c2",
    "Description": "B3_10r11c2: No additional treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_10"
  },
  {
    "Column": "B3_10r1dum1",
    "Description": "B3_10r1dum1: Leqvio - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r2dum1",
    "Description": "B3_10r2dum1: PRALUENT - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r3dum1",
    "Description": "B3_10r3dum1: REPATHA - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r4dum1",
    "Description": "B3_10r4dum1: Product W - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r5dum1",
    "Description": "B3_10r5dum1: Product X - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r6dum1",
    "Description": "B3_10r6dum1: Product Y - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r7dum1",
    "Description": "B3_10r7dum1: Product Z - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r8dum1",
    "Description": "B3_10r8dum1: NEXLETOL / NEXLIZET - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r9dum1",
    "Description": "B3_10r9dum1: ZETIA (ezetimibe) - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r10dum1",
    "Description": "B3_10r10dum1: Other treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r11dum1",
    "Description": "B3_10r11dum1: No additional treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r1dum2",
    "Description": "B3_10r1dum2: Leqvio - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r2dum2",
    "Description": "B3_10r2dum2: PRALUENT - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r3dum2",
    "Description": "B3_10r3dum2: REPATHA - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r4dum2",
    "Description": "B3_10r4dum2: Product W - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r5dum2",
    "Description": "B3_10r5dum2: Product X - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r6dum2",
    "Description": "B3_10r6dum2: Product Y - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r7dum2",
    "Description": "B3_10r7dum2: Product Z - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r8dum2",
    "Description": "B3_10r8dum2: NEXLETOL / NEXLIZET - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r9dum2",
    "Description": "B3_10r9dum2: ZETIA (ezetimibe) - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r10dum2",
    "Description": "B3_10r10dum2: Other treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r11dum2",
    "Description": "B3_10r11dum2: No additional treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r1dum3",
    "Description": "B3_10r1dum3: Leqvio - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r2dum3",
    "Description": "B3_10r2dum3: PRALUENT - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r3dum3",
    "Description": "B3_10r3dum3: REPATHA - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r4dum3",
    "Description": "B3_10r4dum3: Product W - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r5dum3",
    "Description": "B3_10r5dum3: Product X - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r6dum3",
    "Description": "B3_10r6dum3: Product Y - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r7dum3",
    "Description": "B3_10r7dum3: Product Z - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r8dum3",
    "Description": "B3_10r8dum3: NEXLETOL / NEXLIZET - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r9dum3",
    "Description": "B3_10r9dum3: ZETIA (ezetimibe) - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r10dum3",
    "Description": "B3_10r10dum3: Other treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r11dum3",
    "Description": "B3_10r11dum3: No additional treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r1dum4",
    "Description": "B3_10r1dum4: Leqvio - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r2dum4",
    "Description": "B3_10r2dum4: PRALUENT - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r3dum4",
    "Description": "B3_10r3dum4: REPATHA - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r4dum4",
    "Description": "B3_10r4dum4: Product W - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r5dum4",
    "Description": "B3_10r5dum4: Product X - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r6dum4",
    "Description": "B3_10r6dum4: Product Y - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r7dum4",
    "Description": "B3_10r7dum4: Product Z - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r8dum4",
    "Description": "B3_10r8dum4: NEXLETOL / NEXLIZET - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r9dum4",
    "Description": "B3_10r9dum4: ZETIA (ezetimibe) - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r10dum4",
    "Description": "B3_10r10dum4: Other treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r11dum4",
    "Description": "B3_10r11dum4: No additional treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r1dum5",
    "Description": "B3_10r1dum5: Leqvio - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r2dum5",
    "Description": "B3_10r2dum5: PRALUENT - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r3dum5",
    "Description": "B3_10r3dum5: REPATHA - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r4dum5",
    "Description": "B3_10r4dum5: Product W - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r5dum5",
    "Description": "B3_10r5dum5: Product X - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r6dum5",
    "Description": "B3_10r6dum5: Product Y - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r7dum5",
    "Description": "B3_10r7dum5: Product Z - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r8dum5",
    "Description": "B3_10r8dum5: NEXLETOL / NEXLIZET - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r9dum5",
    "Description": "B3_10r9dum5: ZETIA (ezetimibe) - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r10dum5",
    "Description": "B3_10r10dum5: Other treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_10r11dum5",
    "Description": "B3_10r11dum5: No additional treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "hPatientType_11",
    "Description": "hPatientType_11: PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_PatientType_11",
    "Description": "Leqvio_PatientType_11: Leqvio_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_Efficacy_11",
    "Description": "Leqvio_Efficacy_11: Leqvio_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~50%80% of patients persistent to treatment at 12m, compared to 57% on,2=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,3=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,4=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o"
  },
  {
    "Column": "Leqvio_Dosing_11",
    "Description": "Leqvio_Dosing_11: Leqvio_Dosing",
    "Answer_Options": "1=Q6MHCP-Administered Injectable(Maintenance Dosing),2=Q6MHCP-Administered Injectable(Maintenance Dosing),3=Q6MHCP-Administered Injectable(Maintenance Dosing),4=Q6MHCP-Administered Injectable(Maintenance Dosing)"
  },
  {
    "Column": "Leqvio_MOA_11",
    "Description": "Leqvio_MOA_11: Leqvio_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor,3=PCSK9 inhibitor,4=PCSK9 inhibitor"
  },
  {
    "Column": "Leqvio_Indication_11",
    "Description": "Leqvio_Indication_11: Leqvio_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,3=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,4=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of CV death (including CHD death"
  },
  {
    "Column": "Praluent_PatientType_11",
    "Description": "Praluent_PatientType_11: Praluent_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Praluent_Efficacy_11",
    "Description": "Praluent_Efficacy_11: Praluent_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~50% In another clinical study of adults with HoFH, PRALUENT lowered bad choleste,2="
  },
  {
    "Column": "Praluent_Dosing_11",
    "Description": "Praluent_Dosing_11: Praluent_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2="
  },
  {
    "Column": "Praluent_MOA_11",
    "Description": "Praluent_MOA_11: Praluent_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Praluent_Indication_11",
    "Description": "Praluent_Indication_11: Praluent_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Repatha_PatientType_11",
    "Description": "Repatha_PatientType_11: Repatha_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Repatha_Efficacy_11",
    "Description": "Repatha_Efficacy_11: Repatha_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,"
  },
  {
    "Column": "Repatha_Dosing_11",
    "Description": "Repatha_Dosing_11: Repatha_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2=Q2WPatient self-administered Injectable"
  },
  {
    "Column": "Repatha_MOA_11",
    "Description": "Repatha_MOA_11: Repatha_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor"
  },
  {
    "Column": "Repatha_Indication_11",
    "Description": "Repatha_Indication_11: Repatha_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: Indicated to reduce risk of CV events in patients with clinical ASCVD (without a prior CV"
  },
  {
    "Column": "Product_W_PatientType_11",
    "Description": "Product_W_PatientType_11: Product_W_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_W_Efficacy_11",
    "Description": "Product_W_Efficacy_11: Product_W_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~49% Mean % change in Lp(a) from Baseline to end of study is ~63%,2="
  },
  {
    "Column": "Product_W_Dosing_11",
    "Description": "Product_W_Dosing_11: Product_W_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2="
  },
  {
    "Column": "Product_W_MOA_11",
    "Description": "Product_W_MOA_11: Product_W_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor plus selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Product_W_Indication_11",
    "Description": "Product_W_Indication_11: Product_W_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2="
  },
  {
    "Column": "Product_X_PatientType_11",
    "Description": "Product_X_PatientType_11: Product_X_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_X_Efficacy_11",
    "Description": "Product_X_Efficacy_11: Product_X_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to Day 365 is ~33% Mean % change in Lp(a) from Baseline to end of study is ~55% In Es,2=Mean % change in LDL from Baseline to end of study is ~45% Mean % change in Lp(a) from Baseline to end of study is ~55%"
  },
  {
    "Column": "Product_X_Dosing_11",
    "Description": "Product_X_Dosing_11: Product_X_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2=QDnon-fasting oral"
  },
  {
    "Column": "Product_X_MOA_11",
    "Description": "Product_X_MOA_11: Product_X_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor,2=Cholesterol ester transfer protein (CETP) inhibitor"
  },
  {
    "Column": "Product_X_Indication_11",
    "Description": "Product_X_Indication_11: Product_X_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Y_PatientType_11",
    "Description": "Product_Y_PatientType_11: Product_Y_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Y_Efficacy_11",
    "Description": "Product_Y_Efficacy_11: Product_Y_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60%,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: Primary Endpoint: 20% RRR on MACE+ (including MA"
  },
  {
    "Column": "Product_Y_Dosing_11",
    "Description": "Product_Y_Dosing_11: Product_Y_Dosing",
    "Answer_Options": "1=QDfasting oral,2=QDfasting oral"
  },
  {
    "Column": "Product_Y_MOA_11",
    "Description": "Product_Y_MOA_11: Product_Y_MOA",
    "Answer_Options": "1=Small molecule PCSK9 inhibitor,2=Small molecule PCSK9 inhibitor"
  },
  {
    "Column": "Product_Y_Indication_11",
    "Description": "Product_Y_Indication_11: Product_Y_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Z_PatientType_11",
    "Description": "Product_Z_PatientType_11: Product_Z_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Z_Efficacy_11",
    "Description": "Product_Z_Efficacy_11: Product_Z_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~65%,2="
  },
  {
    "Column": "Product_Z_Dosing_11",
    "Description": "Product_Z_Dosing_11: Product_Z_Dosing",
    "Answer_Options": "1=QM Patient Self-administered Injectable,2="
  },
  {
    "Column": "Product_Z_MOA_11",
    "Description": "Product_Z_MOA_11: Product_Z_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Product_Z_Indication_11",
    "Description": "Product_Z_Indication_11: Product_Z_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, t,2="
  },
  {
    "Column": "Nexlitol_PatientType_11",
    "Description": "Nexlitol_PatientType_11: Nexlitol_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Nexlitol_Efficacy_11",
    "Description": "Nexlitol_Efficacy_11: Nexlitol_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Nexlitol_Dosing_11",
    "Description": "Nexlitol_Dosing_11: Nexlitol_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Nexlitol_MOA_11",
    "Description": "Nexlitol_MOA_11: Nexlitol_MOA",
    "Answer_Options": "1=ACL inhibitor,2="
  },
  {
    "Column": "Nexlitol_Indication_11",
    "Description": "Nexlitol_Indication_11: Nexlitol_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Zetia_PatientType_11",
    "Description": "Zetia_PatientType_11: Zetia_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Zetia_Efficacy_11",
    "Description": "Zetia_Efficacy_11: Zetia_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Zetia_Dosing_11",
    "Description": "Zetia_Dosing_11: Zetia_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Zetia_MOA_11",
    "Description": "Zetia_MOA_11: Zetia_MOA",
    "Answer_Options": "1=selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Zetia_Indication_11",
    "Description": "Zetia_Indication_11: Zetia_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Other_Therapies_PatientType_11",
    "Description": "Other_Therapies_PatientType_11: Other_Therapies_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Other_Therapies_Efficacy_11",
    "Description": "Other_Therapies_Efficacy_11: Other_Therapies_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Dosing_11",
    "Description": "Other_Therapies_Dosing_11: Other_Therapies_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_MOA_11",
    "Description": "Other_Therapies_MOA_11: Other_Therapies_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Indication_11",
    "Description": "Other_Therapies_Indication_11: Other_Therapies_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_PatientType_11",
    "Description": "No_Addl_Therap_PatientType_11: No_Addl_Therap_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "No_Addl_Therap_Efficacy_11",
    "Description": "No_Addl_Therap_Efficacy_11: No_Addl_Therap_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Dosing_11",
    "Description": "No_Addl_Therap_Dosing_11: No_Addl_Therap_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_MOA_11",
    "Description": "No_Addl_Therap_MOA_11: No_Addl_Therap_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Indication_11",
    "Description": "No_Addl_Therap_Indication_11: No_Addl_Therap_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "B3_11r1c1",
    "Description": "B3_11r1c1: Leqvio - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_11"
  },
  {
    "Column": "B3_11r2c1",
    "Description": "B3_11r2c1: PRALUENT - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_11"
  },
  {
    "Column": "B3_11r3c1",
    "Description": "B3_11r3c1: REPATHA - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_11"
  },
  {
    "Column": "B3_11r4c1",
    "Description": "B3_11r4c1: Product W - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_11"
  },
  {
    "Column": "B3_11r5c1",
    "Description": "B3_11r5c1: Product X - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_11"
  },
  {
    "Column": "B3_11r6c1",
    "Description": "B3_11r6c1: Product Y - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_11"
  },
  {
    "Column": "B3_11r7c1",
    "Description": "B3_11r7c1: Product Z - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_11"
  },
  {
    "Column": "B3_11r8c1",
    "Description": "B3_11r8c1: NEXLETOL / NEXLIZET - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_11"
  },
  {
    "Column": "B3_11r9c1",
    "Description": "B3_11r9c1: ZETIA (ezetimibe) - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_11"
  },
  {
    "Column": "B3_11r10c1",
    "Description": "B3_11r10c1: Other treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_11"
  },
  {
    "Column": "B3_11r11c1",
    "Description": "B3_11r11c1: No additional treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_11"
  },
  {
    "Column": "B3_11r1c2",
    "Description": "B3_11r1c2: Leqvio - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_11"
  },
  {
    "Column": "B3_11r2c2",
    "Description": "B3_11r2c2: PRALUENT - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_11"
  },
  {
    "Column": "B3_11r3c2",
    "Description": "B3_11r3c2: REPATHA - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_11"
  },
  {
    "Column": "B3_11r4c2",
    "Description": "B3_11r4c2: Product W - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_11"
  },
  {
    "Column": "B3_11r5c2",
    "Description": "B3_11r5c2: Product X - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_11"
  },
  {
    "Column": "B3_11r6c2",
    "Description": "B3_11r6c2: Product Y - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_11"
  },
  {
    "Column": "B3_11r7c2",
    "Description": "B3_11r7c2: Product Z - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_11"
  },
  {
    "Column": "B3_11r8c2",
    "Description": "B3_11r8c2: NEXLETOL / NEXLIZET - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_11"
  },
  {
    "Column": "B3_11r9c2",
    "Description": "B3_11r9c2: ZETIA (ezetimibe) - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_11"
  },
  {
    "Column": "B3_11r10c2",
    "Description": "B3_11r10c2: Other treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_11"
  },
  {
    "Column": "B3_11r11c2",
    "Description": "B3_11r11c2: No additional treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_11"
  },
  {
    "Column": "B3_11r1dum1",
    "Description": "B3_11r1dum1: Leqvio - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r2dum1",
    "Description": "B3_11r2dum1: PRALUENT - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r3dum1",
    "Description": "B3_11r3dum1: REPATHA - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r4dum1",
    "Description": "B3_11r4dum1: Product W - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r5dum1",
    "Description": "B3_11r5dum1: Product X - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r6dum1",
    "Description": "B3_11r6dum1: Product Y - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r7dum1",
    "Description": "B3_11r7dum1: Product Z - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r8dum1",
    "Description": "B3_11r8dum1: NEXLETOL / NEXLIZET - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r9dum1",
    "Description": "B3_11r9dum1: ZETIA (ezetimibe) - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r10dum1",
    "Description": "B3_11r10dum1: Other treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r11dum1",
    "Description": "B3_11r11dum1: No additional treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r1dum2",
    "Description": "B3_11r1dum2: Leqvio - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r2dum2",
    "Description": "B3_11r2dum2: PRALUENT - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r3dum2",
    "Description": "B3_11r3dum2: REPATHA - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r4dum2",
    "Description": "B3_11r4dum2: Product W - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r5dum2",
    "Description": "B3_11r5dum2: Product X - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r6dum2",
    "Description": "B3_11r6dum2: Product Y - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r7dum2",
    "Description": "B3_11r7dum2: Product Z - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r8dum2",
    "Description": "B3_11r8dum2: NEXLETOL / NEXLIZET - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r9dum2",
    "Description": "B3_11r9dum2: ZETIA (ezetimibe) - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r10dum2",
    "Description": "B3_11r10dum2: Other treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r11dum2",
    "Description": "B3_11r11dum2: No additional treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r1dum3",
    "Description": "B3_11r1dum3: Leqvio - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r2dum3",
    "Description": "B3_11r2dum3: PRALUENT - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r3dum3",
    "Description": "B3_11r3dum3: REPATHA - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r4dum3",
    "Description": "B3_11r4dum3: Product W - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r5dum3",
    "Description": "B3_11r5dum3: Product X - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r6dum3",
    "Description": "B3_11r6dum3: Product Y - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r7dum3",
    "Description": "B3_11r7dum3: Product Z - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r8dum3",
    "Description": "B3_11r8dum3: NEXLETOL / NEXLIZET - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r9dum3",
    "Description": "B3_11r9dum3: ZETIA (ezetimibe) - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r10dum3",
    "Description": "B3_11r10dum3: Other treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r11dum3",
    "Description": "B3_11r11dum3: No additional treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r1dum4",
    "Description": "B3_11r1dum4: Leqvio - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r2dum4",
    "Description": "B3_11r2dum4: PRALUENT - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r3dum4",
    "Description": "B3_11r3dum4: REPATHA - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r4dum4",
    "Description": "B3_11r4dum4: Product W - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r5dum4",
    "Description": "B3_11r5dum4: Product X - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r6dum4",
    "Description": "B3_11r6dum4: Product Y - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r7dum4",
    "Description": "B3_11r7dum4: Product Z - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r8dum4",
    "Description": "B3_11r8dum4: NEXLETOL / NEXLIZET - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r9dum4",
    "Description": "B3_11r9dum4: ZETIA (ezetimibe) - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r10dum4",
    "Description": "B3_11r10dum4: Other treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r11dum4",
    "Description": "B3_11r11dum4: No additional treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r1dum5",
    "Description": "B3_11r1dum5: Leqvio - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r2dum5",
    "Description": "B3_11r2dum5: PRALUENT - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r3dum5",
    "Description": "B3_11r3dum5: REPATHA - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r4dum5",
    "Description": "B3_11r4dum5: Product W - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r5dum5",
    "Description": "B3_11r5dum5: Product X - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r6dum5",
    "Description": "B3_11r6dum5: Product Y - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r7dum5",
    "Description": "B3_11r7dum5: Product Z - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r8dum5",
    "Description": "B3_11r8dum5: NEXLETOL / NEXLIZET - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r9dum5",
    "Description": "B3_11r9dum5: ZETIA (ezetimibe) - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r10dum5",
    "Description": "B3_11r10dum5: Other treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_11r11dum5",
    "Description": "B3_11r11dum5: No additional treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "hPatientType_12",
    "Description": "hPatientType_12: PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_PatientType_12",
    "Description": "Leqvio_PatientType_12: Leqvio_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Leqvio_Efficacy_12",
    "Description": "Leqvio_Efficacy_12: Leqvio_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~50%80% of patients persistent to treatment at 12m, compared to 57% on,2=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,3=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o,4=Mean % change in LDL from Baseline to month 17 is ~50% 80% of patients persistent to treatment at 12m, compared to 57% o"
  },
  {
    "Column": "Leqvio_Dosing_12",
    "Description": "Leqvio_Dosing_12: Leqvio_Dosing",
    "Answer_Options": "1=Q6MHCP-Administered Injectable(Maintenance Dosing),2=Q6MHCP-Administered Injectable(Maintenance Dosing),3=Q6MHCP-Administered Injectable(Maintenance Dosing),4=Q6MHCP-Administered Injectable(Maintenance Dosing)"
  },
  {
    "Column": "Leqvio_MOA_12",
    "Description": "Leqvio_MOA_12: Leqvio_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor,3=PCSK9 inhibitor,4=PCSK9 inhibitor"
  },
  {
    "Column": "Leqvio_Indication_12",
    "Description": "Leqvio_Indication_12: Leqvio_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,3=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of major adverse CV events (CV d,4=As currently indicated, plus: - Indicated in adults with established CVD to reduce risk of CV death (including CHD death"
  },
  {
    "Column": "Praluent_PatientType_12",
    "Description": "Praluent_PatientType_12: Praluent_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Praluent_Efficacy_12",
    "Description": "Praluent_Efficacy_12: Praluent_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~50% In another clinical study of adults with HoFH, PRALUENT lowered bad choleste,2="
  },
  {
    "Column": "Praluent_Dosing_12",
    "Description": "Praluent_Dosing_12: Praluent_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2="
  },
  {
    "Column": "Praluent_MOA_12",
    "Description": "Praluent_MOA_12: Praluent_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Praluent_Indication_12",
    "Description": "Praluent_Indication_12: Praluent_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Repatha_PatientType_12",
    "Description": "Repatha_PatientType_12: Repatha_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Repatha_Efficacy_12",
    "Description": "Repatha_Efficacy_12: Repatha_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: - 15% RRR in time to 1st occurrence of CV death,"
  },
  {
    "Column": "Repatha_Dosing_12",
    "Description": "Repatha_Dosing_12: Repatha_Dosing",
    "Answer_Options": "1=Q2WPatient self-administered Injectable,2=Q2WPatient self-administered Injectable"
  },
  {
    "Column": "Repatha_MOA_12",
    "Description": "Repatha_MOA_12: Repatha_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2=PCSK9 inhibitor"
  },
  {
    "Column": "Repatha_Indication_12",
    "Description": "Repatha_Indication_12: Repatha_Indication",
    "Answer_Options": "1=As currently indicated,2=As currently indicated, plus: Indicated to reduce risk of CV events in patients with clinical ASCVD (without a prior CV"
  },
  {
    "Column": "Product_W_PatientType_12",
    "Description": "Product_W_PatientType_12: Product_W_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_W_Efficacy_12",
    "Description": "Product_W_Efficacy_12: Product_W_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to month 17 is ~49% Mean % change in Lp(a) from Baseline to end of study is ~63%,2="
  },
  {
    "Column": "Product_W_Dosing_12",
    "Description": "Product_W_Dosing_12: Product_W_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2="
  },
  {
    "Column": "Product_W_MOA_12",
    "Description": "Product_W_MOA_12: Product_W_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor plus selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Product_W_Indication_12",
    "Description": "Product_W_Indication_12: Product_W_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2="
  },
  {
    "Column": "Product_X_PatientType_12",
    "Description": "Product_X_PatientType_12: Product_X_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_X_Efficacy_12",
    "Description": "Product_X_Efficacy_12: Product_X_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline to Day 365 is ~33% Mean % change in Lp(a) from Baseline to end of study is ~55% In Es,2=Mean % change in LDL from Baseline to end of study is ~45% Mean % change in Lp(a) from Baseline to end of study is ~55%"
  },
  {
    "Column": "Product_X_Dosing_12",
    "Description": "Product_X_Dosing_12: Product_X_Dosing",
    "Answer_Options": "1=QDnon-fasting oral,2=QDnon-fasting oral"
  },
  {
    "Column": "Product_X_MOA_12",
    "Description": "Product_X_MOA_12: Product_X_MOA",
    "Answer_Options": "1=Cholesterol ester transfer protein (CETP) inhibitor,2=Cholesterol ester transfer protein (CETP) inhibitor"
  },
  {
    "Column": "Product_X_Indication_12",
    "Description": "Product_X_Indication_12: Product_X_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Y_PatientType_12",
    "Description": "Product_Y_PatientType_12: Product_Y_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Y_Efficacy_12",
    "Description": "Product_Y_Efficacy_12: Product_Y_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~60%,2=Mean % change in LDL from Baseline is ~60% In Established CVD patients: Primary Endpoint: 20% RRR on MACE+ (including MA"
  },
  {
    "Column": "Product_Y_Dosing_12",
    "Description": "Product_Y_Dosing_12: Product_Y_Dosing",
    "Answer_Options": "1=QDfasting oral,2=QDfasting oral"
  },
  {
    "Column": "Product_Y_MOA_12",
    "Description": "Product_Y_MOA_12: Product_Y_MOA",
    "Answer_Options": "1=Small molecule PCSK9 inhibitor,2=Small molecule PCSK9 inhibitor"
  },
  {
    "Column": "Product_Y_Indication_12",
    "Description": "Product_Y_Indication_12: Product_Y_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re,2=Indicated as adjunct to diet & statin therapy for treatment of adults with primary hyperlipidemia, including HeFH, to re"
  },
  {
    "Column": "Product_Z_PatientType_12",
    "Description": "Product_Z_PatientType_12: Product_Z_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Product_Z_Efficacy_12",
    "Description": "Product_Z_Efficacy_12: Product_Z_Efficacy",
    "Answer_Options": "1=Mean % change in LDL from Baseline is ~65%,2="
  },
  {
    "Column": "Product_Z_Dosing_12",
    "Description": "Product_Z_Dosing_12: Product_Z_Dosing",
    "Answer_Options": "1=QM Patient Self-administered Injectable,2="
  },
  {
    "Column": "Product_Z_MOA_12",
    "Description": "Product_Z_MOA_12: Product_Z_MOA",
    "Answer_Options": "1=PCSK9 inhibitor,2="
  },
  {
    "Column": "Product_Z_Indication_12",
    "Description": "Product_Z_Indication_12: Product_Z_Indication",
    "Answer_Options": "1=Indicated as adjunct to diet & other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, t,2="
  },
  {
    "Column": "Nexlitol_PatientType_12",
    "Description": "Nexlitol_PatientType_12: Nexlitol_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Nexlitol_Efficacy_12",
    "Description": "Nexlitol_Efficacy_12: Nexlitol_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Nexlitol_Dosing_12",
    "Description": "Nexlitol_Dosing_12: Nexlitol_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Nexlitol_MOA_12",
    "Description": "Nexlitol_MOA_12: Nexlitol_MOA",
    "Answer_Options": "1=ACL inhibitor,2="
  },
  {
    "Column": "Nexlitol_Indication_12",
    "Description": "Nexlitol_Indication_12: Nexlitol_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Zetia_PatientType_12",
    "Description": "Zetia_PatientType_12: Zetia_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Zetia_Efficacy_12",
    "Description": "Zetia_Efficacy_12: Zetia_Efficacy",
    "Answer_Options": "1=As currently known,2="
  },
  {
    "Column": "Zetia_Dosing_12",
    "Description": "Zetia_Dosing_12: Zetia_Dosing",
    "Answer_Options": "1=QD oral,2="
  },
  {
    "Column": "Zetia_MOA_12",
    "Description": "Zetia_MOA_12: Zetia_MOA",
    "Answer_Options": "1=selective cholesterol-absorption inhibitor,2="
  },
  {
    "Column": "Zetia_Indication_12",
    "Description": "Zetia_Indication_12: Zetia_Indication",
    "Answer_Options": "1=As currently indicated,2="
  },
  {
    "Column": "Other_Therapies_PatientType_12",
    "Description": "Other_Therapies_PatientType_12: Other_Therapies_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "Other_Therapies_Efficacy_12",
    "Description": "Other_Therapies_Efficacy_12: Other_Therapies_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Dosing_12",
    "Description": "Other_Therapies_Dosing_12: Other_Therapies_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_MOA_12",
    "Description": "Other_Therapies_MOA_12: Other_Therapies_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "Other_Therapies_Indication_12",
    "Description": "Other_Therapies_Indication_12: Other_Therapies_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_PatientType_12",
    "Description": "No_Addl_Therap_PatientType_12: No_Addl_Therap_PatientType",
    "Answer_Options": "1=$ {res.Patient_Type_1},2=$ {res.Patient_Type_2}"
  },
  {
    "Column": "No_Addl_Therap_Efficacy_12",
    "Description": "No_Addl_Therap_Efficacy_12: No_Addl_Therap_Efficacy",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Dosing_12",
    "Description": "No_Addl_Therap_Dosing_12: No_Addl_Therap_Dosing",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_MOA_12",
    "Description": "No_Addl_Therap_MOA_12: No_Addl_Therap_MOA",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "No_Addl_Therap_Indication_12",
    "Description": "No_Addl_Therap_Indication_12: No_Addl_Therap_Indication",
    "Answer_Options": "1=,2="
  },
  {
    "Column": "B3_12r1c1",
    "Description": "B3_12r1c1: Leqvio - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_12"
  },
  {
    "Column": "B3_12r2c1",
    "Description": "B3_12r2c1: PRALUENT - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_12"
  },
  {
    "Column": "B3_12r3c1",
    "Description": "B3_12r3c1: REPATHA - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_12"
  },
  {
    "Column": "B3_12r4c1",
    "Description": "B3_12r4c1: Product W - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_12"
  },
  {
    "Column": "B3_12r5c1",
    "Description": "B3_12r5c1: Product X - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_12"
  },
  {
    "Column": "B3_12r6c1",
    "Description": "B3_12r6c1: Product Y - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_12"
  },
  {
    "Column": "B3_12r7c1",
    "Description": "B3_12r7c1: Product Z - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_12"
  },
  {
    "Column": "B3_12r8c1",
    "Description": "B3_12r8c1: NEXLETOL / NEXLIZET - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_12"
  },
  {
    "Column": "B3_12r9c1",
    "Description": "B3_12r9c1: ZETIA (ezetimibe) - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_12"
  },
  {
    "Column": "B3_12r10c1",
    "Description": "B3_12r10c1: Other treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_12"
  },
  {
    "Column": "B3_12r11c1",
    "Description": "B3_12r11c1: No additional treatment - Original Allocation - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_12"
  },
  {
    "Column": "B3_12r1c2",
    "Description": "B3_12r1c2: Leqvio - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_12"
  },
  {
    "Column": "B3_12r2c2",
    "Description": "B3_12r2c2: PRALUENT - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_12"
  },
  {
    "Column": "B3_12r3c2",
    "Description": "B3_12r3c2: REPATHA - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_12"
  },
  {
    "Column": "B3_12r4c2",
    "Description": "B3_12r4c2: Product W - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_12"
  },
  {
    "Column": "B3_12r5c2",
    "Description": "B3_12r5c2: Product X - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_12"
  },
  {
    "Column": "B3_12r6c2",
    "Description": "B3_12r6c2: Product Y - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_12"
  },
  {
    "Column": "B3_12r7c2",
    "Description": "B3_12r7c2: Product Z - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_12"
  },
  {
    "Column": "B3_12r8c2",
    "Description": "B3_12r8c2: NEXLETOL / NEXLIZET - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_12"
  },
  {
    "Column": "B3_12r9c2",
    "Description": "B3_12r9c2: ZETIA (ezetimibe) - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_12"
  },
  {
    "Column": "B3_12r10c2",
    "Description": "B3_12r10c2: Other treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_12"
  },
  {
    "Column": "B3_12r11c2",
    "Description": "B3_12r11c2: No additional treatment - Next 100 Patients - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA",
    "ParentQuestion": "B3_12"
  },
  {
    "Column": "B3_12r1dum1",
    "Description": "B3_12r1dum1: Leqvio - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r2dum1",
    "Description": "B3_12r2dum1: PRALUENT - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r3dum1",
    "Description": "B3_12r3dum1: REPATHA - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r4dum1",
    "Description": "B3_12r4dum1: Product W - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r5dum1",
    "Description": "B3_12r5dum1: Product X - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r6dum1",
    "Description": "B3_12r6dum1: Product Y - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r7dum1",
    "Description": "B3_12r7dum1: Product Z - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r8dum1",
    "Description": "B3_12r8dum1: NEXLETOL / NEXLIZET - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r9dum1",
    "Description": "B3_12r9dum1: ZETIA (ezetimibe) - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r10dum1",
    "Description": "B3_12r10dum1: Other treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r11dum1",
    "Description": "B3_12r11dum1: No additional treatment - Product - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r1dum2",
    "Description": "B3_12r1dum2: Leqvio - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r2dum2",
    "Description": "B3_12r2dum2: PRALUENT - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r3dum2",
    "Description": "B3_12r3dum2: REPATHA - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r4dum2",
    "Description": "B3_12r4dum2: Product W - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r5dum2",
    "Description": "B3_12r5dum2: Product X - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r6dum2",
    "Description": "B3_12r6dum2: Product Y - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r7dum2",
    "Description": "B3_12r7dum2: Product Z - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r8dum2",
    "Description": "B3_12r8dum2: NEXLETOL / NEXLIZET - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r9dum2",
    "Description": "B3_12r9dum2: ZETIA (ezetimibe) - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r10dum2",
    "Description": "B3_12r10dum2: Other treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r11dum2",
    "Description": "B3_12r11dum2: No additional treatment - MOA - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r1dum3",
    "Description": "B3_12r1dum3: Leqvio - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r2dum3",
    "Description": "B3_12r2dum3: PRALUENT - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r3dum3",
    "Description": "B3_12r3dum3: REPATHA - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r4dum3",
    "Description": "B3_12r4dum3: Product W - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r5dum3",
    "Description": "B3_12r5dum3: Product X - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r6dum3",
    "Description": "B3_12r6dum3: Product Y - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r7dum3",
    "Description": "B3_12r7dum3: Product Z - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r8dum3",
    "Description": "B3_12r8dum3: NEXLETOL / NEXLIZET - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r9dum3",
    "Description": "B3_12r9dum3: ZETIA (ezetimibe) - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r10dum3",
    "Description": "B3_12r10dum3: Other treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r11dum3",
    "Description": "B3_12r11dum3: No additional treatment - Dosing - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r1dum4",
    "Description": "B3_12r1dum4: Leqvio - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r2dum4",
    "Description": "B3_12r2dum4: PRALUENT - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r3dum4",
    "Description": "B3_12r3dum4: REPATHA - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r4dum4",
    "Description": "B3_12r4dum4: Product W - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r5dum4",
    "Description": "B3_12r5dum4: Product X - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r6dum4",
    "Description": "B3_12r6dum4: Product Y - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r7dum4",
    "Description": "B3_12r7dum4: Product Z - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r8dum4",
    "Description": "B3_12r8dum4: NEXLETOL / NEXLIZET - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r9dum4",
    "Description": "B3_12r9dum4: ZETIA (ezetimibe) - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r10dum4",
    "Description": "B3_12r10dum4: Other treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r11dum4",
    "Description": "B3_12r11dum4: No additional treatment - Indication - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r1dum5",
    "Description": "B3_12r1dum5: Leqvio - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r2dum5",
    "Description": "B3_12r2dum5: PRALUENT - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r3dum5",
    "Description": "B3_12r3dum5: REPATHA - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r4dum5",
    "Description": "B3_12r4dum5: Product W - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r5dum5",
    "Description": "B3_12r5dum5: Product X - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r6dum5",
    "Description": "B3_12r6dum5: Product Y - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r7dum5",
    "Description": "B3_12r7dum5: Product Z - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r8dum5",
    "Description": "B3_12r8dum5: NEXLETOL / NEXLIZET - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r9dum5",
    "Description": "B3_12r9dum5: ZETIA (ezetimibe) - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r10dum5",
    "Description": "B3_12r10dum5: Other treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "B3_12r11dum5",
    "Description": "B3_12r11dum5: No additional treatment - Efficacy - To be used on top of maximally tolerated statin therapy for: Colored Text=differences from current clinical profile",
    "Answer_Options": "NA"
  },
  {
    "Column": "dumRanBlockC",
    "Description": "dumRanBlockC: Hidden for TPPs",
    "Answer_Options": "1=Product W,2=Product X,3=Product Y,4=Product Z"
  },
  {
    "Column": "C1_1c1",
    "Description": "C1_1c1: Adults with established CVD (with history of event) or at high risk for CV events (without a prior event) - Now, thinking about those same patient groups with uncontrolled LDL-C mentioned earlier in the survey, how soon after Product W becomes ava",
    "Answer_Options": "1=As soon as it is available,2=Within 6 months of it being available,3=Within 1 year of it being available,4=Within 2 years of it being available,5=After it has been available for at least 2 years,6=I don’t anticipate prescribing it",
    "ParentQuestion": "C1_1"
  },
  {
    "Column": "C1_1c2",
    "Description": "C1_1c2: Adults with low to medium risk for CV events (without a prior event) - Now, thinking about those same patient groups with uncontrolled LDL-C mentioned earlier in the survey, how soon after Product W becomes available would you prescribe it? To be",
    "Answer_Options": "1=As soon as it is available,2=Within 6 months of it being available,3=Within 1 year of it being available,4=Within 2 years of it being available,5=After it has been available for at least 2 years,6=I don’t anticipate prescribing it",
    "ParentQuestion": "C1_1"
  },
  {
    "Column": "C1_2c1",
    "Description": "C1_2c1: Adults with established CVD (with history of event) or at high risk for CV events (without a prior event) - Now, thinking about those same patient groups with uncontrolled LDL-C mentioned earlier in the survey, how soon after Product X becomes ava",
    "Answer_Options": "1=As soon as it is available,2=Within 6 months of it being available,3=Within 1 year of it being available,4=Within 2 years of it being available,5=After it has been available for at least 2 years,6=I don’t anticipate prescribing it",
    "ParentQuestion": "C1_2"
  },
  {
    "Column": "C1_2c2",
    "Description": "C1_2c2: Adults with low to medium risk for CV events (without a prior event) - Now, thinking about those same patient groups with uncontrolled LDL-C mentioned earlier in the survey, how soon after Product X becomes available would you prescribe it? To be",
    "Answer_Options": "1=As soon as it is available,2=Within 6 months of it being available,3=Within 1 year of it being available,4=Within 2 years of it being available,5=After it has been available for at least 2 years,6=I don’t anticipate prescribing it",
    "ParentQuestion": "C1_2"
  },
  {
    "Column": "C1_3c1",
    "Description": "C1_3c1: Adults with established CVD (with history of event) or at high risk for CV events (without a prior event) - Now, thinking about those same patient groups with uncontrolled LDL-C mentioned earlier in the survey, how soon after Product Y becomes ava",
    "Answer_Options": "1=As soon as it is available,2=Within 6 months of it being available,3=Within 1 year of it being available,4=Within 2 years of it being available,5=After it has been available for at least 2 years,6=I don’t anticipate prescribing it",
    "ParentQuestion": "C1_3"
  },
  {
    "Column": "C1_3c2",
    "Description": "C1_3c2: Adults with low to medium risk for CV events (without a prior event) - Now, thinking about those same patient groups with uncontrolled LDL-C mentioned earlier in the survey, how soon after Product Y becomes available would you prescribe it? To be",
    "Answer_Options": "1=As soon as it is available,2=Within 6 months of it being available,3=Within 1 year of it being available,4=Within 2 years of it being available,5=After it has been available for at least 2 years,6=I don’t anticipate prescribing it",
    "ParentQuestion": "C1_3"
  },
  {
    "Column": "C1_4c1",
    "Description": "C1_4c1: Adults with established CVD (with history of event) or at high risk for CV events (without a prior event) - Now, thinking about those same patient groups with uncontrolled LDL-C mentioned earlier in the survey, how soon after Product Z becomes ava",
    "Answer_Options": "1=As soon as it is available,2=Within 6 months of it being available,3=Within 1 year of it being available,4=Within 2 years of it being available,5=After it has been available for at least 2 years,6=I don’t anticipate prescribing it",
    "ParentQuestion": "C1_4"
  },
  {
    "Column": "C1_4c2",
    "Description": "C1_4c2: Adults with low to medium risk for CV events (without a prior event) - Now, thinking about those same patient groups with uncontrolled LDL-C mentioned earlier in the survey, how soon after Product Z becomes available would you prescribe it? To be",
    "Answer_Options": "1=As soon as it is available,2=Within 6 months of it being available,3=Within 1 year of it being available,4=Within 2 years of it being available,5=After it has been available for at least 2 years,6=I don’t anticipate prescribing it",
    "ParentQuestion": "C1_4"
  },
  {
    "Column": "C2c1",
    "Description": "C2c1: Adults with $ {res.established_CVD} - Now, thinking about those same patient groups mentioned earlier in the survey, how soon after this product becomes available would you prescribe it? To be used on top of maximally tolerated statin therapy for:",
    "Answer_Options": "1=As soon as it is available,2=Within 6 months of it being available,3=Within 1 year of it being available,4=Within 2 years of it being available,5=After it has been available for at least 2 years",
    "ParentQuestion": "C2"
  },
  {
    "Column": "C2c2",
    "Description": "C2c2: Adults with $ {res.risk_factors_for_CV} - Now, thinking about those same patient groups mentioned earlier in the survey, how soon after this product becomes available would you prescribe it? To be used on top of maximally tolerated statin therapy fo",
    "Answer_Options": "1=As soon as it is available,2=Within 6 months of it being available,3=Within 1 year of it being available,4=Within 2 years of it being available,5=After it has been available for at least 2 years",
    "ParentQuestion": "C2"
  },
  {
    "Column": "C2ar1",
    "Description": "C2ar1: A good indicator of the quality of care within a practice setting, would be the proportion of ASCVD patients in that practice who have a LDL-C level of less than <70 mg/dL. - Please indicate how much you agree or disagree with the statements below.",
    "Answer_Options": "1=Strongly disagree 1,2=2,3=3,4=4,5=5,6=6,7=Strongly agree 7,8=Don't know/ unsure",
    "ParentQuestion": "C2a"
  },
  {
    "Column": "C2ar2",
    "Description": "C2ar2: Providing a 'good quality of care' for hypercholesterolemia patients involves treating elevated LDL-C aggressively. - Please indicate how much you agree or disagree with the statements below.",
    "Answer_Options": "1=Strongly disagree 1,2=2,3=3,4=4,5=5,6=6,7=Strongly agree 7,8=Don't know/ unsure",
    "ParentQuestion": "C2a"
  },
  {
    "Column": "C2ar3",
    "Description": "C2ar3: For ASCVD patients, the ideal LDL-C level would be even lower than the current AHA/ACC guideline of 70mg/dL - Please indicate how much you agree or disagree with the statements below.",
    "Answer_Options": "1=Strongly disagree 1,2=2,3=3,4=4,5=5,6=6,7=Strongly agree 7,8=Don't know/ unsure",
    "ParentQuestion": "C2a"
  },
  {
    "Column": "C2ar4",
    "Description": "C2ar4: For ASCVD patients whose LDL-C is substantially above 70mg/dL, putting them at high risk of a recurrent event, I'm inclined to forgo ezetimibe and move directly to a more effective LDL-C lowering therapy instead - Please indicate how much you agree",
    "Answer_Options": "1=Strongly disagree 1,2=2,3=3,4=4,5=5,6=6,7=Strongly agree 7,8=Don't know/ unsure",
    "ParentQuestion": "C2a"
  },
  {
    "Column": "C2ar5",
    "Description": "C2ar5: My personal goal is to bring ALL my ASCVD patients to a LDL-C level of <70 mg/dL - Please indicate how much you agree or disagree with the statements below.",
    "Answer_Options": "1=Strongly disagree 1,2=2,3=3,4=4,5=5,6=6,7=Strongly agree 7,8=Don't know/ unsure",
    "ParentQuestion": "C2a"
  },
  {
    "Column": "C2ar6",
    "Description": "C2ar6: It's important to understand the complete risk profile of an ASCVD patient when devising a lipid treatment approach - Please indicate how much you agree or disagree with the statements below.",
    "Answer_Options": "1=Strongly disagree 1,2=2,3=3,4=4,5=5,6=6,7=Strongly agree 7,8=Don't know/ unsure",
    "ParentQuestion": "C2a"
  },
  {
    "Column": "C3r1",
    "Description": "C3r1: Buy-and-bill: Healthcare provider directly purchases and stocks the medication, prescribes and administers the drug, and subsequently bills the payer or patient - HCP-administered medications may be acquired in many ways. Please indicate your degree",
    "Answer_Options": "1=Never utilize,2=Rarely utilize,3=Sometimes utilize,4=Often utilize,5=Always utilize",
    "ParentQuestion": "C3"
  },
  {
    "Column": "C3r2",
    "Description": "C3r2: Brown bagging: Medication is dispensed directly to the patient at the pharmacy (usually a specialty pharmacy) and is transported by the patient to the site of care (e.g., physician's office, hospital, or clinic, etc.) where it is then administered b",
    "Answer_Options": "1=Never utilize,2=Rarely utilize,3=Sometimes utilize,4=Often utilize,5=Always utilize",
    "ParentQuestion": "C3"
  },
  {
    "Column": "C3r3",
    "Description": "C3r3: White bagging: Medication is distributed from the pharmacy (usually a specialty pharmacy) directly to the site of care (e.g., physician's office, hospital, or clinic, etc.) where it is then administered by a healthcare provider - HCP-administered me",
    "Answer_Options": "1=Never utilize,2=Rarely utilize,3=Sometimes utilize,4=Often utilize,5=Always utilize",
    "ParentQuestion": "C3"
  },
  {
    "Column": "C3r4",
    "Description": "C3r4: Sending the patient to an alternate site of care, where medication(s) can be administered (for example by injection) by a healthcare professional within a setting designed to deliver injectable or infused medications - HCP-administered medications m",
    "Answer_Options": "1=Never utilize,2=Rarely utilize,3=Sometimes utilize,4=Often utilize,5=Always utilize",
    "ParentQuestion": "C3"
  },
  {
    "Column": "C4c1",
    "Description": "C4c1: Adopt a Buy & Bill Model - To what extent is your practice willing to do each of the following for HCP-administered medications:",
    "Answer_Options": "1=Not willing,2=Somewhat willing,3=Willing,4=Very willing,5=Already have adopted this approach",
    "ParentQuestion": "C4"
  },
  {
    "Column": "C4c2",
    "Description": "C4c2: Send Patients to an Alternate Site of Care - To what extent is your practice willing to do each of the following for HCP-administered medications:",
    "Answer_Options": "1=Not willing,2=Somewhat willing,3=Willing,4=Very willing,5=Already have adopted this approach",
    "ParentQuestion": "C4"
  },
  {
    "Column": "C5r1",
    "Description": "C5r1: Duration of action of 6 months - To what extent would each of the following increase your willingness to buy & bill a lipid lowering therapy?",
    "Answer_Options": "1=1 Not at all likely to increase willingness to buy & bill,2=2,3=3,4=4,5=5 Very likely to increase willingness to buy & bill",
    "ParentQuestion": "C5"
  },
  {
    "Column": "C5r2",
    "Description": "C5r2: Duration of action of 12 months - To what extent would each of the following increase your willingness to buy & bill a lipid lowering therapy?",
    "Answer_Options": "1=1 Not at all likely to increase willingness to buy & bill,2=2,3=3,4=4,5=5 Very likely to increase willingness to buy & bill",
    "ParentQuestion": "C5"
  },
  {
    "Column": "C5r3",
    "Description": "C5r3: Broad coverage (i.e., no/low risk of non-coverage) - To what extent would each of the following increase your willingness to buy & bill a lipid lowering therapy?",
    "Answer_Options": "1=1 Not at all likely to increase willingness to buy & bill,2=2,3=3,4=4,5=5 Very likely to increase willingness to buy & bill",
    "ParentQuestion": "C5"
  },
  {
    "Column": "C5r4",
    "Description": "C5r4: Eliminate administrative burden on office staff - To what extent would each of the following increase your willingness to buy & bill a lipid lowering therapy?",
    "Answer_Options": "1=1 Not at all likely to increase willingness to buy & bill,2=2,3=3,4=4,5=5 Very likely to increase willingness to buy & bill",
    "ParentQuestion": "C5"
  },
  {
    "Column": "C6",
    "Description": "C6: What is the one thing that would have to change for you to adopt a buy & bill model in your practice in the next 6 months?",
    "Answer_Options": "NA"
  },
  {
    "Column": "C2b",
    "Description": "C2b: You can click on the image to enlarge.[rel Product_Y_v2.png]If you assume this product did not require a prior authorization, by how much might that increase your prescribing of the product?",
    "Answer_Options": "NA"
  },
  {
    "Column": "noanswerC2b_n1",
    "Description": "noanswerC2b_n1: You can click on the image to enlarge.[rel Product_Y_v2.png]If you assume this product did not require a prior authorization, by how much might that increase your prescribing of the product?: Would not increase my prescribing - No Answer",
    "Answer_Options": "0=NO TO: You can click on the image to enlarge.[rel Product_Y_v2.png]If you assume this product did not require a prior au,1=You can click on the image to enlarge.[rel Product_Y_v2.png]If you assume this product did not require a prior authoriza"
  },
  {
    "Column": "C5ar1c1",
    "Description": "C5ar1c1: Adults with established CVD (with history of event) or at high risk for CV events (without a prior event) - Thinking more broadly about the patient types we have been reviewing in this survey, please estimate what % of those patients are currentl",
    "Answer_Options": "NA",
    "ParentQuestion": "C5a"
  },
  {
    "Column": "C5ar1c2",
    "Description": "C5ar1c2: Adults with low to medium risk for CV events (without a prior event) - Thinking more broadly about the patient types we have been reviewing in this survey, please estimate what % of those patients are currently taking a GLP-1 inhibitor (e.g., Oze",
    "Answer_Options": "NA",
    "ParentQuestion": "C5a"
  },
  {
    "Column": "C5b",
    "Description": "C5b: How important are guideline recommendations (e.g., AHA/ACC Class Ia, IIa recommendations) in determining your choice of advanced lipid-lowering therapies?",
    "Answer_Options": "1=Not important,2=Somewhat important,3=Very important"
  },
  {
    "Column": "C6ar1",
    "Description": "C6ar1: Buy-and-bill through practice: Healthcare provider directly purchases and stocks the medication, prescribes and administers the drug, and subsequently bills the payer or patient - HCP-administered medications may be acquired in many ways. Please in",
    "Answer_Options": "1=Never utilize,2=Rarely utilize,3=Sometimes utilize,4=Often utilize,5=Always utilize",
    "ParentQuestion": "C6a"
  },
  {
    "Column": "C6ar2",
    "Description": "C6ar2: Buy-and-bill through affiliated healthcare system: System or hospital purchases and stocks the medication and healthcare provider administers. The hospital or system bills the payer or patient. - HCP-administered medications may be acquired in many",
    "Answer_Options": "1=Never utilize,2=Rarely utilize,3=Sometimes utilize,4=Often utilize,5=Always utilize",
    "ParentQuestion": "C6a"
  },
  {
    "Column": "C6ar3",
    "Description": "C6ar3: Brown bagging: Medication is dispensed directly to the patient at the pharmacy (usually a specialty pharmacy) and is transported by the patient to the site of care (e.g., physician's office, hospital, or clinic, etc.) where it is then administered",
    "Answer_Options": "1=Never utilize,2=Rarely utilize,3=Sometimes utilize,4=Often utilize,5=Always utilize",
    "ParentQuestion": "C6a"
  },
  {
    "Column": "C6ar4",
    "Description": "C6ar4: White bagging: Medication is distributed from the pharmacy (usually a specialty pharmacy) directly to the site of care (e.g., physician's office, hospital, or clinic, etc.) where it is then administered by a healthcare provider - HCP-administered m",
    "Answer_Options": "1=Never utilize,2=Rarely utilize,3=Sometimes utilize,4=Often utilize,5=Always utilize",
    "ParentQuestion": "C6a"
  },
  {
    "Column": "C6ar5",
    "Description": "C6ar5: Sending the patient to an alternate site of care, where medication(s) can be administered (for example by injection) by a healthcare professional within a setting designed to deliver injectable or infused medications - HCP-administered medications",
    "Answer_Options": "1=Never utilize,2=Rarely utilize,3=Sometimes utilize,4=Often utilize,5=Always utilize",
    "ParentQuestion": "C6a"
  },
  {
    "Column": "C6ar6",
    "Description": "C6ar6: Meds-for-beds program: A medication is provided directly to a patient while still in hospital (after a CV event) to initiate therapy. Drug manufacturer provides a coupon for the first dose since the patient’s insurer will not yet have approved th",
    "Answer_Options": "1=Never utilize,2=Rarely utilize,3=Sometimes utilize,4=Often utilize,5=Always utilize",
    "ParentQuestion": "C6a"
  },
  {
    "Column": "C7c1",
    "Description": "C7c1: Adopt a Buy & Bill Model - To what extent is your practice willing to do each of the following for HCP-administered medications:",
    "Answer_Options": "1=Not willing,2=Somewhat willing,3=Willing,4=Very willing,5=Already have adopted this approach",
    "ParentQuestion": "C7"
  },
  {
    "Column": "C7c2",
    "Description": "C7c2: Send Patients to an Alternate Site of Care - To what extent is your practice willing to do each of the following for HCP-administered medications:",
    "Answer_Options": "1=Not willing,2=Somewhat willing,3=Willing,4=Very willing,5=Already have adopted this approach",
    "ParentQuestion": "C7"
  },
  {
    "Column": "D1r1c1",
    "Description": "D1r1c1: <70 mg/dL - Distribution of hypercholesterolemia patients based on *baseline LDL-C, prior to ANY prescription medication(s), including statins*\"BEFORE\" - Thank you for your time so far. Just a few more questions…For this next question, we'd like",
    "Answer_Options": "NA",
    "ParentQuestion": "D1"
  },
  {
    "Column": "D1r2c1",
    "Description": "D1r2c1: 70-100 mg/dL - Distribution of hypercholesterolemia patients based on *baseline LDL-C, prior to ANY prescription medication(s), including statins*\"BEFORE\" - Thank you for your time so far. Just a few more questions…For this next question, we'd l",
    "Answer_Options": "NA",
    "ParentQuestion": "D1"
  },
  {
    "Column": "D1r3c1",
    "Description": "D1r3c1: 101-130 mg/dL - Distribution of hypercholesterolemia patients based on *baseline LDL-C, prior to ANY prescription medication(s), including statins*\"BEFORE\" - Thank you for your time so far. Just a few more questions…For this next question, we'd",
    "Answer_Options": "NA",
    "ParentQuestion": "D1"
  },
  {
    "Column": "D1r4c1",
    "Description": "D1r4c1: >130 mg/dL - Distribution of hypercholesterolemia patients based on *baseline LDL-C, prior to ANY prescription medication(s), including statins*\"BEFORE\" - Thank you for your time so far. Just a few more questions…For this next question, we'd lik",
    "Answer_Options": "NA",
    "ParentQuestion": "D1"
  },
  {
    "Column": "D1r1c2",
    "Description": "D1r1c2: <70 mg/dL - Distribution of hypercholesterolemia patients based on *current LDL-C levels as a result of prescription medication(s)*\"AFTER\" - Thank you for your time so far. Just a few more questions…For this next question, we'd like to understan",
    "Answer_Options": "NA",
    "ParentQuestion": "D1"
  },
  {
    "Column": "D1r2c2",
    "Description": "D1r2c2: 70-100 mg/dL - Distribution of hypercholesterolemia patients based on *current LDL-C levels as a result of prescription medication(s)*\"AFTER\" - Thank you for your time so far. Just a few more questions…For this next question, we'd like to unders",
    "Answer_Options": "NA",
    "ParentQuestion": "D1"
  },
  {
    "Column": "D1r3c2",
    "Description": "D1r3c2: 101-130 mg/dL - Distribution of hypercholesterolemia patients based on *current LDL-C levels as a result of prescription medication(s)*\"AFTER\" - Thank you for your time so far. Just a few more questions…For this next question, we'd like to under",
    "Answer_Options": "NA",
    "ParentQuestion": "D1"
  },
  {
    "Column": "D1r4c2",
    "Description": "D1r4c2: >130 mg/dL - Distribution of hypercholesterolemia patients based on *current LDL-C levels as a result of prescription medication(s)*\"AFTER\" - Thank you for your time so far. Just a few more questions…For this next question, we'd like to understa",
    "Answer_Options": "NA",
    "ParentQuestion": "D1"
  },
  {
    "Column": "D2c1",
    "Description": "D2c1: Repatha (evolucumab) - Thank you for your time so far. Just a few more questions…Please indicate how long after each of the following medication(s) were approved as treatments for lowering LDL-C you waited to prescribe them for the first time. ",
    "Answer_Options": "1=Within 1 month,2=Within 1-3 months,3=Within 4-6 months,4=Within 7-12 months,5=Longer than 12 months or more,6=I am unsure,7=Have never prescribed",
    "ParentQuestion": "D2"
  },
  {
    "Column": "D2c2",
    "Description": "D2c2: Praluent (alirocumab) - Thank you for your time so far. Just a few more questions…Please indicate how long after each of the following medication(s) were approved as treatments for lowering LDL-C you waited to prescribe them for the first time. ",
    "Answer_Options": "1=Within 1 month,2=Within 1-3 months,3=Within 4-6 months,4=Within 7-12 months,5=Longer than 12 months or more,6=I am unsure,7=Have never prescribed",
    "ParentQuestion": "D2"
  },
  {
    "Column": "D2c3",
    "Description": "D2c3: Leqvio (inclisiran) - Thank you for your time so far. Just a few more questions…Please indicate how long after each of the following medication(s) were approved as treatments for lowering LDL-C you waited to prescribe them for the first time. ",
    "Answer_Options": "1=Within 1 month,2=Within 1-3 months,3=Within 4-6 months,4=Within 7-12 months,5=Longer than 12 months or more,6=I am unsure,7=Have never prescribed",
    "ParentQuestion": "D2"
  },
  {
    "Column": "D2a",
    "Description": "D2a: At what level do you consider a patient with “uncontrolled LDL-C,” assuming they are already taking maximally tolerated statin therapy?",
    "Answer_Options": "1=≥ 55 mg/dL,2=≥ 70 mg/dL,3=≥ 100 mg/dL,4=≥ 130 mg/dL,5=≥ 170 mg/dL,6=≥ 200 mg/dL,7=None/other"
  },
  {
    "Column": "D8r1",
    "Description": "D8r1: Leqvio (inclisiran) - Based on your experience and knowledge, how would you rate your level of comfort with the following treatments?",
    "Answer_Options": "1=1$ {\" – \" if gv.request.device.isMobileDevice() else \"\"}Very Uncomfortable,2=2,3=3,4=4,5=5,6=6,7=7$ {\" – \" if gv.request.device.isMobileDevice() else \"\"}Extremely Comfortable",
    "ParentQuestion": "D8"
  },
  {
    "Column": "D8r2",
    "Description": "D8r2: Repatha (evolocumab) - Based on your experience and knowledge, how would you rate your level of comfort with the following treatments?",
    "Answer_Options": "1=1$ {\" – \" if gv.request.device.isMobileDevice() else \"\"}Very Uncomfortable,2=2,3=3,4=4,5=5,6=6,7=7$ {\" – \" if gv.request.device.isMobileDevice() else \"\"}Extremely Comfortable",
    "ParentQuestion": "D8"
  },
  {
    "Column": "D9",
    "Description": "D9: What % of your patients with established cardiovascular disease (CVD) (e.g., MI, stroke, or symptomatic PAD) require injectable therapy (e.g., Repatha, Leqvio, Praluent) to control their LDL-C?",
    "Answer_Options": "NA"
  },
  {
    "Column": "D10r1",
    "Description": "D10r1: It is easy to convince my patients to take an advanced therapy to lower LDL-C - How much do agree with the following statements?",
    "Answer_Options": "1=Do not agree at all,2=Agree slightly,3=Agree somewhat,4=Agree strongly,5=Agree completely",
    "ParentQuestion": "D10"
  },
  {
    "Column": "D10r2",
    "Description": "D10r2: My patients taking injectable therapy are more compliant than those taking only oral treatments to lower LDL-C - How much do agree with the following statements?",
    "Answer_Options": "1=Do not agree at all,2=Agree slightly,3=Agree somewhat,4=Agree strongly,5=Agree completely",
    "ParentQuestion": "D10"
  },
  {
    "Column": "D10r3",
    "Description": "D10r3: There are too many barriers to prescribing advanced therapies (e.g., Leqvio, Repatha, Nexletol/Nexlizet) - How much do agree with the following statements?",
    "Answer_Options": "1=Do not agree at all,2=Agree slightly,3=Agree somewhat,4=Agree strongly,5=Agree completely",
    "ParentQuestion": "D10"
  },
  {
    "Column": "D10r4",
    "Description": "D10r4: My treatment decisions for advanced therapies (e.g., Leqvio, Repatha, Nexletol/Nexlizet) are strongly impacted by patients' insurance coverage - How much do agree with the following statements?",
    "Answer_Options": "1=Do not agree at all,2=Agree slightly,3=Agree somewhat,4=Agree strongly,5=Agree completely",
    "ParentQuestion": "D10"
  },
  {
    "Column": "D10r5",
    "Description": "D10r5: I am responsible for ensuring my CVD patients have their LDL-C under control - How much do agree with the following statements?",
    "Answer_Options": "1=Do not agree at all,2=Agree slightly,3=Agree somewhat,4=Agree strongly,5=Agree completely",
    "ParentQuestion": "D10"
  },
  {
    "Column": "D10r6",
    "Description": "D10r6: My CVD patients are responsible for ensuring their LDL-C is under control - How much do agree with the following statements?",
    "Answer_Options": "1=Do not agree at all,2=Agree slightly,3=Agree somewhat,4=Agree strongly,5=Agree completely",
    "ParentQuestion": "D10"
  },
  {
    "Column": "D10r7",
    "Description": "D10r7: My CVD patients and I must collaborate to ensure their LDL-C is under control - How much do agree with the following statements?",
    "Answer_Options": "1=Do not agree at all,2=Agree slightly,3=Agree somewhat,4=Agree strongly,5=Agree completely",
    "ParentQuestion": "D10"
  },
  {
    "Column": "D3r1c1",
    "Description": "D3r1c1: Not insured - Adults with established CVD (with history of event) or at high risk for CV events (without a prior event) - What percentage of your current patients are covered by each type of insurance?",
    "Answer_Options": "NA",
    "ParentQuestion": "D3"
  },
  {
    "Column": "D3r2c1",
    "Description": "D3r2c1: Private insurance provided by employer / purchased in exchange - Adults with established CVD (with history of event) or at high risk for CV events (without a prior event) - What percentage of your current patients are covered by each type of insur",
    "Answer_Options": "NA",
    "ParentQuestion": "D3"
  },
  {
    "Column": "D3r3c1",
    "Description": "D3r3c1: Traditional Medicare (Medicare Part B Fee for Service) - Adults with established CVD (with history of event) or at high risk for CV events (without a prior event) - What percentage of your current patients are covered by each type of insurance?",
    "Answer_Options": "NA",
    "ParentQuestion": "D3"
  },
  {
    "Column": "D3r4c1",
    "Description": "D3r4c1: Traditional Medicare with supplemental insurance - Adults with established CVD (with history of event) or at high risk for CV events (without a prior event) - What percentage of your current patients are covered by each type of insurance?",
    "Answer_Options": "NA",
    "ParentQuestion": "D3"
  },
  {
    "Column": "D3r5c1",
    "Description": "D3r5c1: Private Medicare (Medicare Advantage / Part C managed through Private payer) - Adults with established CVD (with history of event) or at high risk for CV events (without a prior event) - What percentage of your current patients are covered by each",
    "Answer_Options": "NA",
    "ParentQuestion": "D3"
  },
  {
    "Column": "D3r6c1",
    "Description": "D3r6c1: Medicaid - Adults with established CVD (with history of event) or at high risk for CV events (without a prior event) - What percentage of your current patients are covered by each type of insurance?",
    "Answer_Options": "NA",
    "ParentQuestion": "D3"
  },
  {
    "Column": "D3r7c1",
    "Description": "D3r7c1: Veterans Administration (VA) - Adults with established CVD (with history of event) or at high risk for CV events (without a prior event) - What percentage of your current patients are covered by each type of insurance?",
    "Answer_Options": "NA",
    "ParentQuestion": "D3"
  },
  {
    "Column": "D3r8c1",
    "Description": "D3r8c1: Other - Adults with established CVD (with history of event) or at high risk for CV events (without a prior event) - What percentage of your current patients are covered by each type of insurance?",
    "Answer_Options": "NA",
    "ParentQuestion": "D3"
  },
  {
    "Column": "D3r1c2",
    "Description": "D3r1c2: Not insured - Adults with low to medium risk for CV events (without a prior event) - What percentage of your current patients are covered by each type of insurance?",
    "Answer_Options": "NA",
    "ParentQuestion": "D3"
  },
  {
    "Column": "D3r2c2",
    "Description": "D3r2c2: Private insurance provided by employer / purchased in exchange - Adults with low to medium risk for CV events (without a prior event) - What percentage of your current patients are covered by each type of insurance?",
    "Answer_Options": "NA",
    "ParentQuestion": "D3"
  },
  {
    "Column": "D3r3c2",
    "Description": "D3r3c2: Traditional Medicare (Medicare Part B Fee for Service) - Adults with low to medium risk for CV events (without a prior event) - What percentage of your current patients are covered by each type of insurance?",
    "Answer_Options": "NA",
    "ParentQuestion": "D3"
  },
  {
    "Column": "D3r4c2",
    "Description": "D3r4c2: Traditional Medicare with supplemental insurance - Adults with low to medium risk for CV events (without a prior event) - What percentage of your current patients are covered by each type of insurance?",
    "Answer_Options": "NA",
    "ParentQuestion": "D3"
  },
  {
    "Column": "D3r5c2",
    "Description": "D3r5c2: Private Medicare (Medicare Advantage / Part C managed through Private payer) - Adults with low to medium risk for CV events (without a prior event) - What percentage of your current patients are covered by each type of insurance?",
    "Answer_Options": "NA",
    "ParentQuestion": "D3"
  },
  {
    "Column": "D3r6c2",
    "Description": "D3r6c2: Medicaid - Adults with low to medium risk for CV events (without a prior event) - What percentage of your current patients are covered by each type of insurance?",
    "Answer_Options": "NA",
    "ParentQuestion": "D3"
  },
  {
    "Column": "D3r7c2",
    "Description": "D3r7c2: Veterans Administration (VA) - Adults with low to medium risk for CV events (without a prior event) - What percentage of your current patients are covered by each type of insurance?",
    "Answer_Options": "NA",
    "ParentQuestion": "D3"
  },
  {
    "Column": "D3r8c2",
    "Description": "D3r8c2: Other - Adults with low to medium risk for CV events (without a prior event) - What percentage of your current patients are covered by each type of insurance?",
    "Answer_Options": "NA",
    "ParentQuestion": "D3"
  },
  {
    "Column": "D4",
    "Description": "D4: What is the zip code of your main practice location?",
    "Answer_Options": "NA"
  },
  {
    "Column": "US_State",
    "Description": "US_State: US_State",
    "Answer_Options": "1=Alaska,2=Alabama,3=Arkansas,4=Arizona,5=California,6=Colorado,7=Connecticut,8=District of Columbia,9=Delaware,10=Florida,11=Georgia,12=Hawaii,13=Iowa,14=Idaho,15=Illinois,16=Indiana,17=Kansas,18=Kentucky,19=Louisiana,20=Massachusetts,21=Maryland,22=Maine,23=Michigan,24=Minnesota,25=Missouri,26=Mississippi,27=Montana,28=North Carolina,29=North Dakota,30=Nebraska,31=New Hampshire,32=New Jersey,33=New Mexico,34=Nevada,35=New York,36=Ohio,37=Oklahoma,38=Oregon,39=Pennsylvania,40=Rhode Island,41=South Carolina,42=South Dakota,43=Tennessee,44=Texas,45=Utah,46=Virginia,47=Vermont,48=Washington,49=Wisconsin,50=West Virginia,51=Wyoming,52=Other,53=Invalid State"
  },
  {
    "Column": "Region",
    "Description": "Region: Region",
    "Answer_Options": "1=Northeast,2=South,3=Midwest,4=West,5=Other,6=Invalid Region"
  },
  {
    "Column": "D5",
    "Description": "D5: Which of the following best describes where your primary practice is located?",
    "Answer_Options": "1=Urban,2=Suburban,3=Rural"
  },
  {
    "Column": "D6",
    "Description": "D6: How many physicians are in your practice?",
    "Answer_Options": "NA"
  },
  {
    "Column": "CONSENT",
    "Description": "CONSENT: If you would be willing to participate in future research to further elaborate on the responses from this survey, please indicate below:",
    "Answer_Options": "1=Yes, I would be willing to participate in a follow-up interview for additional compensation,2=No, I am not interested in participating in a follow-up interview for additional compensation"
  },
  {
    "Column": "D7",
    "Description": "D7: How do you identify?",
    "Answer_Options": "1=Man,2=Woman,3=Non-binary,4=Prefer to self-describe:,5=Prefer not to answer"
  },
  {
    "Column": "D7r4oe",
    "Description": "D7r4oe: How do you identify? - Prefer to self-describe:",
    "Answer_Options": "NA",
    "ParentQuestion": "D7",
    "Context": "D7: D7: How do you identify?"
  },
  {
    "Column": "qtime",
    "Description": "qtime: Total Interview Time",
    "Answer_Options": "NA"
  },
  {
    "Column": "NPI",
    "Description": "NPI: on List Sample Data",
    "Answer_Options": "NA"
  },
  {
    "Column": "IMS_NUM",
    "Description": "IMS_NUM: on List Sample Data",
    "Answer_Options": "NA"
  },
  {
    "Column": "FRST_NM",
    "Description": "FRST_NM: on List Sample Data",
    "Answer_Options": "NA"
  },
  {
    "Column": "LST_NM",
    "Description": "LST_NM: on List Sample Data",
    "Answer_Options": "NA"
  },
  {
    "Column": "ADDR_LINE_1",
    "Description": "ADDR_LINE_1: on List Sample Data",
    "Answer_Options": "NA"
  },
  {
    "Column": "ADDR_LINE_2",
    "Description": "ADDR_LINE_2: on List Sample Data",
    "Answer_Options": "NA"
  },
  {
    "Column": "ADDR_LINE_3",
    "Description": "ADDR_LINE_3: on List Sample Data",
    "Answer_Options": "NA"
  },
  {
    "Column": "CITY",
    "Description": "CITY: on List Sample Data",
    "Answer_Options": "NA"
  },
  {
    "Column": "STATE",
    "Description": "STATE: on List Sample Data",
    "Answer_Options": "NA"
  },
  {
    "Column": "ZIP_CD",
    "Description": "ZIP_CD: on List Sample Data",
    "Answer_Options": "NA"
  },
  {
    "Column": "LEQ_TIERS",
    "Description": "LEQ_TIERS: on List Sample Data",
    "Answer_Options": "NA"
  },
  {
    "Column": "SPEC_CD",
    "Description": "SPEC_CD: on List Sample Data",
    "Answer_Options": "NA"
  },
  {
    "Column": "SPEC_DESC",
    "Description": "SPEC_DESC: on List Sample Data",
    "Answer_Options": "NA"
  },
  {
    "Column": "SPEC_GRP_CD",
    "Description": "SPEC_GRP_CD: on List Sample Data",
    "Answer_Options": "NA"
  },
  {
    "Column": "SPEC_GRP_DESC",
    "Description": "SPEC_GRP_DESC: on List Sample Data",
    "Answer_Options": "NA"
  },
  {
    "Column": "PRIORITY_ACC_FLAG",
    "Description": "PRIORITY_ACC_FLAG: on List Sample Data",
    "Answer_Options": "NA"
  },
  {
    "Column": "Pela_Segment",
    "Description": "Pela_Segment: on List Sample Data",
    "Answer_Options": "NA"
  },
  {
    "Column": "HP_segment_code",
    "Description": "HP_segment_code: on List Sample Data",
    "Answer_Options": "NA"
  },
  {
    "Column": "HP_segment_name",
    "Description": "HP_segment_name: on List Sample Data",
    "Answer_Options": "NA"
  },
  {
    "Column": "AAID",
    "Description": "AAID: Captured variable",
    "Answer_Options": "NA"
  }
]